10-Q

--12-31
0001865782
false
Q3
http://fasb.org/srt/2025#ChiefExecutiveOfficerMember
0001865782
us-gaap:OperatingSegmentsMember
us-gaap:ServiceMember
2025-01-01
2025-09-30
0001865782
btsg:MaturedContractsMember
2024-12-31
0001865782
btsg:OtherMember
2025-07-01
2025-09-30
0001865782
btsg:TrancheB5TermLoanMember
btsg:FirstLienCreditAgreementMember
2024-12-11
0001865782
btsg:PharmacySolutionsMember
btsg:MedicaidMember
2024-01-01
2024-09-30
0001865782
btsg:CommunityLivingBusinessMember
us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember
2024-07-01
2024-09-30
0001865782
btsg:PharmacySolutionsMember
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
btsg:MedicaidMember
2024-07-01
2024-09-30
0001865782
2025-01-01
2025-09-30
0001865782
us-gaap:ServiceMember
2024-07-01
2024-09-30
0001865782
btsg:PharmacySolutionsMember
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
2024-07-01
2024-09-30
0001865782
btsg:ProviderServicesMember
btsg:MedicareBMember
2025-07-01
2025-09-30
0001865782
btsg:MonitoringAgreementMember
btsg:KohlbergKravisRobertsCoLPAndWalgreensBootsAllianceIncMember
2024-10-01
2024-12-31
0001865782
2025-10-24
0001865782
us-gaap:CommonStockMember
2024-09-30
0001865782
btsg:PrivateAndOtherMember
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
2024-01-01
2024-09-30
0001865782
btsg:CreditAgricoleCorporateAndInvestmentBankOneMember
btsg:ExistingContractsInterestRateSwapAgreementsMember
2025-01-01
2025-09-30
0001865782
us-gaap:FairValueMeasurementsRecurringMember
us-gaap:IncomeApproachValuationTechniqueMember
2024-12-31
0001865782
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
btsg:MedicareDMember
2024-01-01
2024-09-30
0001865782
us-gaap:RevolvingCreditFacilityMember
btsg:AlternateBaseRateMember
btsg:SwinglineLoansMember
2025-01-01
2025-03-31
0001865782
btsg:PharmacySolutionsMember
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
btsg:MedicareAMember
2024-07-01
2024-09-30
0001865782
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
btsg:MedicareBMember
2024-01-01
2024-09-30
0001865782
btsg:TrancheB1TermLoanMember
btsg:FirstLienCreditAgreementMember
2019-03-05
0001865782
btsg:TangibleEquityUnitsMember
srt:MaximumMember
2024-09-30
0001865782
2024-07-01
2024-09-30
0001865782
us-gaap:NoncontrollingInterestMember
2024-07-01
2024-09-30
0001865782
us-gaap:CommonStockMember
2024-07-01
2024-09-30
0001865782
btsg:RevolvingCreditLoansPayableToLendersAtSofrPlusApplicableMarginMember
2025-09-30
0001865782
btsg:ProviderServicesMember
us-gaap:OperatingSegmentsMember
2025-07-01
2025-09-30
0001865782
2024-12-31
0001865782
us-gaap:EmployeeStockOptionMember
2024-01-01
2024-09-30
0001865782
btsg:PharmacySolutionsMember
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
btsg:CommercialInsuranceMember
2024-07-01
2024-09-30
0001865782
us-gaap:CommonStockMember
2025-09-30
0001865782
btsg:HavenHospiceIncMember
2024-09-01
0001865782
btsg:DoctorPayorNetworkMember
2024-12-31
0001865782
btsg:PharmacySolutionsMember
btsg:PrivateAndOtherMember
2025-07-01
2025-09-30
0001865782
btsg:MedicareAMember
2024-07-01
2024-09-30
0001865782
btsg:PharmacySolutionsMember
us-gaap:OperatingSegmentsMember
2024-07-01
2024-09-30
0001865782
btsg:PharmacySolutionsMember
btsg:PrivateAndOtherMember
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
2024-01-01
2024-09-30
0001865782
us-gaap:CommonStockMember
2025-01-01
2025-09-30
0001865782
btsg:HavenHospiceIncMember
2024-07-01
2024-09-30
0001865782
us-gaap:RetainedEarningsMember
2024-09-30
0001865782
btsg:ProviderServicesMember
btsg:PrivateAndOtherMember
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
2025-01-01
2025-09-30
0001865782
us-gaap:FairValueInputsLevel3Member
us-gaap:FairValueMeasurementsRecurringMember
us-gaap:IncomeApproachValuationTechniqueMember
btsg:ContingentConsiderationMember
2024-12-31
0001865782
us-gaap:OperatingSegmentsMember
us-gaap:ServiceMember
2024-01-01
2024-09-30
0001865782
us-gaap:ProductMember
2024-07-01
2024-09-30
0001865782
btsg:TangibleEquityUnitsMember
2025-01-01
2025-09-30
0001865782
btsg:IndefiniteLivedLicensesMember
btsg:HavenHospiceIncMember
2024-09-01
2024-09-01
0001865782
btsg:MedicareCMember
2024-01-01
2024-09-30
0001865782
btsg:CommunityLivingBusinessMember
us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember
2025-01-01
2025-09-30
0001865782
btsg:PharmacySolutionsMember
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
btsg:MedicaidMember
2025-07-01
2025-09-30
0001865782
2024-01-25
0001865782
btsg:OtherMember
2024-01-01
2024-09-30
0001865782
btsg:FirstLienCreditAgreementMember
2024-02-21
2024-02-21
0001865782
btsg:SwinglineLoansAndBaseRateLoans-PayableToLendersAtABRPlusApplicableMarginMember
2024-12-31
0001865782
2024-06-30
0001865782
us-gaap:RevolvingCreditFacilityMember
2024-02-21
2024-02-21
0001865782
us-gaap:CustomerRelationshipsMember
2025-09-30
0001865782
btsg:MorganStanleyMember
btsg:ExistingContractsInterestRateSwapAgreementsMember
2025-09-30
0001865782
btsg:ProviderServicesMember
btsg:MedicareAMember
2024-01-01
2024-09-30
0001865782
us-gaap:NoncontrollingInterestMember
2024-01-01
2024-09-30
0001865782
btsg:TrancheB4TermLoanMember
btsg:FirstLienCreditAgreementMember
2024-02-21
0001865782
us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember
2024-09-30
0001865782
btsg:PharmacySolutionsMember
btsg:PrivateAndOtherMember
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
2025-07-01
2025-09-30
0001865782
btsg:CommunityLivingBusinessMember
us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember
2024-12-31
0001865782
btsg:PrivateAndOtherMember
2025-01-01
2025-09-30
0001865782
btsg:HavenHospiceIncMember
us-gaap:TradeNamesMember
2024-09-01
2024-09-01
0001865782
btsg:RevolvingCreditLoansPayableToLendersAtSofrPlusApplicableMarginMember
2024-12-31
0001865782
btsg:ProviderServicesMember
2025-09-30
0001865782
btsg:ProviderServicesMember
btsg:TwoThousandTwentyFiveAcquisitionMember
2025-01-01
2025-09-30
0001865782
us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember
2025-06-30
0001865782
btsg:MaturedContractsMember
btsg:MorganStanleyMember
2025-09-30
0001865782
btsg:MedicareAMember
2024-01-01
2024-09-30
0001865782
us-gaap:IPOMember
2025-01-01
2025-09-30
0001865782
2024-01-01
2024-09-30
0001865782
us-gaap:OperatingSegmentsMember
2025-01-01
2025-09-30
0001865782
us-gaap:RevolvingCreditFacilityMember
btsg:AlternateBaseRateMember
btsg:SwinglineLoansMember
2024-01-01
2024-12-31
0001865782
btsg:PharmacySolutionsMember
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
btsg:MedicareAMember
2025-07-01
2025-09-30
0001865782
btsg:CovenantsNotToCompleteMember
2024-12-31
0001865782
btsg:PharmacySolutionsMember
btsg:MedicareDMember
2025-01-01
2025-09-30
0001865782
btsg:ProviderServicesMember
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
btsg:CommercialInsuranceMember
2024-07-01
2024-09-30
0001865782
btsg:PharmacySolutionsMember
2024-12-31
0001865782
us-gaap:RevolvingCreditFacilityMember
btsg:SwinglineLoansMember
2025-01-01
2025-09-30
0001865782
us-gaap:RetainedEarningsMember
2024-06-30
0001865782
btsg:KkrCapitalMarketsLlcMember
2025-07-01
2025-09-30
0001865782
srt:MinimumMember
2025-01-01
2025-09-30
0001865782
btsg:KkrCapitalMarketsLlcMember
2024-01-01
2024-03-31
0001865782
btsg:ProviderServicesMember
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
btsg:MedicaidMember
2024-07-01
2024-09-30
0001865782
btsg:TwoThousandTwentyFourAcquisitionsMember
2025-01-01
2025-09-30
0001865782
btsg:PharmacySolutionsMember
btsg:MedicareAMember
2025-01-01
2025-09-30
0001865782
us-gaap:CommonStockMember
2025-01-01
2025-09-30
0001865782
btsg:PharmacySolutionsMember
btsg:MedicareBMember
2025-07-01
2025-09-30
0001865782
btsg:MedicaidMember
2025-07-01
2025-09-30
0001865782
btsg:TangibleEquityUnitsMember
2024-01-01
2024-09-30
0001865782
btsg:ProviderServicesMember
btsg:CommercialInsuranceMember
2025-07-01
2025-09-30
0001865782
us-gaap:LicensingAgreementsMember
srt:MaximumMember
2025-09-30
0001865782
us-gaap:CustomerRelationshipsMember
2024-12-31
0001865782
btsg:PharmacySolutionsMember
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
btsg:MedicareBMember
2025-01-01
2025-09-30
0001865782
btsg:PharmacySolutionsAndProviderServicesSegmentsMember
2024-07-01
2024-09-30
0001865782
btsg:PharmacySolutionsAndProviderServicesSegmentsMember
us-gaap:CustomerRelationshipsMember
2024-01-01
2024-12-31
0001865782
us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember
2025-01-01
2025-09-30
0001865782
btsg:ProviderServicesMember
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
btsg:MedicareAMember
2025-07-01
2025-09-30
0001865782
btsg:TwoThousandTwentyFourAcquisitionsMember
2024-01-01
2024-12-31
0001865782
btsg:PharmacySolutionsMember
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
btsg:MedicareCMember
2025-07-01
2025-09-30
0001865782
btsg:ProviderServicesMember
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
btsg:MedicareAMember
2024-07-01
2024-09-30
0001865782
btsg:EqualToOrLessThanFifteenPointTwoEightButGreaterThanOrEqualToThirteenPointZeroZeroMember
srt:MaximumMember
2025-09-30
0001865782
btsg:TangibleEquityUnitsMember
2024-01-31
0001865782
btsg:TangibleEquityUnitsMember
2025-07-01
2025-09-30
0001865782
us-gaap:MarketApproachValuationTechniqueMember
us-gaap:FairValueMeasurementsRecurringMember
2024-12-31
0001865782
us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember
2025-07-01
2025-09-30
0001865782
btsg:MedicareCMember
2025-07-01
2025-09-30
0001865782
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
2025-01-01
2025-09-30
0001865782
btsg:PharmacySolutionsMember
2025-09-30
0001865782
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
2024-01-01
2024-09-30
0001865782
us-gaap:OperatingSegmentsMember
us-gaap:ProductMember
2024-07-01
2024-09-30
0001865782
btsg:ProviderServicesMember
btsg:CommercialInsuranceMember
2024-01-01
2024-09-30
0001865782
btsg:PharmacySolutionsMember
btsg:MedicareBMember
2024-07-01
2024-09-30
0001865782
btsg:PharmacySolutionsMember
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
btsg:MedicareCMember
2024-07-01
2024-09-30
0001865782
btsg:TangibleEquityUnitsMember
2024-01-01
2024-12-31
0001865782
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
btsg:MedicareAMember
2025-01-01
2025-09-30
0001865782
us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember
2024-01-01
2024-09-30
0001865782
us-gaap:RetainedEarningsMember
2025-01-01
2025-09-30
0001865782
btsg:FirstLienCreditAgreementMember
btsg:TrancheB3TermLoanMember
2021-12-31
0001865782
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2024-07-01
2024-09-30
0001865782
btsg:OctoberTwoThousandTwentyFiveOfferingMember
us-gaap:SubsequentEventMember
2025-10-22
2025-10-22
0001865782
us-gaap:DiscontinuedOperationsHeldforsaleMember
2025-09-30
0001865782
btsg:PharmacySolutionsMember
btsg:PrivateAndOtherMember
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
2024-07-01
2024-09-30
0001865782
btsg:MaturedContractsMember
btsg:CreditSuisseMember
2025-09-30
0001865782
us-gaap:TradeNamesMember
srt:MaximumMember
2025-09-30
0001865782
btsg:PharmacySolutionsMember
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
btsg:CommercialInsuranceMember
2025-01-01
2025-09-30
0001865782
btsg:PharmacySolutionsMember
2025-07-01
2025-09-30
0001865782
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
btsg:MedicaidMember
2024-01-01
2024-09-30
0001865782
btsg:ProviderServicesMember
us-gaap:SalesRevenueNetMember
btsg:MedicareBMember
us-gaap:ProductConcentrationRiskMember
2024-07-01
2024-09-30
0001865782
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
btsg:MedicareDMember
2025-01-01
2025-09-30
0001865782
btsg:MaturedContractsMember
btsg:CreditSuisseMember
2025-01-01
2025-09-30
0001865782
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2024-12-31
0001865782
us-gaap:OperatingSegmentsMember
us-gaap:ServiceMember
2025-07-01
2025-09-30
0001865782
us-gaap:MaterialReconcilingItemsMember
2025-07-01
2025-09-30
0001865782
btsg:LcFacilityMember
2024-12-31
0001865782
btsg:PharmacySolutionsMember
us-gaap:SalesRevenueNetMember
btsg:MedicareBMember
us-gaap:ProductConcentrationRiskMember
2024-07-01
2024-09-30
0001865782
btsg:LessThanThirteenPointZeroZeroMember
srt:MaximumMember
2025-09-30
0001865782
btsg:LongTermLiabilitiesCurrentMember
2025-04-01
2025-04-30
0001865782
btsg:ProviderServicesMember
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
btsg:CommercialInsuranceMember
2024-01-01
2024-09-30
0001865782
us-gaap:NoncontrollingInterestMember
2025-01-01
2025-09-30
0001865782
btsg:PrivateAndOtherMember
2025-07-01
2025-09-30
0001865782
btsg:ProviderServicesMember
btsg:MedicareBMember
2024-01-01
2024-09-30
0001865782
btsg:ProviderServicesMember
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
2024-07-01
2024-09-30
0001865782
us-gaap:SalesRevenueNetMember
btsg:PrivateAndOtherMember
us-gaap:ProductConcentrationRiskMember
2025-01-01
2025-09-30
0001865782
btsg:ProviderServicesMember
btsg:MedicaidMember
2025-07-01
2025-09-30
0001865782
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2023-12-31
0001865782
btsg:PharmacySolutionsMember
btsg:MedicaidMember
2024-07-01
2024-09-30
0001865782
srt:MaximumMember
2025-09-30
0001865782
btsg:LongTermLiabilitiesCurrentMember
2024-06-01
2024-06-30
0001865782
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
btsg:CommercialInsuranceMember
2024-07-01
2024-09-30
0001865782
btsg:PharmacySolutionsMember
btsg:PrivateAndOtherMember
2025-01-01
2025-09-30
0001865782
btsg:PharmacySolutionsMember
us-gaap:OperatingSegmentsMember
us-gaap:ProductMember
2024-07-01
2024-09-30
0001865782
btsg:PharmacySolutionsMember
btsg:MedicareBMember
2025-01-01
2025-09-30
0001865782
btsg:PharmacySolutionsAndProviderServicesSegmentsMember
2025-07-01
2025-09-30
0001865782
btsg:MedicaidMember
2025-01-01
2025-09-30
0001865782
us-gaap:RevolvingCreditFacilityMember
2025-09-30
0001865782
btsg:PharmacySolutionsMember
us-gaap:OperatingSegmentsMember
us-gaap:ProductMember
2025-01-01
2025-09-30
0001865782
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
btsg:MedicareDMember
2025-07-01
2025-09-30
0001865782
btsg:PharmacySolutionsMember
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
btsg:MedicareCMember
2024-01-01
2024-09-30
0001865782
btsg:SecondLienCreditAgreementMember
2024-01-01
2024-03-31
0001865782
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
btsg:MedicareCMember
2025-07-01
2025-09-30
0001865782
btsg:ProviderServicesMember
btsg:MedicareAMember
2025-01-01
2025-09-30
0001865782
us-gaap:CommonStockMember
us-gaap:IPOMember
2024-01-01
2024-01-31
0001865782
us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember
2025-09-30
0001865782
btsg:ProviderServicesMember
2024-12-31
0001865782
us-gaap:RestrictedStockUnitsRSUMember
2025-01-01
2025-09-30
0001865782
us-gaap:EmployeeStockOptionMember
2025-07-01
2025-09-30
0001865782
us-gaap:InterestRateSwapMember
us-gaap:FairValueInputsLevel2Member
us-gaap:MarketApproachValuationTechniqueMember
us-gaap:FairValueMeasurementsRecurringMember
2025-09-30
0001865782
btsg:CommunityLivingBusinessMember
us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember
2025-01-17
0001865782
btsg:MedicaidMember
2024-07-01
2024-09-30
0001865782
btsg:MedicareBMember
2025-07-01
2025-09-30
0001865782
btsg:CommercialInsuranceMember
2025-01-01
2025-09-30
0001865782
us-gaap:OperatingSegmentsMember
us-gaap:ProductMember
2025-07-01
2025-09-30
0001865782
btsg:PrivateAndOtherMember
2024-07-01
2024-09-30
0001865782
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
btsg:MedicareAMember
2024-07-01
2024-09-30
0001865782
us-gaap:CommonStockMember
2024-01-01
2024-09-30
0001865782
btsg:EqualToOrLessThanFifteenPointTwoEightButGreaterThanOrEqualToThirteenPointZeroZeroMember
2025-01-01
2025-09-30
0001865782
btsg:TangibleEquityUnitsAmortizingNotesMember
2024-07-01
2024-09-30
0001865782
btsg:ProviderServicesMember
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
btsg:CommercialInsuranceMember
2025-01-01
2025-09-30
0001865782
btsg:ProviderServicesMember
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
btsg:MedicareCMember
2024-07-01
2024-09-30
0001865782
us-gaap:RetainedEarningsMember
2025-06-30
0001865782
btsg:MaturedContractsMember
btsg:CreditAgricoleCorporateAndInvestmentBankMember
2024-12-31
0001865782
btsg:SwinglineLoansAndBaseRateLoans-PayableToLendersAtABRPlusApplicableMarginMember
2025-09-30
0001865782
us-gaap:SalesRevenueNetMember
btsg:PrivateAndOtherMember
us-gaap:ProductConcentrationRiskMember
2025-07-01
2025-09-30
0001865782
btsg:PharmacySolutionsMember
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
btsg:CommercialInsuranceMember
2025-07-01
2025-09-30
0001865782
us-gaap:OperatingSegmentsMember
us-gaap:ProductMember
2024-01-01
2024-09-30
0001865782
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
btsg:MedicareCMember
2024-01-01
2024-09-30
0001865782
btsg:OtherMember
2025-01-01
2025-09-30
0001865782
btsg:GreaterThanFifteenPointTwoEightMember
srt:MinimumMember
2025-09-30
0001865782
2024-01-24
2024-01-24
0001865782
us-gaap:NoncontrollingInterestMember
2025-06-30
0001865782
us-gaap:MaterialReconcilingItemsMember
2025-01-01
2025-09-30
0001865782
btsg:FirstLienCreditAgreementMember
2019-03-05
2019-03-05
0001865782
us-gaap:CommonStockMember
2025-07-01
2025-09-30
0001865782
btsg:ProviderServicesMember
btsg:MedicaidMember
2024-01-01
2024-09-30
0001865782
btsg:PharmacySolutionsMember
btsg:MedicareAMember
2025-07-01
2025-09-30
0001865782
btsg:CovenantsNotToCompleteMember
srt:MaximumMember
2025-09-30
0001865782
btsg:NotesPayableAndOtherMember
2025-09-30
0001865782
btsg:ProviderServicesMember
us-gaap:OperatingSegmentsMember
2025-01-01
2025-09-30
0001865782
btsg:PharmacySolutionsMember
btsg:CommercialInsuranceMember
2025-07-01
2025-09-30
0001865782
btsg:ProviderServicesMember
btsg:MedicareCMember
2024-07-01
2024-09-30
0001865782
btsg:CreditAgricoleCorporateAndInvestmentBankOneMember
btsg:ExistingContractsInterestRateSwapAgreementsMember
2025-09-30
0001865782
btsg:MaturedContractsMember
btsg:CreditAgricoleCorporateAndInvestmentBankMember
2025-09-30
0001865782
btsg:IndefiniteLivedLicensesMember
2024-12-31
0001865782
btsg:PharmacySolutionsMember
us-gaap:OperatingSegmentsMember
2025-01-01
2025-09-30
0001865782
us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember
us-gaap:RevolvingCreditFacilityMember
2025-01-01
2025-03-31
0001865782
btsg:ProviderServicesMember
btsg:PrivateAndOtherMember
2025-01-01
2025-09-30
0001865782
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
btsg:MedicaidMember
2025-01-01
2025-09-30
0001865782
btsg:OtherMember
2024-07-01
2024-09-30
0001865782
us-gaap:ServiceMember
2025-07-01
2025-09-30
0001865782
btsg:FirstLienIncrementalTermLoanTrancheB5PayableToLendersAtSofrPlusApplicableMarginMember
2024-12-31
0001865782
btsg:CommunityLivingBusinessMember
us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember
2025-09-30
0001865782
btsg:PharmacySolutionsMember
btsg:PrivateAndOtherMember
2024-07-01
2024-09-30
0001865782
btsg:PharmacySolutionsMember
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
2025-07-01
2025-09-30
0001865782
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
2024-07-01
2024-09-30
0001865782
btsg:MedicareCMember
2024-07-01
2024-09-30
0001865782
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2024-09-30
0001865782
btsg:MedicareBMember
2025-01-01
2025-09-30
0001865782
btsg:MedicareBMember
2024-07-01
2024-09-30
0001865782
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
btsg:MedicareCMember
2024-07-01
2024-09-30
0001865782
btsg:MizuhoCapitalMarketsMember
btsg:ExistingContractsInterestRateSwapAgreementsMember
2025-09-30
0001865782
us-gaap:CommonStockMember
btsg:OctoberTwoThousandTwentyFiveOfferingMember
us-gaap:SubsequentEventMember
2025-10-22
2025-10-22
0001865782
btsg:PharmacySolutionsMember
us-gaap:OperatingSegmentsMember
us-gaap:ProductMember
2025-07-01
2025-09-30
0001865782
btsg:PharmacySolutionsMember
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
btsg:CommercialInsuranceMember
2024-01-01
2024-09-30
0001865782
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2025-09-30
0001865782
btsg:ProviderServicesMember
btsg:PrivateAndOtherMember
2025-07-01
2025-09-30
0001865782
us-gaap:RevolvingCreditFacilityMember
btsg:LcSublimitMember
2025-01-01
2025-09-30
0001865782
btsg:HavenHospiceIncMember
2025-01-01
2025-09-30
0001865782
btsg:ProviderServicesMember
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
2024-01-01
2024-09-30
0001865782
us-gaap:LicensingAgreementsMember
2024-12-31
0001865782
btsg:TangibleEquityUnitsAmortizingNotesMember
2024-01-01
2024-01-31
0001865782
srt:MaximumMember
2025-01-01
2025-09-30
0001865782
btsg:AmortizingNotesMember
2025-09-30
0001865782
btsg:ProviderServicesMember
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
2025-07-01
2025-09-30
0001865782
us-gaap:OperatingSegmentsMember
2024-07-01
2024-09-30
0001865782
us-gaap:RevolvingCreditFacilityMember
2024-12-31
0001865782
us-gaap:RetainedEarningsMember
2023-12-31
0001865782
btsg:MedicareDMember
2024-01-01
2024-09-30
0001865782
us-gaap:OtherIntangibleAssetsMember
srt:MinimumMember
2025-09-30
0001865782
btsg:TangibleEquityUnitsPurchaseContractsMember
2024-07-01
2024-09-30
0001865782
btsg:HarvestGroveLTCLLCMember
2024-07-01
2024-09-30
0001865782
btsg:KkrCapitalMarketsLlcMember
2024-07-01
2024-09-30
0001865782
srt:MinimumMember
us-gaap:LicensingAgreementsMember
2025-09-30
0001865782
btsg:PharmacySolutionsMember
us-gaap:OperatingSegmentsMember
2024-01-01
2024-09-30
0001865782
srt:MinimumMember
btsg:TangibleEquityUnitsMember
2025-09-30
0001865782
us-gaap:EmployeeStockOptionMember
2024-07-01
2024-09-30
0001865782
us-gaap:RetainedEarningsMember
2024-07-01
2024-09-30
0001865782
2025-07-01
2025-09-30
0001865782
btsg:KkrCapitalMarketsLlcMember
2025-01-01
2025-09-30
0001865782
btsg:PharmacySolutionsMember
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
btsg:MedicareBMember
2024-01-01
2024-09-30
0001865782
us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember
2024-12-31
0001865782
btsg:NotesPayableAndOtherMember
2024-12-31
0001865782
btsg:PrivateAndOtherMember
2024-01-01
2024-09-30
0001865782
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
btsg:MedicaidMember
2024-07-01
2024-09-30
0001865782
btsg:PharmacySolutionsMember
us-gaap:OperatingSegmentsMember
us-gaap:ProductMember
2024-01-01
2024-09-30
0001865782
btsg:PharmacySolutionsMember
btsg:PrivateAndOtherMember
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
2025-01-01
2025-09-30
0001865782
us-gaap:EmployeeStockOptionMember
2025-01-01
2025-09-30
0001865782
btsg:ProviderServicesMember
2024-07-01
2024-09-30
0001865782
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2024-01-01
2024-09-30
0001865782
us-gaap:FairValueMeasurementsRecurringMember
us-gaap:IncomeApproachValuationTechniqueMember
2025-09-30
0001865782
us-gaap:RestrictedStockUnitsRSUMember
2024-01-01
2024-09-30
0001865782
btsg:LessThanThirteenPointZeroZeroMember
2025-01-01
2025-09-30
0001865782
btsg:PharmacySolutionsMember
2024-01-01
2024-09-30
0001865782
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2024-06-30
0001865782
us-gaap:NoncontrollingInterestMember
2025-07-01
2025-09-30
0001865782
btsg:ProviderServicesMember
btsg:MedicareCMember
2025-07-01
2025-09-30
0001865782
btsg:PharmacySolutionsMember
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
2025-01-01
2025-09-30
0001865782
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
btsg:MedicareCMember
2025-01-01
2025-09-30
0001865782
us-gaap:RetainedEarningsMember
2024-12-31
0001865782
btsg:ProviderServicesMember
btsg:PrivateAndOtherMember
2024-01-01
2024-09-30
0001865782
btsg:TangibleEquityUnitsMember
2025-01-01
2025-09-30
0001865782
us-gaap:ServiceMember
2025-01-01
2025-09-30
0001865782
us-gaap:RetainedEarningsMember
2024-01-01
2024-09-30
0001865782
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2025-06-30
0001865782
btsg:CommunityLivingBusinessMember
us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember
2024-01-01
2024-09-30
0001865782
btsg:DoctorPayorNetworkMember
srt:MinimumMember
2025-09-30
0001865782
btsg:ProviderServicesMember
btsg:MedicareAMember
2025-07-01
2025-09-30
0001865782
btsg:ProviderServicesMember
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
btsg:MedicareCMember
2025-07-01
2025-09-30
0001865782
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
2025-07-01
2025-09-30
0001865782
btsg:PharmacySolutionsMember
btsg:MedicareDMember
2024-01-01
2024-09-30
0001865782
us-gaap:CommonStockMember
us-gaap:IPOMember
2024-01-31
0001865782
btsg:IndefiniteLivedLicensesMember
btsg:PharmacySolutionsAndProviderServicesSegmentsMember
2024-01-01
2024-12-31
0001865782
btsg:SecondLienCreditAgreementMember
2024-02-21
2024-02-21
0001865782
btsg:TangibleEquityUnitsPurchaseContractsMember
2024-01-01
2024-09-30
0001865782
us-gaap:LetterOfCreditMember
2025-09-30
0001865782
btsg:ProviderServicesMember
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
btsg:MedicareCMember
2024-01-01
2024-09-30
0001865782
btsg:LongTermLiabilitiesCurrentMember
2024-07-01
2024-07-31
0001865782
btsg:CovenantsNotToCompleteMember
srt:MinimumMember
2025-09-30
0001865782
btsg:PharmacySolutionsMember
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
btsg:MedicareDMember
2024-01-01
2024-09-30
0001865782
btsg:CommercialInsuranceMember
2024-07-01
2024-09-30
0001865782
btsg:GreaterThanFifteenPointTwoEightMember
2025-01-01
2025-09-30
0001865782
btsg:ProviderServicesMember
btsg:PrivateAndOtherMember
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
2025-07-01
2025-09-30
0001865782
btsg:MedicareCMember
2025-01-01
2025-09-30
0001865782
btsg:ProviderServicesMember
btsg:MedicaidMember
2025-01-01
2025-09-30
0001865782
srt:MaximumMember
us-gaap:CustomerRelationshipsMember
2025-09-30
0001865782
us-gaap:OtherIntangibleAssetsMember
2025-09-30
0001865782
btsg:MonitoringAgreementMember
btsg:KohlbergKravisRobertsCoLPAndWalgreensBootsAllianceIncMember
us-gaap:SellingGeneralAndAdministrativeExpensesMember
2024-01-01
2024-03-31
0001865782
btsg:TangibleEquityUnitsMember
2024-01-01
2024-01-31
0001865782
us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember
us-gaap:RevolvingCreditFacilityMember
2024-02-21
2024-02-21
0001865782
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
btsg:MedicareBMember
2024-07-01
2024-09-30
0001865782
us-gaap:DiscontinuedOperationsHeldforsaleMember
2024-12-31
0001865782
us-gaap:RestrictedStockUnitsRSUMember
2024-07-01
2024-09-30
0001865782
btsg:ProviderServicesMember
us-gaap:OperatingSegmentsMember
us-gaap:ServiceMember
2025-01-01
2025-09-30
0001865782
btsg:PharmacySolutionsMember
btsg:MedicareDMember
2025-07-01
2025-09-30
0001865782
btsg:PharmacySolutionsMember
btsg:MedicareAMember
2024-01-01
2024-09-30
0001865782
btsg:TangibleEquityUnitsAmortizingNotesMember
2024-01-01
2024-09-30
0001865782
btsg:ProviderServicesMember
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
2025-01-01
2025-09-30
0001865782
btsg:MaturedContractsMember
btsg:CreditSuisseMember
2024-12-31
0001865782
btsg:PharmacySolutionsMember
btsg:MedicareAMember
2024-07-01
2024-09-30
0001865782
us-gaap:NoncontrollingInterestMember
2024-06-30
0001865782
us-gaap:OperatingSegmentsMember
us-gaap:ProductMember
2025-01-01
2025-09-30
0001865782
btsg:PharmacySolutionsMember
2024-07-01
2024-09-30
0001865782
btsg:PharmacySolutionsMember
2025-01-01
2025-09-30
0001865782
btsg:ProviderServicesMember
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
btsg:MedicareBMember
2025-07-01
2025-09-30
0001865782
btsg:PharmacySolutionsMember
btsg:MedicareCMember
2025-01-01
2025-09-30
0001865782
btsg:PharmacySolutionsAndProviderServicesSegmentsMember
us-gaap:TradeNamesMember
2024-01-01
2024-12-31
0001865782
btsg:TangibleEquityUnitsMember
2024-12-31
0001865782
btsg:HavenHospiceIncMember
2024-09-01
2024-09-01
0001865782
btsg:MedicareAMember
2025-01-01
2025-09-30
0001865782
2024-09-30
0001865782
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
btsg:MedicareDMember
2024-07-01
2024-09-30
0001865782
btsg:ExistingContractsInterestRateSwapAgreementsMember
btsg:MizuhoCapitalMarketsMember
2025-01-01
2025-09-30
0001865782
2025-09-30
0001865782
btsg:HavenHospiceIncMember
2024-01-01
2024-09-30
0001865782
btsg:PharmacySolutionsMember
btsg:MedicareCMember
2024-01-01
2024-09-30
0001865782
btsg:CommercialInsuranceMember
2025-07-01
2025-09-30
0001865782
btsg:TwoThousandTwentyFiveAcquisitionMember
2025-01-01
2025-09-30
0001865782
btsg:PharmacySolutionsMember
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
btsg:MedicaidMember
2025-01-01
2025-09-30
0001865782
btsg:ProviderServicesMember
us-gaap:SalesRevenueNetMember
btsg:MedicareBMember
us-gaap:ProductConcentrationRiskMember
2025-01-01
2025-09-30
0001865782
btsg:MedicareBMember
2024-01-01
2024-09-30
0001865782
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
btsg:CommercialInsuranceMember
2025-07-01
2025-09-30
0001865782
srt:MinimumMember
btsg:TangibleEquityUnitsMember
2024-09-30
0001865782
us-gaap:RetainedEarningsMember
2025-07-01
2025-09-30
0001865782
us-gaap:ProductMember
2025-07-01
2025-09-30
0001865782
srt:MinimumMember
btsg:EqualToOrLessThanFifteenPointTwoEightButGreaterThanOrEqualToThirteenPointZeroZeroMember
2025-09-30
0001865782
btsg:MaturedContractsMember
btsg:MorganStanleyMember
2025-01-01
2025-09-30
0001865782
btsg:AmortizingNotesMember
2024-12-31
0001865782
us-gaap:SalesRevenueNetMember
us-gaap:CustomerConcentrationRiskMember
2025-01-01
2025-09-30
0001865782
btsg:PharmacySolutionsMember
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
btsg:MedicareDMember
2025-01-01
2025-09-30
0001865782
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2025-01-01
2025-09-30
0001865782
btsg:PharmacySolutionsMember
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
btsg:MedicaidMember
2024-01-01
2024-09-30
0001865782
btsg:PharmacySolutionsMember
btsg:PrivateAndOtherMember
2024-01-01
2024-09-30
0001865782
btsg:ProviderServicesMember
2024-01-01
2024-09-30
0001865782
btsg:PharmacySolutionsMember
us-gaap:OperatingSegmentsMember
2025-07-01
2025-09-30
0001865782
us-gaap:MarketApproachValuationTechniqueMember
us-gaap:FairValueMeasurementsRecurringMember
2025-09-30
0001865782
btsg:SeniorAmortizingNoteMember
2024-01-01
2024-01-31
0001865782
btsg:TangibleEquityUnitsAmortizingNotesMember
2025-07-01
2025-09-30
0001865782
btsg:PharmacySolutionsMember
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
2024-01-01
2024-09-30
0001865782
btsg:TangibleEquityUnitsPurchaseContractsMember
2025-01-01
2025-09-30
0001865782
btsg:SecondLienCreditAgreementMember
2025-09-30
0001865782
btsg:ProviderServicesMember
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
btsg:MedicareBMember
2024-01-01
2024-09-30
0001865782
btsg:ProviderServicesMember
btsg:PrivateAndOtherMember
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
2024-01-01
2024-09-30
0001865782
btsg:PharmacySolutionsMember
btsg:MedicaidMember
2025-07-01
2025-09-30
0001865782
btsg:PharmacySolutionsMember
btsg:MedicareDMember
2024-07-01
2024-09-30
0001865782
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
btsg:CommercialInsuranceMember
2024-01-01
2024-09-30
0001865782
srt:MinimumMember
2025-09-30
0001865782
btsg:ProviderServicesMember
btsg:MedicareAMember
2024-07-01
2024-09-30
0001865782
btsg:GatewayPediatricTherapyLlcMember
2024-01-01
2024-03-31
0001865782
us-gaap:NoncompeteAgreementsMember
btsg:PharmacySolutionsAndProviderServicesSegmentsMember
2024-01-01
2024-12-31
0001865782
btsg:PharmacySolutionsMember
btsg:MedicareCMember
2024-07-01
2024-09-30
0001865782
btsg:ProviderServicesMember
btsg:MedicareCMember
2024-01-01
2024-09-30
0001865782
us-gaap:MaterialReconcilingItemsMember
2024-01-01
2024-09-30
0001865782
btsg:ProviderServicesMember
btsg:CommercialInsuranceMember
2025-01-01
2025-09-30
0001865782
us-gaap:NoncontrollingInterestMember
2025-09-30
0001865782
us-gaap:RestrictedStockUnitsRSUMember
2025-07-01
2025-09-30
0001865782
btsg:MaturedContractsMember
btsg:CreditAgricoleCorporateAndInvestmentBankMember
2025-01-01
2025-09-30
0001865782
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
btsg:MedicareAMember
2025-07-01
2025-09-30
0001865782
btsg:ProviderServicesMember
btsg:MedicareBMember
2025-01-01
2025-09-30
0001865782
btsg:ProviderServicesMember
2025-01-01
2025-09-30
0001865782
btsg:HavenHospiceIncMember
2025-07-01
2025-09-30
0001865782
btsg:MedicareAMember
2025-07-01
2025-09-30
0001865782
btsg:MedicareDMember
2024-07-01
2024-09-30
0001865782
btsg:MonitoringAgreementMember
btsg:KohlbergKravisRobertsCoLPAndWalgreensBootsAllianceIncMember
2025-09-30
0001865782
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
btsg:MedicaidMember
2025-07-01
2025-09-30
0001865782
us-gaap:NoncontrollingInterestMember
2023-12-31
0001865782
btsg:ProviderServicesMember
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
btsg:MedicareAMember
2024-01-01
2024-09-30
0001865782
btsg:TangibleEquityUnitsMember
2024-07-01
2024-09-30
0001865782
btsg:DoctorPayorNetworkMember
srt:MaximumMember
2025-09-30
0001865782
us-gaap:ProductMember
2025-01-01
2025-09-30
0001865782
us-gaap:ProductMember
2024-01-01
2024-09-30
0001865782
btsg:CommunityLivingBusinessMember
us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember
2025-07-01
2025-09-30
0001865782
btsg:PharmacySolutionsMember
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
btsg:MedicareDMember
2025-07-01
2025-09-30
0001865782
us-gaap:RetainedEarningsMember
2025-09-30
0001865782
us-gaap:OperatingSegmentsMember
us-gaap:ServiceMember
2024-07-01
2024-09-30
0001865782
us-gaap:TradeNamesMember
2024-12-31
0001865782
us-gaap:CommonStockMember
2024-12-31
0001865782
us-gaap:LetterOfCreditMember
2024-12-31
0001865782
us-gaap:CommonStockMember
2025-06-30
0001865782
btsg:ProviderServicesMember
btsg:MedicaidMember
2024-07-01
2024-09-30
0001865782
btsg:PharmacySolutionsMember
btsg:CommercialInsuranceMember
2025-01-01
2025-09-30
0001865782
btsg:PharmacySolutionsMember
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
btsg:MedicareCMember
2025-01-01
2025-09-30
0001865782
btsg:ProviderServicesMember
us-gaap:OperatingSegmentsMember
2024-07-01
2024-09-30
0001865782
us-gaap:MaterialReconcilingItemsMember
2024-07-01
2024-09-30
0001865782
btsg:ProviderServicesMember
btsg:PrivateAndOtherMember
2024-07-01
2024-09-30
0001865782
btsg:ProviderServicesMember
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
btsg:MedicareAMember
2025-01-01
2025-09-30
0001865782
btsg:LcFacilityMember
2025-09-30
0001865782
btsg:KkrCapitalMarketsLlcMember
2024-04-01
2024-09-30
0001865782
us-gaap:OperatingSegmentsMember
2025-07-01
2025-09-30
0001865782
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2025-07-01
2025-09-30
0001865782
btsg:PharmacySolutionsMember
btsg:MedicaidMember
2025-01-01
2025-09-30
0001865782
btsg:PharmacySolutionsMember
btsg:MedicareBMember
2024-01-01
2024-09-30
0001865782
btsg:MaturedContractsMember
btsg:MorganStanleyMember
2024-12-31
0001865782
us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember
2024-07-01
2024-09-30
0001865782
btsg:CreditAgricoleCorporateAndInvestmentBankMember
btsg:ExistingContractsInterestRateSwapAgreementsMember
2025-09-30
0001865782
btsg:PharmacySolutionsMember
us-gaap:SalesRevenueNetMember
btsg:MedicareBMember
us-gaap:ProductConcentrationRiskMember
2025-07-01
2025-09-30
0001865782
btsg:MedicareDMember
2025-01-01
2025-09-30
0001865782
srt:MinimumMember
us-gaap:TradeNamesMember
2025-09-30
0001865782
btsg:MorganStanleyMember
btsg:ExistingContractsInterestRateSwapAgreementsMember
2025-01-01
2025-09-30
0001865782
us-gaap:SalesRevenueNetMember
btsg:PrivateAndOtherMember
us-gaap:ProductConcentrationRiskMember
2024-07-01
2024-09-30
0001865782
btsg:TangibleEquityUnitsAmortizingNotesMember
2024-12-31
0001865782
btsg:ProviderServicesMember
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
btsg:MedicaidMember
2025-07-01
2025-09-30
0001865782
us-gaap:CommonStockMember
2024-06-30
0001865782
btsg:PharmacySolutionsMember
btsg:CommercialInsuranceMember
2024-07-01
2024-09-30
0001865782
us-gaap:LicensingAgreementsMember
2025-09-30
0001865782
btsg:ProviderServicesMember
us-gaap:OperatingSegmentsMember
us-gaap:ServiceMember
2025-07-01
2025-09-30
0001865782
us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember
btsg:TrancheB5TermLoanMember
btsg:FirstLienCreditAgreementMember
2024-12-11
2024-12-11
0001865782
us-gaap:CommonStockMember
2024-01-01
2024-01-31
0001865782
us-gaap:TradeNamesMember
2025-09-30
0001865782
btsg:PharmacySolutionsAndProviderServicesSegmentsMember
2024-12-31
0001865782
btsg:PharmacySolutionsMember
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
btsg:MedicareDMember
2024-07-01
2024-09-30
0001865782
us-gaap:FairValueInputsLevel3Member
us-gaap:FairValueMeasurementsRecurringMember
us-gaap:IncomeApproachValuationTechniqueMember
btsg:ContingentConsiderationMember
2025-09-30
0001865782
btsg:PharmacySolutionsMember
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
btsg:MedicareAMember
2025-01-01
2025-09-30
0001865782
btsg:KkrCapitalMarketsLlcMember
2024-01-01
2024-01-31
0001865782
btsg:TangibleEquityUnitsAmortizingNotesMember
2025-09-30
0001865782
us-gaap:OtherIntangibleAssetsMember
2024-12-31
0001865782
btsg:ProviderServicesMember
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
btsg:MedicareCMember
2025-01-01
2025-09-30
0001865782
btsg:ProviderServicesMember
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
btsg:CommercialInsuranceMember
2025-07-01
2025-09-30
0001865782
btsg:FirstLienIncrementalTermLoanTrancheB5PayableToLendersAtSofrPlusApplicableMarginMember
2025-09-30
0001865782
btsg:TrancheB2TermLoanMember
btsg:FirstLienCreditAgreementMember
2020-12-31
0001865782
btsg:PharmacySolutionsAndProviderServicesMember
btsg:TwoThousandTwentyFourAcquisitionsMember
2024-01-01
2024-12-31
0001865782
btsg:CovenantsNotToCompleteMember
2025-09-30
0001865782
us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember
2023-12-31
0001865782
btsg:ProviderServicesMember
btsg:MedicareCMember
2025-01-01
2025-09-30
0001865782
us-gaap:InterestRateSwapMember
us-gaap:FairValueInputsLevel2Member
us-gaap:MarketApproachValuationTechniqueMember
us-gaap:FairValueMeasurementsRecurringMember
2024-12-31
0001865782
btsg:ProviderServicesMember
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
btsg:MedicaidMember
2024-01-01
2024-09-30
0001865782
btsg:ProviderServicesMember
2025-07-01
2025-09-30
0001865782
btsg:CommercialInsuranceMember
2024-01-01
2024-09-30
0001865782
btsg:ProviderServicesMember
us-gaap:OperatingSegmentsMember
us-gaap:ServiceMember
2024-07-01
2024-09-30
0001865782
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
btsg:CommercialInsuranceMember
2025-01-01
2025-09-30
0001865782
btsg:PharmacySolutionsMember
btsg:CommercialInsuranceMember
2024-01-01
2024-09-30
0001865782
btsg:PharmacySolutionsMember
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
btsg:MedicareAMember
2024-01-01
2024-09-30
0001865782
btsg:ProviderServicesMember
us-gaap:OperatingSegmentsMember
2024-01-01
2024-09-30
0001865782
btsg:ProviderServicesMember
btsg:PrivateAndOtherMember
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
2024-07-01
2024-09-30
0001865782
us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember
2024-06-30
0001865782
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
btsg:MedicareBMember
2025-07-01
2025-09-30
0001865782
btsg:TrancheB5TermLoanMember
btsg:FirstLienCreditAgreementMember
btsg:AlternateBaseRateMember
2024-12-11
2024-12-11
0001865782
2024-01-01
2024-01-31
0001865782
btsg:ProviderServicesMember
us-gaap:OperatingSegmentsMember
us-gaap:ServiceMember
2024-01-01
2024-09-30
0001865782
us-gaap:ServiceMember
2024-01-01
2024-09-30
0001865782
btsg:MedicareDMember
2025-07-01
2025-09-30
0001865782
srt:MinimumMember
us-gaap:CustomerRelationshipsMember
2025-09-30
0001865782
btsg:TangibleEquityUnitsPurchaseContractsMember
2025-07-01
2025-09-30
0001865782
btsg:TangibleEquityUnitsAmortizingNotesMember
2024-05-01
0001865782
us-gaap:NoncontrollingInterestMember
2024-09-30
0001865782
btsg:PharmacySolutionsAndProviderServicesSegmentsMember
2024-01-01
2024-09-30
0001865782
us-gaap:OperatingSegmentsMember
2024-01-01
2024-09-30
0001865782
btsg:MedicaidMember
2024-01-01
2024-09-30
0001865782
2023-12-31
0001865782
btsg:PharmacySolutionsAndProviderServicesSegmentsMember
2025-01-01
2025-09-30
0001865782
us-gaap:SalesRevenueNetMember
btsg:MedicareBMember
us-gaap:ProductConcentrationRiskMember
2025-01-01
2025-09-30
0001865782
btsg:PharmacySolutionsMember
btsg:MedicareCMember
2025-07-01
2025-09-30
0001865782
btsg:TangibleEquityUnitsAmortizingNotesMember
2024-01-31
0001865782
btsg:DoctorPayorNetworkMember
2025-09-30
0001865782
btsg:ProviderServicesMember
btsg:MedicareBMember
2024-07-01
2024-09-30
0001865782
btsg:ProviderServicesMember
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
btsg:MedicaidMember
2025-01-01
2025-09-30
0001865782
us-gaap:CommonStockMember
2023-12-31
0001865782
2024-01-31
0001865782
btsg:DefiniteLivedLicensesMember
btsg:PharmacySolutionsAndProviderServicesSegmentsMember
2024-01-01
2024-12-31
0001865782
btsg:PharmacySolutionsAndProviderServicesSegmentsMember
2024-01-01
2024-12-31
0001865782
btsg:CreditAgricoleCorporateAndInvestmentBankMember
btsg:ExistingContractsInterestRateSwapAgreementsMember
2025-01-01
2025-09-30
0001865782
btsg:TangibleEquityUnitsAmortizingNotesMember
2025-01-01
2025-09-30
0001865782
2025-06-30
0001865782
us-gaap:OtherIntangibleAssetsMember
srt:MaximumMember
2025-09-30
0001865782
btsg:IndefiniteLivedLicensesMember
2025-09-30
0001865782
btsg:ProviderServicesMember
btsg:CommercialInsuranceMember
2024-07-01
2024-09-30
0001865782
us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember
btsg:MedicareAMember
2024-01-01
2024-09-30
xbrli:pure
iso4217:USD
xbrli:shares
btsg:Acquisitions
btsg:Unit
xbrli:shares
iso4217:USD
btsg:Unit
btsg:Customer
iso4217:USD

ROC

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 
10-Q

(Mark One)

☒

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended 
September 30, 
2025
OR

☐

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                               to
Commission File Number: 
001-41938

BrightSpring Health Services, Inc.
(Exact Name of Registrant as Specified in its Charter)

Delaware

82-2956404

(State or other jurisdiction of
incorporation or organization)

(I.R.S. Employer
Identification No.)

805 N. Whittington Parkway
Louisville
,
 Kentucky

40222

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (
502
) 
394-2100

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading
Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.01 per share
6.75% Tangible Equity Units

BTSG
BTSGU

The Nasdaq Stock Market LLC
The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     
Yes

☒ 
   No  
☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).     
Yes

☒ 
   No  
☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

☐

Accelerated filer

☐

Non-accelerated filer

☒

Smaller reporting company

☐

Emerging growth company

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 
☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).     Yes  
☐ 
   No  
☒
The number of shares of Registrant’s Common Stock outstanding as o
f October 24, 2025 was 
180,352,297
.

Table of Contents

Page

PART I.

FINANCIAL INFORMATION

3

Item 1.

Financial Statements (Unaudited)

3

Condensed Consolidated Balance Sheets

3

Condensed Consolidated Statements of Operations

4

Condensed Consolidated Statements of Comprehensive Income (Loss)

5

Condensed Consolidated Statements of Shareholders' Equity

6

Condensed Consolidated Statements of Cash Flows

8

Notes to Condensed Consolidated Financial Statements

10

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

28

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

48

Item 4.

Controls and Procedures

49

PART II.

OTHER INFORMATION

50

Item 1.

Legal Proceedings

50

Item 1A.

Risk Factors

50

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

50

Item 3.

Defaults Upon Senior Securities

50

Item 4.

Mine Safety Disclosures

50

Item 5.

Other Information

50

Item 6.

Exhibits

51

Signatures

52

i

Unless the context requires otherwise, references in this Quarterly Report on Form 10-Q (this “Form 10-Q”) to “BrightSpring,” the “Company,” “we,” “us,” and “our” refer to BrightSpring Health Services, Inc. and its consolidated subsidiaries.
FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q includes forward-looking statements that reflect our current views with respect to, among other things, our operations, and financial performance. We have used the words “anticipate,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “future,” “will,” “seek,” “foreseeable,” the negative version of these words, or similar terms and phrases to identify forward-looking statements.
Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our industries, business strategy, goals and expectations concerning our market position, future operations, margins, profitability, capital expenditures, liquidity and capital resources and other financial and operating information. We believe that these factors include but are not limited to the following:
•
our operation in a highly competitive industry;
•
our inability to maintain relationships with existing patient referral sources or establish new referral sources;
•
changes to Medicare and Medicaid rates or methods governing Medicare and Medicaid payments for our services;
•
cost containment initiatives of third-party payors, including post-payment audits;
•
the implementation of alternative payment models and the transition of Medicaid and Medicare beneficiaries to managed care organizations may limit our market share and could adversely affect our revenues;
•
changes in the case mix of patients, as well as payor mix and payment methodologies, and decisions and operations of third-party organizations;
•
our reliance on federal and state spending, budget decisions, and continuous governmental operations which may fluctuate under different political conditions;
•
changes in drug utilization and/or pricing, PBM contracts, and Medicare Part D/Medicaid reimbursement, which may negatively impact our profitability;
•
changes in our relationships with pharmaceutical suppliers, including changes in drug availability or pricing;
•
reliance on the continual recruitment and retention of nurses, pharmacists, therapists, caregivers, direct support professionals, and other qualified personnel, including senior management;
•
compliance with or changes to federal, state, and local laws and regulations that govern our employment practices, including minimum wage, living wage, and paid time-off requirements;
•
fluctuation of our results of operations on a quarterly basis;
•
harm caused by labor relation matters;
•
limitations in our ability to control reimbursement rates received for our services if we are unable to maintain or reduce our costs to provide such services;
•
delays in collection or non-collection of our accounts receivable, particularly during the business integration process;
•
failure to manage our growth effectively, which may inhibit our ability to execute our business plan, maintain high levels of service and satisfaction or adequately address competitive challenges;
•
our ability to identify, successfully complete and manage acquisitions, joint ventures, and other strategic initiatives, including the pending sale of our Community Living business;
•
our ability to continue to provide consistently high quality of care;
•
maintenance of our corporate reputation or the emergence of adverse publicity, including negative information on social media or changes in public perception of our services;
•
contract continuance, expansion and renewal with our existing customers, including renewals at lower fee levels, customers declining to purchase additional services from us, or reduction in the services received from us pursuant to those contracts;

1

•
effective investment in, implementation of improvements to and proper maintenance of the uninterrupted operation and data integrity of our information technology and other business systems;
•
security breaches, loss of data, and other disruptions, which could compromise sensitive business or patient information; cause a loss of confidential patient data, employee data or personal information; or prevent access to critical information and thereby expose us to liability, litigation, and federal and state governmental inquiries and damage our reputation and brand;
•
risks related to credit card payments and other payment methods;
•
potential substantial malpractice or other similar claims;
•
various risks related to governmental inquiries, regulatory actions, and whistleblower and other lawsuits, which may not be entirely covered by insurance;
•
our current insurance program, which may expose us to unexpected costs, particularly if we incur losses not covered by our insurance or if claims or losses differ from our estimates;
•
factors outside of our control, including those listed, which have required and could in the future require us to record an asset impairment of goodwill;
•
a pandemic, epidemic, or outbreak of an infectious disease;
•
inclement weather, natural disasters, acts of terrorism, riots, civil insurrection or social unrest, looting, protests, strikes, or street demonstrations; 
•
our inability to adequately protect our intellectual property rights;
•
risks related to our compliance with our regulatory framework;
•
the interests of KKR Stockholder (as defined below) may conflict with our stockholders’ interests in the future;
•
our substantial indebtedness;  
•
significant changes in tax or trade policies, tariffs, or trade relations between the United States and other countries, such as the imposition of unilateral tariffs on imported products, including impacts on imported drug products, which could result in supply chain disruptions and significant increases in costs; and
•
repurchases of our common stock
 Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. If any of these risks materialize, or if any of our assumptions underlying forward-looking statements prove incorrect, actual results and developments may differ materially from those made in or suggested by the forward-looking statements contained in this Form 10-Q. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, those set forth in Item 1A, “Risk Factors,” of Part I of our Annual Report on Form 10-K for the year ended December 31, 2024 (our “Form 10-K”) filed with the U.S. Securities and Exchange Commission (the “SEC”). Although we have attempted to identify important risk factors, there may be other risk factors not presently known to us or that we presently believe are not material that could cause actual results and developments to differ materially from those made in or suggested by the forward-looking statements contained in this Form 10-Q. We caution you against relying on any forward-looking statements, which should also be read in conjunction with the other cautionary statements that are included elsewhere in this Form 10-Q. Any forward-looking statement made by us in this Form 10-Q speaks only as of the date hereof. We undertake no obligation to publicly update or to revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

2

PART I—FIN
ANCIAL INFORMATION
Ite
m 1. Financial Statements.
BrightSpring Health Services, Inc. and Subsidiaries
Condensed Consolida
ted Balance Sheets
(In thousands, except share and per share data)
(Unaudited)

September 30, 2025

December 31, 2024

Assets

Current assets:

Cash and cash equivalents

$

140,344

$

60,954

Accounts receivable, net of allowance for credit losses

1,012,913

902,782

Inventories

639,195

636,561

Prepaid expenses and other current assets

123,978

161,310

Current assets held for sale

863,846

131,447

Total current assets

2,780,276

1,893,054

Property and equipment, net of accumulated depreciation of $
387,921
 and $
339,892
 at 
    September 30, 2025 and December 31, 2024, respectively

175,494

180,570

Goodwill

2,370,566

2,363,884

Intangible assets, net of accumulated amortization

521,610

595,224

Operating lease right-of-use assets, net

159,589

161,032

Deferred income taxes, net

—

5,288

Other assets

41,962

39,128

Non-current assets held for sale

—

687,960

Total assets

$

6,049,497

$

5,926,140

Liabilities, Redeemable Noncontrolling Interest, and Equity

Current liabilities:

Trade accounts payable

$

954,497

$

923,926

Accrued expenses

304,046

295,746

Current portion of obligations under operating leases

38,217

38,910

Current portion of obligations under financing leases

4,727

3,463

Current portion of long-term debt

51,870

48,725

Current liabilities held for sale

196,613

117,563

Total current liabilities

1,549,970

1,428,333

Obligations under operating leases, net of current portion

128,751

129,467

Obligations under financing leases, net of current portion

10,423

6,530

Long-term debt, net of current portion

2,465,334

2,561,858

Deferred income taxes, net

10,441

—

Long-term liabilities

63,560

71,190

Non-current liabilities held for sale

—

77,177

Total liabilities

4,228,479

4,274,555

Redeemable noncontrolling interest

2,361

3,730

Shareholders' equity:

Common stock, $
0.01
 par value, 
1,500,000,000
 shares authorized, 
180,685,884
 and

174,245,990
 shares issued and outstanding at September 30, 2025 and 
   December 31, 2024, respectively

$

1,807

$

1,742

Preferred stock, $
0.01
 par value, 
250,000,000
 authorized, 
no
 shares issued and 
   outstanding at September 30, 2025 and December 31, 2024

—

—

Additional paid-in capital

1,931,616

1,866,850

Accumulated deficit

(
108,569

)

(
222,155

)

Accumulated other comprehensive (loss) income

(
6,291

)

1,418

Total shareholders' equity

1,818,563

1,647,855

Noncontrolling interest

94

—

Total equity

1,818,657

1,647,855

Total liabilities, redeemable noncontrolling interest, and equity

$

6,049,497

$

5,926,140

See accompanying notes to the condensed consolidated financial statements.

3

BrightSpring Health Services, Inc. and Subsidiaries
Condensed Consolidated S
tatements of Operations
(In thousands, except per share amounts)
(Unaudited)

For the Three Months Ended

For the Nine Months Ended

September 30,

September 30,

2025

2024

2025

2024

Revenues:

Products

$

2,966,966

$

2,265,697

$

8,289,238

$

6,357,223

Services

367,140

335,532

1,070,695

968,026

Total revenues

3,334,106

2,601,229

9,359,933

7,325,249

Cost of goods

2,721,314

2,077,121

7,605,931

5,815,981

Cost of services

220,784

201,016

648,773

581,509

Gross profit

392,008

323,092

1,105,229

927,759

Selling, general, and administrative expenses

304,165

293,995

918,090

875,344

Operating income

87,843

29,097

187,139

52,415

Loss on extinguishment of debt

—

—

—

12,726

Interest expense, net

38,235

46,614

118,776

144,366

Income (loss) from continuing operations before income taxes

49,608

(
17,517

)

68,363

(
104,677

)

Income tax expense (benefit)

12,120

8,155

13,118

(
31,464

)

Income (loss) from continuing operations, net of income taxes

37,488

(
25,672

)

55,245

(
73,213

)

Income from discontinued operations, net of income taxes

17,753

16,691

56,548

37,288

Net income (loss)

55,241

(
8,981

)

111,793

(
35,925

)

Net loss attributable to noncontrolling interests included in 
   continuing operations

(
595

)

(
751

)

(
1,793

)

(
1,864

)

Net income (loss) attributable to BrightSpring Health Services, Inc. 
   and subsidiaries

$

55,836

$

(
8,230

)

$

113,586

$

(
34,061

)

Net income (loss) per common share (Note 10):

Basic income (loss) per share attributable to common shareholders:

Continuing operations

$

0.19

$

(
0.13

)

$

0.28

$

(
0.37

)

Discontinued operations

$

0.08

$

0.09

$

0.28

$

0.19

Net income (loss)

$

0.27

$

(
0.04

)

$

0.56

$

(
0.18

)

Diluted income (loss) per share attributable to common shareholders:

Continuing operations

$

0.17

$

(
0.13

)

$

0.26

$

(
0.37

)

Discontinued operations

$

0.09

$

0.09

$

0.26

$

0.19

Net income (loss)

$

0.26

$

(
0.04

)

$

0.52

$

(
0.18

)

Weighted average shares outstanding:

Basic

203,487

198,491

202,067

190,541

Diluted

217,982

198,491

218,519

190,541

See accompanying notes to the condensed consolidated financial statements.

4

BrightSpring Health Services, Inc. and Subsidiaries
Condensed Consolidated Statements of 
Comprehensive Income (Loss)
(In thousands)
(Unaudited)

For the Three Months Ended

For the Nine Months Ended

September 30,

September 30,

2025

2024

2025

2024

Net income (loss)

$

55,241

$

(
8,981

)

$

111,793

$

(
35,925

)

Other comprehensive loss, net of tax:

Foreign currency translation adjustments

(
97

)

72

111

(
123

)

Cash flow hedges:

Net change in fair value, net of tax 
(1)

1,570

(
12,429

)

2,292

8,675

Amounts reclassified to earnings, net of tax 
(2)

(
3,434

)

(
7,373

)

(
10,112

)

(
21,801

)

Total other comprehensive loss, net of tax

(
1,961

)

(
19,730

)

(
7,709

)

(
13,249

)

Total comprehensive income (loss)

53,280

(
28,711

)

104,084

(
49,174

)

Comprehensive loss attributable to redeemable noncontrolling 
   interests

(
455

)

(
573

)

(
1,370

)

(
1,395

)

Comprehensive loss attributable to noncontrolling interest

(
140

)

(
178

)

(
423

)

(
469

)

Comprehensive income (loss) attributable to BrightSpring 
   Health Services, Inc. and subsidiaries

$

53,875

$

(
27,960

)

$

105,877

$

(
47,310

)

(1)
The income tax effects of the net change in fair value were 
$(
510
)
 and 
$(
744
)
 for the three and nine months ended September 30, 2025, respectively, and 
$
4,024
 and 
$(
2,809
)
 for the three and nine months ended September 30, 2024, respectively.
(2)
The income tax effects of amounts reclassified to earnings were 
$
1,114
 and 
$
3,281
 for the three and nine months ended September 30, 2025, respectively, and 
$
2,387
 and 
$
7,059
 for the three and nine months ended September 30, 2024, respectively. 
See accompanying notes to the condensed consolidated financial statements.

5

BrightSpring Health Services, Inc. and Subsidiaries
Condensed Consolidated Statements of 
Shareholders’ Equity
(In thousands, except share data)
(Unaudited)

For the Three Months Ended September 30, 2025

Common Stock

Additional 
Paid-In Capital

Accumulated Deficit

Accumulated Other 
Comprehensive Loss

Noncontrolling
Interest

Total

Shares

Amount

Balances at June 30, 2025

177,055,327

$

1,771

$

1,909,854

$

(
164,405

)

$

(
4,330

)

$

(
283

)

$

1,742,607

Net income 
(1)

—

—

—

55,836

—

377

56,213

Other comprehensive loss, net of tax

—

—

—

—

(
1,961

)

—

(
1,961

)

Share-based compensation

—

—

17,250

—

—

—

17,250

Exercise of stock options

735,483

7

5,612

—

—

—

5,619

Issuance of common stock for settlement 
    of RSUs

115,810

1

(
1

)

—

—

—

—

Tax effect of net share settlement of equity 
    awards

(
52,203

)

—

(
1,071

)

—

—

—

(
1,071

)

Conversion of tangible equity units into 
   common stock

2,831,467

28

(
28

)

—

—

—

—

Balances at September 30, 2025

180,685,884

$

1,807

$

1,931,616

$

(
108,569

)

$

(
6,291

)

$

94

$

1,818,657

For the Three Months Ended September 30, 2024

Common Stock

Additional 
Paid-In Capital

Accumulated Deficit

Accumulated Other Comprehensive Income (Loss)

Noncontrolling
Interest

Total

Shares

Amount

Balances at June 30, 2024

171,397,030

$

1,714

$

1,804,965

$

(
226,150

)

$

19,025

$

379

$

1,599,933

Net loss 
(1)

—

—

—

(
8,230

)

—

(
178

)

(
8,408

)

Other comprehensive loss, net of tax

—

—

—

—

(
19,730

)

—

(
19,730

)

Share-based compensation

—

—

15,210

—

—

—

15,210

Shares issued under share-based compensation
    plan, including tax effects

210,696

2

507

—

—

—

509

Shares issued for payment of acquisition

2,471,251

25

29,975

—

—

—

30,000

Derecognition of redeemable noncontrolling 
    interest

—

—

(
2,542

)

—

—

—

(
2,542

)

Balances at September 30, 2024

174,078,977

$

1,741

$

1,848,115

$

(
234,380

)

$

(
705

)

$

201

$

1,614,972

(1)
 Net income (loss) to the Company for the three months ended September 30, 2025 and 2024 excludes 
$(
455
)
 and 
$(
573
)
, respectively, allocable to the redeemable noncontrolling interests for our joint venture arrangements.

6

BrightSpring Health Services, Inc. and Subsidiaries
Condensed Consolidated Statements of Shareholders’ Equity (continued)
(In thousands, except share data)
(Unaudited)

For the Nine Months Ended September 30, 2025

Common Stock

Additional 
Paid-In Capital

Accumulated Deficit

Accumulated Other Comprehensive Income (Loss)

Noncontrolling
Interest

Total

Shares

Amount

Balances at December 31, 2024

174,245,990

$

1,742

$

1,866,850

$

(
222,155

)

$

1,418

$

—

$

1,647,855

Net income 
(1)

—

—

—

113,586

—

94

113,680

Other comprehensive loss, net of tax

—

—

—

—

(
7,709

)

—

(
7,709

)

Share-based compensation

—

—

55,733

—

—

—

55,733

Exercise of stock options

2,055,618

21

14,660

—

—

—

14,681

Issuance of common stock for settlement 
    of RSUs

1,817,356

18

(
18

)

—

—

—

—

Tax effect of net share settlement of equity 
    awards

(
264,547

)

(
2

)

(
5,581

)

—

—

—

(
5,583

)

Conversion of tangible equity units into 
   common stock

2,831,467

28

(
28

)

—

—

—

—

Balances at September 30, 2025

180,685,884

$

1,807

$

1,931,616

$

(
108,569

)

$

(
6,291

)

$

94

$

1,818,657

For the Nine Months Ended September 30, 2024

Common Stock

Additional 
Paid-In Capital

Accumulated Deficit

Accumulated Other Comprehensive Income (Loss)

Noncontrolling
Interest

Total

Shares

Amount

Balances at December 31, 2023

117,857,055

$

1,179

$

771,336

$

(
200,319

)

$

12,544

$

670

$

585,410

Net loss 
(1)

—

—

—

(
34,061

)

—

(
469

)

(
34,530

)

Other comprehensive loss, net of tax

—

—

—

—

(
13,249

)

—

(
13,249

)

Share-based compensation

—

—

55,194

—

—

—

55,194

Shares issued under share-based compensation
    plan, including tax effects

318,085

3

528

—

—

—

531

Shares issued for payment of acquisition

2,570,503

26

31,055

—

—

—

31,081

Derecognition of redeemable noncontrolling 
    interest

—

—

12,439

—

—

—

12,439

Issuance of common stock on initial public 
    offering, net 
(2)

53,333,334

533

655,952

—

—

—

656,485

Proceeds from stock purchase contract 
    issued under tangible equity units, net 
(3)

—

—

321,611

—

—

—

321,611

Balances at September 30, 2024

174,078,977

$

1,741

$

1,848,115

$

(
234,380

)

$

(
705

)

$

201

$

1,614,972

(1)
 Net income (loss) to the Company for the nine months ended September 30, 2025 and 2024 excludes 
$(
1,370
)
 and 
$(
1,395
)
, respectively, allocable to the redeemable noncontrolling interests for our joint venture arrangements.
(2) 
Issuance of common stock on initial public offering is presented net of underwriting discounts and commissions, and offering-related expenses of $
36.8
 million.
(3)
 Proceeds from stock purchase contract issued under tangible equity units is presented net of underwriting discounts and commissions of $
9.1
 million.

7

BrightSpring Health Services, Inc. and Subsidiaries
Condensed Consolidated St
atements of Cash Flows

(In thousands)
(Unaudited)

For the Nine Months Ended

September 30,

2025

2024

Operating activities:

Net income (loss)

$

111,793

$

(
35,925

)

Adjustments to reconcile net income (loss) to cash provided by (used in) operating activities:

Depreciation and amortization

124,753

149,601

Impairment of long-lived assets

6,526

4,781

Change in fair value of contingent consideration, net

(
1,266

)

—

Payment of contingent consideration in excess of acquisition date fair value

(
6,170

)

—

Provision for credit losses

48,723

21,896

Amortization of deferred debt issuance costs

8,384

9,477

Share-based compensation

55,733

55,194

Deferred income taxes, net

18,266

(
27,781

)

Loss on extinguishment of debt

—

12,726

Loss (gain) on disposition of fixed assets

1,503

(
55

)

Other

(
1,838

)

(
959

)

Change in operating assets and liabilities, net of acquisitions:

        Accounts receivable

(
162,689

)

(
163,996

)

        Prepaid expenses and other current assets

24,857

(
2,470

)

        Inventories

(
2,279

)

(
74,265

)

        Trade accounts payable

42,836

155,563

        Accrued expenses

17,212

(
150,032

)

        Other assets and liabilities

(
27,734

)

(
20,593

)

Net cash provided by (used in) operating activities

$

258,610

$

(
66,838

)

Investing activities:

Purchases of property and equipment

$

(
57,819

)

$

(
65,602

)

Acquisitions of businesses

(
8,308

)

(
59,755

)

Other

(
5,068

)

900

Net cash used in investing activities

$

(
71,195

)

$

(
124,457

)

Financing activities:

Long-term debt borrowings

$

—

$

2,566,000

Long-term debt repayments

(
37,933

)

(
3,384,633

)

Proceeds from issuance of common stock on initial public offering, net

—

656,485

Proceeds from issuance of tangible equity units, net

—

389,000

(Repayments) borrowings of the Revolving Credit Facility, net

(
63,300

)

46,400

Payments of debt issuance costs

—

(
43,188

)

Repurchase of shares of common stock

—

(
650

)

Proceeds from shares issued under share-based compensation plan

14,681

531

Taxes paid related to net share settlement of equity awards

(
5,583

)

—

Payment of acquisition earn-outs

—

(
4,156

)

Purchase of redeemable noncontrolling interest

(
5,100

)

(
2,316

)

Payments of financing lease obligations

(
10,133

)

(
9,276

)

Net cash (used in) provided by financing activities

$

(
107,368

)

$

214,197

Net increase in cash and cash equivalents

80,047

22,902

Cash and cash equivalents at beginning of period

61,253

13,071

Cash and cash equivalents at end of period

$

141,300

$

35,973

Cash and cash equivalents included in assets held for sale at end of period

956

427

Cash and cash equivalents included in continuing operations at end of period

$

140,344

$

35,546

8

BrightSpring Health Services, Inc. and Subsidiaries
Condensed Consolidated Statements of Cash Flows (continued)
(In thousands)
(Unaudited)

For the Nine Months Ended

September 30,

2025

2024

Supplemental disclosures of cash flow information:

Cash paid for:

Interest, net

$

137,872

$

164,927

Income taxes, net of refunds

$

14,851

$

24,312

Supplemental schedule of non-cash investing and financing activities:

Notes issued in connection with acquisitions

$

—

$

23,408

Financing lease obligations assumed

$

10,452

$

9,625

Purchases of property and equipment in accounts payable

$

2,856

$

3,593

Consideration for purchase of redeemable noncontrolling interest in accounts payable

$

—

$

5,100

Common stock issued in connection with acquisitions

$

—

$

31,081

See accompanying notes to the condensed consolidated financial statements.

9

Index to Notes to Condensed Consolidated Financial Statements

Page

Note 1 - Significant Accounting Policies

11

Note 2 - Discontinued Operations

13

Note 3 - Revenue

14

Note 4 - Acquisitions

15

Note 5 - Goodwill and Intangible Assets

17

Note 6 - Debt and Derivatives

18

Note 7 - TEUs

20

Note 8 - Income Taxes

21

Note 9 - Detail of Certain Balance Sheet Accounts

21

Note 10 - Earnings Per Share

22

Note 11 - Common Stock, Preferred Stock, and Share-Based Compensation

24

Note 12 - Fair Value

24

Note 13 - Commitments and Contingencies

25

Note 14 - Related Party Transactions

25

Note 15 - Segment Information

26

10

BrightSpring Health Services, Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
1. Significant Accounting Policies
Description of Business
BrightSpring Health Services, Inc. and its subsidiaries (“BrightSpring”, the “Company”, “we,” “us,” or “our”) is a leading home and community-based healthcare services platform, focused on delivering complementary pharmacy and provider services to complex patients. Our platform delivers clinical services and pharmacy solutions across Medicare, Medicaid, and commercially-insured populations.
On December 7, 2017, affiliates of Kohlberg Kravis Roberts & Co. L.P. (“KKR” or “KKR Stockholder”) and Walgreens Boots Alliance, Inc. (“WBA”) purchased PharMerica Corporation (“PharMerica”) and on March 5, 2019, expanded with the acquisition of BrightSpring Health Holdings Corp. The surviving entity was renamed BrightSpring Health Services, Inc.
BrightSpring Health Services, Inc. completed its initial public offering (“IPO”) of 
53,333,334
 shares of its common stock at a price of $
13.00
 per share and its concurrent offering of 
8,000,000

6.75
% tangible equity units (“TEUs”) with a stated amount of $
50.00
 per unit in January 2024 (collectively, “the IPO Offerings”). The net proceeds from the IPO Offerings amounted to $
656.5
 million and $
389.0
 million for the common stock and TEUs, respectively, after deducting underwriting discounts and commissions, and offering-related expenses.

On January 17, 2025, the Company entered into a purchase agreement to divest its community living services, home and community based waiver programs, and intermediate care facilities (the “Community Living business”). The transaction is subject to customary closing conditions and certain other antitrust laws, and is expected to close in the first fiscal quarter of 2026.

During the second quarter of 2025, WBA sold their remaining ownership interests in the Company through open market transactions and is no longer considered a related party of the Company. In June 2025, KKR Stockholder and certain management selling stockholders completed a registered secondary public offering of the Company’s common stock. The Company did not purchase or sell any shares of common stock that were offered in the secondary public offering. The Company did not receive any proceeds from the secondary public offering, other than proceeds received in connection with the cash exercise of stock options by the management selling stockholders in connection with the secondary public offering. As a result of the aforementioned transactions, the Company no longer qualifies as a “controlled company” under the Nasdaq Stock Market LLC listing standards and is therefore required to comply with all applicable corporate governance requirements of Nasdaq, subject to phase-in rules.
On October 22, 2025, KKR Stockholder and certain management selling stockholders completed a registered secondary public offering of 
15,000,000
 shares of the Company’s common stock (the “October 2025 Offering”). The Company did not sell any shares of common stock that were offered in the October 2025 Offering. The Company did not receive any proceeds from the October 2025 Offering, other than proceeds received in connection with the cash exercise of stock options by the management selling stockholders in connection with the October 2025 Offering.
In connection with the October 2025 Offering, the Company concurrently purchased from the underwriter, out of the aggregate of 
15,000,000
 shares of common stock that were the subject of the October 2025 Offering, 
1,500,000
 shares of common stock. The price per share paid by the Company was equal to the price at which the underwriter purchased the shares from the selling stockholders in the October 2025 Offering.
Principles of Consolidation
The accompanying unaudited condensed consolidated financial statements include the accounts of BrightSpring Health Services, Inc. and its subsidiaries. The Company consolidates its majority-owned and controlled entities, including variable interest entities (“VIEs”) for which the Company is the primary beneficiary. All intercompany balances and transactions have been eliminated.
We record a noncontrolling interest for the allocable portion of income or loss and comprehensive income or loss to which the noncontrolling interest holders are entitled based upon their ownership share of the affiliate. The Company determined noncontrolling interests for certain of these VIEs to be redeemable noncontrolling interests, which are presented in the unaudited condensed consolidated balance sheets as redeemable noncontrolling interests.
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting solely of normal recurring adjustments) necessary to present fairly our financial position, our results of operations, and our cash flows in accordance

11

with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial reporting. Our results of operations for the interim periods presented are not necessarily indicative of the results of our operations for the entire year.
As a result of the Company's plan to divest the Community Living business discussed in Note 2, the Community Living business met the criteria to be reported as discontinued operations and held for sale during the first fiscal quarter of 2025. Therefore, the Company has reported the historical results of the Community Living business, including the results of operations, cash flows, and related assets and liabilities, as discontinued operations and held for sale for all periods presented herein. Unless otherwise noted, all activities and amounts reported in the accompanying notes to the unaudited condensed consolidated financial statements relate to the continuing operations of the Company and exclude activities and amounts related to the Community Living business.
This report should be read in conjunction with our consolidated financial statements and related notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2024, as well as the revised and recasted consolidated financial statements and related notes thereto for the year ended December 31, 2024 that reflect the Community Living business as discontinued operations included in our Current Report on Form 8-K as filed on June 10, 2025, which includes information and disclosures not included herein. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from the interim financial information presented, as allowed by the rules and regulations of the Securities and Exchange Commission.
Use of Estimates
The preparation of consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts and related disclosures. We rely on historical experience and on various other assumptions that we believe to be reasonable under the circumstances to make judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Significant estimates are involved in the valuation of accounts receivable, inventory, long-lived assets, intangible assets, derivatives, contingent consideration, taxes, insurance reserves, share-based compensation, and goodwill. Actual amounts may differ from these estimates.
Recently Adopted Accounting Standards

There were no new accounting standards adopted during the nine months ended September 30, 2025
.
Recently Issued Accounting Standards
In December 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-09, 
Income Taxes (Topic 740): Improvements to Income Tax Disclosures
. This ASU requires the following disclosures on an annual basis:

•
A tabular rate reconciliation using both percentages and amounts, broken out into specific categories with certain reconciling items at or above 5% of the statutory tax further broken out by nature and/or jurisdiction; 
•
Qualitative disclosure of the nature and effect of significant reconciling items by specific categories and individual jurisdictions; and 
•
Income taxes paid (net of refunds received), broken out between federal, state/local and foreign, and amounts paid to an individual jurisdiction when 5% or more of the total income taxes paid. 
The amendments in this ASU are effective for annual periods beginning after December 15, 2024, with early adoption permitted, and should be applied on a prospective basis. This ASU will have no impact on the Company’s consolidated financial condition or results of operations. The Company is currently evaluating the impact to the income tax disclosures.
In November 2024, the FASB issued ASU 2024-03, 
Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses
, which was further clarified in January 2025 through the issuance of ASU 2025-01. These ASUs require new financial statement disclosures to provide disaggregated information for certain types of expenses, including purchases of inventory, employee compensation, depreciation, and amortization in commonly presented expense captions such as cost of goods and services and selling, general, and administrative expenses. The amendments in these ASUs are effective for annual periods beginning after December 15, 2026, with early adoption permitted. The adoption of this guidance will have no impact on the Company's consolidated financial condition or results of operations. The Company is currently evaluating the impact to the related disclosures.
In September 2025, the FASB issued ASU 2025-06,
 Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software
, 
which modernizes the accounting for internal-use software costs by removing all references to prescriptive and sequential software development stages. The new standard requires entities to consider whether significant development uncertainty has been resolved before starting to capitalize software costs and aligns disclosure requirements with ASC 360, Property, Plant, and Equipment. The ASU is effective for annual and interim reporting periods beginning

12

after 
December 15, 2027, and can be applied prospectively, retrospectively, or using a modified transition method, with early adoption permitted. The Company is currently evaluating the impacts of this guidance on the consolidated financial statements and related disclosures.
2. Discontinued Operations
On January 17, 2025, BrightSpring entered into a definitive agreement to sell its Community Living business to National Mentor Holdings, Inc. (the “Purchaser”), for $
835.0
 million in cash upon closing, subject to certain post-closing adjustments. We entered into the transaction in order to streamline our service offerings and further focus on the senior and specialty populations. The transaction is expected to close in the first fiscal quarter of 2026, subject to receipt of customary regulatory approvals and satisfaction of other closing conditions.
The Company has determined the divestiture of the Community Living business represents a strategic shift that will have a major effect on its business and has concluded the criteria for classification as discontinued operations were met during the first fiscal quarter of 2025. Accordingly, the Community Living business is reported as discontinued operations in accordance with Accounting Standards Codification (“ASC”) 205-20, 
Discontinued Operations
. The related assets and liabilities of the Community Living business are classified as assets and liabilities held for sale in the accompanying unaudited condensed consolidated balance sheet as of September 30, 2025, and the results of operations from the Community Living business are classified as discontinued operations in the unaudited condensed consolidated statements of operations. Applicable amounts in prior years have been recast to conform to this discontinued operations presentation. The Community Living business was historically presented as a part of the Provider Services reportable segment.
In accordance with ASC 205-20, 
Allocation of Interest to Discontinued Operations
, the Company elected to allocate interest expense to discontinued operations for the Company’s debt that is not directly attributed to the Community Living business. Interest expense was allocated based on a ratio of net assets held for sale to the sum of consolidated net assets and consolidated debt. In addition, upon closing of the divestiture, we will enter into a transition services agreement with the Purchaser to support the Purchaser's post-closing operations of the Community Living business by providing the Purchaser with certain transition services in exchange for service fees in the form of both fixed-price and pass through costs. Transition services will primarily include finance and accounting, human resources, IT, facilities management, and compliance services.
The financial results of the Community Living business are presented as income from discontinued operations on our unaudited condensed consolidated statements of operations through September 30, 2025
. 
The following table presents the financial results of the Community Living business (in thousands):

For the Three Months Ended

For the Nine Months Ended

September 30,

September 30,

2025

2024

2025

2024

Services revenue

$

314,605

$

305,594

$

921,394

$

888,422

Cost of services

212,251

220,574

628,048

649,645

Gross profit

102,354

85,020

293,346

238,777

Selling, general, and administrative expenses

70,940

57,277

195,423

163,871

Operating income of discontinued operations

31,414

27,743

97,923

74,906

Interest expense, net

7,404

9,447

22,901

29,154

Income of discontinued operations before incomes taxes

24,010

18,296

75,022

45,752

Income tax expense of discontinued operations

6,257

1,605

18,474

8,464

Income from discontinued operations, net of income taxes

$

17,753

$

16,691

$

56,548

$

37,288

13

The following table presents the aggregate carrying amounts of assets and liabilities held for sale for the Community Living business in the unaudited condensed consolidated balance sheets (in thousands):

September 30, 2025

December 31, 2024

Assets

Current assets:

Cash and cash equivalents

$

956

$

299

Accounts receivable, net of allowance for credit losses

129,707

125,872

Inventories

3,652

4,007

Prepaid expenses and other current assets

3,112

1,269

Total current assets held for sale

137,427

131,447

Property and equipment, net of accumulated depreciation of $
104,774
 and $
110,417
 at 
    September 30, 2025 and December 31, 2024, respectively

78,145

69,715

Goodwill

307,640

307,640

Intangible assets, net of accumulated amortization

216,192

216,258

Operating lease right-of-use assets, net

121,676

88,717

Deferred income taxes, net

287

287

Other assets

2,479

5,343

Total assets held for sale

$

863,846

$

819,407

Liabilities

Current liabilities:

Trade accounts payable

$

20,860

$

17,366

Accrued expenses

61,296

60,791

Current portion of obligations under operating leases

33,095

30,755

Current portion of obligations under financing leases

7,716

8,651

Total current liabilities held for sale

122,967

117,563

Obligations under operating leases, net of current portion

60,056

58,147

Obligations under financing leases, net of current portion

13,068

18,461

Long-term liabilities

522

569

Total liabilities held for sale

$

196,613

$

194,740

In accordance with ASC 205-20, all assets and liabilities held for sale are reported as current at September 30, 2025 as the Community Living transaction is expected to close within one-year of the balance sheet date. The presentation of assets and liabilities held for sale at December 31, 2024 are reported as current and noncurrent, consistent with the conclusion in the period, as the transaction did not meet the requirements of held for sale at that point in time.
The following table presents the significant non-cash items and purchases of property and equipment for the discontinued operations that are included in the accompanying unaudited condensed consolidated statements of cash flows (in thousands):

For the Nine Months Ended

September 30,

2025

2024

Cash flows from discontinued operations operating activities:

Depreciation and amortization

$

1,329

$

30,132

Share-based compensation

9,578

5,402

Impairment of long-lived assets

—

3,020

Cash flows from discontinued operations investing activities:

Purchases of property and equipment

8,755

7,708

3. Revenue
The Company is substantially dependent on revenues received under contracts with federal, state, and local government agencies. Operating funding sources are generally earned from Medicaid, Medicare, commercial insurance reimbursement, and from private and other payors. There is 
no
 single customer whose revenue was 10% or more of our consolidated revenue during the periods presented. 
The following tables set forth revenue by payor type (in millions):

14

Pharmacy Solutions

For the Three Months Ended September 30,

For the Nine Months Ended September 30,

2025

2024

2025

2024

Revenue

% of Revenue

Revenue

% of Revenue

Revenue

% of Revenue

Revenue

% of Revenue

Commercial insurance

$

818.3

24.5

%

$

619.1

23.8

%

$

2,234.8

23.9

%

$

1,693.7

23.1

%

Medicaid

287.4

8.6

%

213.9

8.2

%

791.8

8.5

%

600.9

8.2

%

Medicare A

143.0

4.3

%

141.9

5.5

%

422.3

4.5

%

399.0

5.4

%

Medicare B

18.7

0.6

%

16.8

0.6

%

56.9

0.6

%

50.4

0.7

%

Medicare C

593.0

17.8

%

406.1

15.6

%

1,636.3

17.5

%

1,120.9

15.3

%

Medicare D

1,058.4

31.7

%

826.2

31.8

%

2,977.7

31.8

%

2,352.5

32.1

%

Private & other

48.2

1.5

%

41.7

1.6

%

169.4

1.8

%

139.8

2.0

%

$

2,967.0

89.0

%

$

2,265.7

87.1

%

$

8,289.2

88.6

%

$

6,357.2

86.8

%

Provider Services

For the Three Months Ended September 30,

For the Nine Months Ended September 30,

2025

2024

2025

2024

Revenue

% of Revenue

Revenue

% of Revenue

Revenue

% of Revenue

Revenue

% of Revenue

Commercial insurance

$

51.3

1.5

%

$

41.9

1.6

%

$

136.8

1.5

%

$

125.0

1.7

%

Medicaid

128.3

3.8

%

84.9

3.3

%

301.9

3.2

%

251.4

3.4

%

Medicare A

127.0

3.8

%

114.3

4.4

%

375.2

4.0

%

327.2

4.5

%

Medicare B

1.7

0.1

%

3.7

0.1

%

4.6

0.0

%

18.7

0.3

%

Medicare C

28.8

0.9

%

36.0

1.4

%

96.0

1.0

%

84.3

1.2

%

Private & other

30.0

0.9

%

54.7

2.1

%

156.2

1.7

%

161.4

2.1

%

$

367.1

11.0

%

$

335.5

12.9

%

$

1,070.7

11.4

%

$

968.0

13.2

%

Consolidated

For the Three Months Ended September 30,

For the Nine Months Ended September 30,

2025

2024

2025

2024

Revenue

% of Revenue

Revenue

% of Revenue

Revenue

% of Revenue

Revenue

% of Revenue

Commercial insurance

$

869.6

26.0

%

$

661.0

25.4

%

$

2,371.6

25.4

%

$

1,818.7

24.8

%

Medicaid

415.7

12.4

%

298.8

11.5

%

1,093.7

11.7

%

852.3

11.6

%

Medicare A

270.0

8.1

%

256.2

9.9

%

797.5

8.5

%

726.2

9.9

%

Medicare B

20.4

0.7

%

20.5

0.7

%

61.5

0.6

%

69.1

1.0

%

Medicare C

621.8

18.7

%

442.1

17.0

%

1,732.3

18.5

%

1,205.2

16.5

%

Medicare D

1,058.4

31.7

%

826.2

31.8

%

2,977.7

31.8

%

2,352.5

32.1

%

Private & other

78.2

2.4

%

96.4

3.7

%

325.6

3.5

%

301.2

4.1

%

$

3,334.1

100.0

%

$

2,601.2

100.0

%

$

9,359.9

100.0

%

$

7,325.2

100.0

%

Refer to Note 15 for the disaggregation of revenue by reportable segment.

4. Acquisitions
2025 Acquisitions
During the nine months ended September 30, 2025
, we completed 
two
 acquisitions within the Provider Services segment for aggregate consideration of $
8.5
 million. We entered these transactions in order to expand our services and geographic offerings. No cash was acquired as a part of these transactions. The operating results of the acquisitions are included in our unaudited condensed consolidated financial statements from the date of the acquisition and are not material to our results of operations.

2024 Acquisitions
During the year ended December 31, 2024, we completed 
eight
 acquisitions within the Pharmacy Solutions and Provider Services segments. We entered into these transactions in order to expand our services and geographic offerings. Aggregate consideration net of cash acquired for these acquisitions was approximately $
110.6
 million. The operating results of these acquisitions are included in our unaudited condensed consolidated financial statements from the respective dates of the acquisition.

15

Haven Hospice
The following table summarizes the consideration paid (in thousands) for the September 1, 2024 acquisition of North Central Florida Hospice, Inc. (
“
Haven Hospice
”
) and the fair value of the assets acquired and the liabilities assumed at the acquisition date, which were adjusted for immaterial measurement-period adjustments through September 1, 2025. Haven Hospice provides hospice and palliative care services in the state of Florida. Its results are consolidated within the Provider Services segment.

Inventories

$

45

Property and equipment

495

Goodwill

45,614

Intangible assets

19,860

Operating lease right-of-use assets

7,157

Trade accounts payable

1,264

Current portion of obligations under operating leases

2,235

Obligations under operating leases, net of current portion

4,922

Aggregate purchase price

$

64,750

Consideration for the Haven Hospice acquisition included a $
15.0
 million cash payment, $
15.0
 million seller note payable in 2028, and $
30.0
 million of the Company's common stock equal to 
2,471,251
 shares at the time of the acquisition. The number of shares was calculated by dividing $
30.0
 million by a price per share equal to the average of the volume weighted average trading price of the Company's common stock on each of the fifteen consecutive trading days ending on and including the trading day that is three trading days prior to the closing date, as required by the asset purchase agreement. The sellers were restricted from trading during a 
180-day
 lock-up period from closing with agreed-upon sale volume limitations for four years thereafter. The asset purchase agreement also includes a post-closing adjustment feature to the extent any losses are incurred by the sellers in the sale of their common stock for four years following closing 
with a final equity adjustment feature. See Note 12.
The intangible assets consist of $
14.8
 million in indefinite-lived licenses and $
5.1
 million of trade name. The fair value of acquired licenses and trade name were based upon a third-party valuation. The trade name has an estimated useful life of 
10.0
 years. We expect all of the goodwill will be deductible for tax purposes. The Company believes the resulting amount of goodwill reflects its expectation of synergistic benefits of the acquisition.

Haven Hospice contributed $
17.7
 million and $
50.1
 million in revenue during the three and nine months ended 
September 30, 2025
, respectively, compared to $
4.8
 million in revenue during the three and nine months ended 
September 30, 2024
. Haven Hospice contributed $
1.9
 million and $
5.1
 million of operating income during the three and nine months ended 
September 30, 2025
, respectively, compared to $
0.6
 million of operating income during the three and nine months ended 
September 30, 2024. Pro forma financial data for the Haven Hospice acquisition has not been included as the results of the operations are not material to our unaudited condensed consolidated financial statements.

Others
The following table summarizes the consideration paid (in thousands) for 2024 acquisitions, excluding Haven Hospice, and the estimated fair value of the assets acquired and the liabilities assumed at the acquisition dates, which are adjusted for immaterial measurement-period adjustments through 
September 30, 2025
. Consideration for acquisitions by the Pharmacy Solutions and Provider Services segments was $
27.0
 million and $
18.9
 million, respectively.

16

Accounts receivable

$

3,749

Inventories

1,234

Prepaid expenses and other current assets

174

Property and equipment

398

Goodwill

17,721

Intangible assets

31,233

Operating lease right-of-use assets

364

Other assets

1,438

Trade accounts payable

650

Accrued expenses

7,657

Current portion of obligations under operating leases

56

Current portion of obligations under financing leases

53

Obligations under operating leases, net of current portion

308

Obligations under financing leases, net of current portion

8

Deferred income taxes, net

1,686

Aggregate purchase price, net of cash acquired

$

45,893

We have estimated the fair value of acquired customer relationships, licenses, trade names, and covenants not to compete based upon third-party valuations and/or the values assigned in prior acquisitions that were deemed comparable in nature. The intangible assets consist primarily of $
22.3
 million in customer relationships, $
5.7
 million in definite-lived licenses, $
2.1
 million in indefinite-lived licenses, $
0.6
 million in covenants not to compete, and $
0.5
 million in trade names. Definite-lived intangible assets have an estimated weighted average useful life of 
14.9
 years. We expect 
$
12.0
 million
 of the goodwill will be deductible for tax purposes. The Company believes the resulting amount of goodwill reflects its expectation of synergistic benefits of the acquisitions.
The above acquisitions contributed approximately $
20.5
 million and $
62.3
 million in revenue during the three and nine months ended 
September 30, 2025
, respectively, compared to $
21.8
 million and $
37.7
 million in revenue during the three and nine months ended 
September 30, 2024
. The above acquisitions contributed approximately $
0.3
 million and $
3.1
 million in operating income during the three and nine months ended 
September 30, 2025
, respectively, compared to $
2.0
 million and $
3.0
 million in operating income during the three and nine months ended 
September 30, 2024. Pro forma financial data for the 2024 acquisitions has not been included as the results of the operations are not material to our unaudited condensed consolidated financial statements.
Measurement period adjustments for all aforementioned acquisitions completed in 2024 recorded in the three and nine months ended September 30, 2025 were not material to the unaudited condensed consolidated financial statements. The Company expects to finalize the purchase price allocation for the 2024 acquisitions prior to the one-year anniversary date of each acquisition.
During the three and nine months ended September 30, 2024
, the Company incurred approximately $
0.2
 million and $
2.1
 million in transaction costs, respectively, related to all 2024 acquisitions, including those acquisitions completed in subsequent quarters of 2024. These costs are included in selling, general, and administrative expenses in our unaudited condensed consolidated statements of operations.
The Company also agreed to purchase the remaining 
30
% noncontrolling interest in Gateway Pediatric Therapy, LLC during the first fiscal quarter of 2024 and the remaining 
45
% noncontrolling interest in Harvest Grove LTC, LLC during the third fiscal quarter of 2024. These transactions did not meet the definition of a business combination in accordance with ASC 805
, Business Combinations
.
5. Goodwill and Intangible Assets
A summary of changes to goodwill, by reportable segment, is as follows (in thousands):

Goodwill

Pharmacy Solutions

Provider Services

Total

Goodwill at January 1, 2025*

$

841,052

$

1,522,832

$

2,363,884

Goodwill added through acquisitions

—

6,430

6,430

Measurement period adjustments

—

128

128

Foreign currency adjustments

—

124

124

Goodwill at September 30, 2025*

$

841,052

$

1,529,514

$

2,370,566

* For the periods presented, the carrying amount of goodwill is presented net of accumulated impairment losses of $
40.9
 million.

17

Intangible assets are as follows (in thousands):

September 30, 2025

December 31, 2024

Gross

Accumulated
Amortization

Net Carrying 
Value

Gross

Accumulated
Amortization

Net Carrying 
Value

Life
(Years)

Customer relationships

$

517,753

$

354,982

$

162,771

$

542,137

$

335,647

$

206,490

5
-
20

Trade names

328,968

156,431

172,537

332,977

140,020

192,957

2
-
20

Licenses

60,515

17,970

42,545

68,425

17,528

50,897

10
-
20

Doctor/payor network

5,650

4,800

850

12,730

10,965

1,765

5
-
8

Covenants not to compete

6,874

4,605

2,269

8,790

5,886

2,904

2
-
7

Other intangible assets

10,940

7,535

3,405

10,940

6,362

4,578

5
-
7

Total definite-lived assets

$

930,700

$

546,323

$

384,377

$

975,999

$

516,408

$

459,591

Licenses

137,233

—

137,233

135,633

—

135,633

Indefinite

Total intangible assets

$

1,067,933

$

546,323

$

521,610

$

1,111,632

$

516,408

$

595,224

Amortization expense for the three and nine months ended September 30, 2025 was 
$
22.7
 million
 and 
$
69.7
 million
, respectively, as compared to 
$
24.1
 million
 and 
$
72.0
 million
 for the three and nine months ended September 30, 2024
, respectively.
6. Debt and Derivatives
The table below summarizes the total outstanding debt of the Company (in thousands):

September 30, 2025

December 31, 2024

Rate

$

Rate

$

First Lien Incremental Term Loan Tranche B-5 - payable to lenders at SOFR 
     plus applicable margin

6.66

%

$

2,527,638

6.86

%

$

2,546,787

Revolving Credit Loans - payable to lenders at SOFR plus applicable margin

6.91

%

—

7.61

%

—

Swingline/Base Rate - payable to lenders at ABR plus applicable margin

9.25

%

—

9.75

%

63,300

Amortizing Notes 
(1)

37,181

53,804

Notes payable and other

17,267

19,428

Total debt

2,582,086

2,683,319

Less: debt issuance costs, net

64,882

72,736

Total debt, net of debt issuance costs

2,517,204

2,610,583

Less: current portion of long-term debt

51,870

48,725

Total long-term debt, net of current portion

$

2,465,334

$

2,561,858

(1)
See Note 7 for discussion of Amortizing Notes.
The following discussion summarizes the debt agreements and related modifications for the nine months ended September 30, 2025 and the year ended December 31, 2024. We were in compliance with all applicable financial debt covenants at September 30, 2025 and December 31, 2024.
First Lien Credit Agreement

On 
March 5, 2019
, the Company entered into a First Lien Credit Agreement (the “First Lien”), with Morgan Stanley Senior Funding, Inc., as the Administrative Agent and the Collateral Agent. The First Lien originally consisted of a principal amount of $
1,650.0
 million. In 2019, an additional delayed draw of $
150.0
 million was made on the First Lien, resulting in a gross borrowing of $
1,800.0
 million (“Tranche B-1”). The First Lien, as amended in 2020, provided for the establishment of a Tranche B-2 Term Loan (“Tranche B-2”) in an aggregate principal amount equal to $
550.0
 million. The First Lien, as amended in 2021, provided for the establishment of a Tranche B-3 Term Loan (“Tranche B-3”) in an aggregate principal amount equal to $
675.0
 million.

On February 21, 2024, we used a portion of the net proceeds received from the IPO Offerings to repay $
343.3
 million of the borrowings under the First Lien, and amended the First Lien to establish a new Tranche B-4 Term Loan (“Tranche B-4”) in an aggregate principal amount of $
2,566.0
 million. The proceeds from Tranche B-4 borrowings were used to refinance the equivalent amount of the remaining First Lien Tranches B-1, B-2, and B-3 borrowings and was accounted for as a debt modification.

On December 11, 2024, we amended the First Lien to refinance Tranche B-4 by establishing a Tranche B-5 Term Loan (“Tranche B-5”) in an aggregate principal amount of $
2,553.2
 million at a rate equal to Secured Overnight Financing Rate (“SOFR”) plus 
2.50
% or Alternate Base Rate (“ABR”) plus 
1.50
% with a maturity date of 
February 21, 2031
. 
The non-cash transaction was accounted for as a

18

debt 
modification. Principal payments are due on the last business day of each quarter, which commenced in the first fiscal quarter of 2025 and equate to 
0.25
% of the principal at issuance, with a balloon payment due February 21, 2031.
Revolving Credit Facility

The First Lien also extends credit in the form of a Revolving Credit Facility with a borrowing capacity of $
475.0
 million (the “Revolver”), of which up to $
50.0
 million is available as swingline loans and up to $
82.5
 million is available as letters of credit (the “LC Sublimit”). The Revolver will mature on
 June 30, 2028
. In connection with the First Lien modification on February 21, 2024, borrowings under the Revolver bore interest at a rate equal to SOFR (with a floor of 
0.00
%) plus 
3.25
% for the Revolving Credit Loans or ABR plus 
2.25
% for the Swingline Loans at December 31, 2024. During the first fiscal quarter of 2025, the variable rate on the Revolving Credit Loans and Swingline Loans decreased to SOFR plus 
3.00
% and ABR plus 
2.00
%, respectively, as a result of 
our improved leverage ratio in accordance with the terms of our credit agreement. As of September 30, 2025, the Company had 
$
475.0
 mi
llion
 of borrowing capacity available under the Revolver as there were 
no
 borrowings under the Revolver or letters of credit outstanding. As of December 31, 2024, the Company had 
$
63.3
 million
 of borrowings outstanding under the Revolver and 
no
 letters of credit, reducing the available borrowing capacity to approximately 
$
411.7
 million
.
The Company’s First Lien also provides for an additional $
65.0
 million of letter of credit commitments (the “LC Facility”), which are not subject to the LC Sublimit and do not reduce the Revolver borrowing capacity. As of 
September 30, 2025, there were 
$
62.8
 million
 of letters of credit outstanding under the LC Facility, resulting in an available borrowing capacity of 
$
2.2
 million
. As of December 31, 2024, there were 
$
61.8
 million
 of letters of credit outstanding under the LC Facility, resulting in an available borrowing capacity of 
$
3.2
 million
.
Second Lien Credit Agreement

The Company’s amended and restated Second Lien Credit Agreement (the “Second Lien Facility”), with certain Lenders and Wilmington Trust, National Association, as the Administrative Agent and the Collateral Agent consisted of a principal amount of $
450.0
 million. On January 30, 2024, we used a portion of the net proceeds received from the IPO Offerings to repay all outstanding borrowings under the Second Lien Facility. No remaining obligation exists related to the Second Lien Facility. This transaction was accounted for as a debt extinguishment and the Company incur
red a loss on extinguishment of debt of $
12.7
 million related to the write-off of unamortized debt issuance costs during the first fiscal quarter of 2024.

Derivative Financial Instruments
To manage fluctuations in cash flows resulting from changes in the variable interest rates, the Company entered into receive-variable, pay-fixed interest rate swap agreements. The following table summarizes our interest rate swaps designated as cash flow hedges:

Notional Amount as of

Financial Institution

September 30, 2025

December 31, 2024

Effective Dates

Fixed Rates

Credit Suisse

$

—

$

500

million

3-year
 period ending 
September 30, 2025

3.41650

%

Morgan Stanley

—

1,050

million

3-year
 period ending 
September 30, 2025

3.42000

%

Credit Agricole Corporate and Investment Bank

—

450

million

3-year
 period ending 
September 30, 2025

3.52410

%

Matured contracts

$

—

$

2,000

million

Credit Agricole Corporate and Investment Bank

$

500

million

$

—

1-year
 period ending 
September 30, 2026

3.72500

%

Mizuho Capital Markets

500

million

—

1-year
 period ending 
September 30, 2026

3.61121

%

Credit Agricole Corporate and Investment Bank

250

million

—

3-year
 period ending 
September 30, 2028

3.33150

%

Morgan Stanley

250

million

—

3-year
 period ending 
September 30, 2028

3.17700

%

Existing contracts

$

1,500

million

$

—

The net fair value of the net cash flow hedges as of September 30, 2025 and December 31, 2024 was 
$
0.3
 million
 and 
$
10.6
 million
, respectively, and is reflected in prepaid expenses and other current assets, other assets, and long-term liabilities in the unaudited condensed consolidated balance sheets.

19

Amounts reported in accumulated other comprehensive income (“AOCI”) related to derivatives will be reclassified to interest expense as interest payments are made on the Company’s variable-rate debt. Interest received, including payments made or received under the cash flow hedges, was 
$
4.6
 million
 and 
$
13.4
 million
 for the three and nine months ended September 30, 2025, respectively, as compared to 
$
9.8
 million
 and 
$
28.9
 million
 for the three and nine months ended September 30, 2024
, respectively. The Company expects approximately $
0.9

million of pre-tax gains to be reclassified out of AOCI into earnings within the next twelve months.

7. Tangible Equity Units
Concurrently with the IPO, we issued 
8,000,000
 TEUs, which have a stated amount of $
50.00
 per unit. Each TEU is comprised of a prepaid stock purchase contract (
“Purchase Contract”) and a senior amortizing note (“Amortizing Note”
) due 
February 1, 2027
, each issued by the Company. E
ach TEU may be separated by a holder into its constituent Purchase Contract and Amortizing Note, each of which is considered a freestanding financial instrument. 
The proceeds from the issuance were allocated to equity and debt based on the relative fair value of the respective components of each TEU as follows (in thousands):

Equity Component

Debt Component

Total

Fair value per unit

$

41.3382

$

8.6618

$

50.00

Gross proceeds

$

330,706

$

69,294

$

400,000

Less: issuance costs

9,095

1,905

11,000

Net proceeds

$

321,611

$

67,389

$

389,000

The value allocated to the Purchase Contract is reflected net of issuance costs in additional paid-in capital. The value allocated to the Amortizing Notes is reflected in long-term debt in the unaudited condensed consolidated balance sheet, with payments expected in the next twelve months reflected in current portion of long-term debt. The long-term portion of the Amortizing Notes as of September 30, 2025 and December 31, 2024 wa
s $
13.0
 million and $
32.9
 million, respectively. The short-term portion of the Amortizing Notes as of
 September 30, 2025 and December 31, 2024 wa
s $
24.2
 million and $
20.9
 million, respectively. 
Issuance costs related to the Amortizing Notes are reflected as a reduction of the carrying amount and will be amortized through the maturity date using the effective interest rate method.
Amortizing Notes

The Company pays equal quarterly cash installments of $
0.8438
 per Amortizing Note on February 1, May 1, August 1 and November 1, commencing on May 1, 2024, except for the May 1, 2024 installment payment, which was $
0.8531
 per Amortizing Note, with a final installment payment date of 
February 1, 2027
. In the aggregate, the annual quarterly cash installments are the equivalent of 
6.75
% per year. Each installment payment constitutes a payment of interest and a partial repayment of principal. The Company paid $
6.7
 million and $
20.2
 million in TEU installment payments during the three and nine months ended 
September 30, 2025
, respectively, as compared to $
6.8
 million and $
13.6
 million during the three and nine months ended 
September 30, 2024. The Amortizing Notes rank equally in right of payment with all other existing and future unsecured senior indebtedness and rank senior to all of our existing and future indebtedness, if any, that is subordinated to the Amortizing Notes.

Purchase Contracts
At any time prior to the second scheduled trading day immediately preceding February 1, 2027, a holder may elect to settle its Purchase Contract early, in whole or in part, at an early settlement rate equal to the minimum settlement rate. The Company has the right to settle the Purchase Contracts on or after November 1, 2024, in whole but not in part, on a date fixed by it at an early mandatory settlement rate equal to the maximum settlement rate, subject to certain exceptions. During the three and nine months ended September 30, 2025
, 
865,017
 Purchase Contracts were converted at the holder's option. During the three and nine months ended 
September 30, 2024
, 
no
 Purchase Contracts were converted at the holder's option.
Unless settled earlier at the holder’s option or at the Company's election, each Purchase Contract will, subject to postponement in certain limited circumstances, automatically settle on February 1, 2027 for a number of shares of our common stock, subject to certain anti-dilution adjustments, based upon the 20-day volume-weighted average price (
“VWAP”) of our common stock as follows:

VWAP of BTSG Common Stock

Common Stock Issued

Greater than $
15.28

3.2733
 shares (minimum settlement rate)

Equal to or less than $
15.28
 but greater than or equal to $
13.00

 $
50
 divided by VWAP

Less than $
13.00

3.8461
 shares (maximum settlement rate)

20

The Purchase Contracts are mandatorily convertible into a minimum of 
26.2
 million shares or a maximum of 
30.8
 million shares of our common stock on the mandatory settlement date (unless redeemed by us or settled earlier at the unit holder's option). The 
26.2
 million minimum shares are included in the calculation of basic weighted average shares outstanding. The difference between the minimum and maximum shares represents potentially dilutive securities, which are included in the calculation of diluted weighted average shares outstanding to the extent that the average applicable market value is equal to or greater than $
13.00
 but is less than or equal to $
15.28
 during the period (see Note 10).

8. Income Taxes
The provision for income taxes is attributable to U.S federal, state, and foreign income taxes. The Company’s effective tax rate used for interim periods is based on an estimated annual effective tax rate and includes the tax effect of items required to be recorded discretely in the interim periods in which those items occur.
A reconciliation of the Company’s effective tax rate is as follows:

For the Three Months Ended

For the Nine Months Ended

September 30,

September 30,

2025

2024

2025

2024

Estimated annual effective tax rate before discrete items

26.4

%

(
28.5

)%

26.4

%

20.6

%

Discrete items recognized

(
2.0

)%

(
18.1

)%

(
7.2

)%

9.5

%

Effective tax rate recognized in the statements of operations

24.4

%

(
46.6

)%

19.2

%

30.1

%

During the three months ended September 30, 2025
, the Company’s effective tax rate was lower than the U.S. federal income tax rate, primarily as a result of including $
1.0
 million in tax benefits resulting from the recognition of excess tax benefits from share-based compensation. During the three months ended 
September 30, 2024, the Company's effective tax rate was lower than the U.S. federal income tax rate, primarily as a result of the cumulative impact of the year-to-date estimated tax rate on pre-tax book losses as well as the 2023 return-to-provision adjustments driven by a refinement of pre-tax book income from continuing operations for tax reporting purposes.
During the nine months ended September 30, 2025
, the Company's effective tax rate was lower than the U.S. federal income tax rate, primarily as a result of including $
4.7
 million in tax benefits resulting from the recognition of excess tax benefits from share-based compensation. During the nine months ended 
September 30, 2024, the Company’s effective tax rate was higher than the U.S. federal income tax rate, primarily as a result of limitations on the deductibility of certain executive compensation that now apply to the Company after the IPO Offerings, which were completed in January 2024. In addition, the discrete tax benefit related to the Silver matter increased the effective tax rate on pre-tax book losses to date.
On July 4, 2025, H.R.1, new tax legislation commonly referred to as the One Big Beautiful Bill Act ("OBBBA"), which includes a broad range of tax provisions, was enacted in the U.S. The Company does not expect the OBBBA will have a material impact on its estimated annual effective tax rate in 2025, however will continue to monitor the cash tax benefits as a result of favorable tax treatment for certain business provisions.

See Note 13 for further discussion of the Silver matter.
9. Detail of Certain Balance Sheet Accounts
Prepaid expenses and other current assets consist of the following (in thousands):

September 30, 2025

December 31, 2024

Rebate receivable

$

38,188

$

49,538

Non-trade receivables

25,068

45,428

Prepaid insurance

15,383

13,892

Income tax receivable

14,366

13,468

Inventory returns receivable

9,855

11,245

Prepaid maintenance

3,663

3,644

Interest rate swaps

—

10,633

Other prepaid expenses and current assets

17,455

13,462

Total prepaid expenses and other current assets

$

123,978

$

161,310

21

Other assets consist of the following (in thousands):

September 30, 2025

December 31, 2024

Insurance recoveries

$

6,890

$

7,564

Notes receivable

6,712

8,577

Cloud computing

6,054

7,362

Equity method investments

5,821

670

Deposits

5,666

6,733

Deferred compensation

4,505

3,777

Deferred debt issuance costs

1,940

2,470

Interest rate swaps

1,037

—

Other assets

3,337

1,975

Total other assets

$

41,962

$

39,128

Accrued expenses consist of the following (in thousands):

September 30, 2025

December 31, 2024

Wages and payroll taxes

$

121,480

$

98,245

Checks in excess of cash balance

27,202

27,643

Compensated absences

26,930

24,360

Workers compensation insurance reserves

24,006

19,966

Health insurance reserves

19,146

14,934

Property insurance reserves

11,568

9,879

Deferred revenue

8,302

10,196

Legal settlements and professional fees

8,060

13,982

General and professional liability insurance reserves

6,639

8,328

Automobile insurance reserves

4,338

21,353

Taxes other than income taxes

2,700

1,985

Interest

1,398

8,779

Interest rate swaps

717

—

Contingent consideration

200

3,136

Other

41,360

32,960

Total accrued expenses

$

304,046

$

295,746

Long-term liabilities consist of the following (in thousands):

September 30, 2025

December 31, 2024

Workers compensation insurance reserves

$

23,442

$

25,360

General and professional liability insurance reserves

23,090

21,182

Automobile insurance reserves

9,514

9,034

Deferred compensation

4,505

3,777

Contingent consideration

750

5,250

Employee incentives

—

3,993

Other

2,259

2,594

Total long-term liabilities

$

63,560

$

71,190

10. Earnings Per Share 
(“EPS”)
Basic net income (loss) per share excludes dilution and is reported separately for continuing operations and discontinued operations. Basic net income (loss) per share of common stock for continuing operations and discontinued operations is calculated by dividing net income (loss) from continuing operations and discontinued operations attributable to common shareholders by the weighted average number of shares outstanding for the reporting period. Diluted net income (loss) per share of common stock is computed by giving effect to all potential weighted average dilutive common stock. In periods of net loss, no potentially dilutive common shares are included in the diluted shares outstanding as the effect is anti-dilutive.

22

The number of additional shares of common stock related to restricted stock units (“RSUs”) and stock option awards is calculated using the treasury stock method, if dilutive.

For the three and nine months ended September 30, 2025 and 2024, the TEUs were assumed to be outstanding at the minimum settlement amount for weighted-average shares for basic EPS. For the three and nine months ended September 30, 2025
, the Company's average applicable market value was greater than $
15.28
, resulting in no dilutive impact to EPS for TEUs. For the three and nine months ended 
September 30, 2024
, the Company's average applicable market value was equal to or less than $
15.28
 but greater than or equal to $
13.00
. Thus, the TEUs were assumed to be settled at a conversion factor based on the 20-day VWAP per share of the Company's common stock not to exceed 
3.8461
 shares per Purchase Contract, if dilutive. See Note 7 for further discussion of TEUs.
The following table sets forth the computation of basic and diluted net income (loss) per share attributable to common shareholders (in thousands, except per share amounts):

For the Three Months Ended

For the Nine Months Ended

September 30,

September 30,

2025

2024

2025

2024

Numerator:

Net income (loss) from continuing operations

$

37,488

$

(
25,672

)

$

55,245

$

(
73,213

)

Less: Net loss attributable to noncontrolling interests

(
595

)

(
751

)

(
1,793

)

(
1,864

)

Net income (loss) from continuing operations attributable to 
    common shareholders

38,083

(
24,921

)

57,038

(
71,349

)

Net income from discontinued operations

17,753

16,691

56,548

37,288

Net income (loss) attributable to common shareholders

$

55,836

$

(
8,230

)

$

113,586

$

(
34,061

)

Denominator:

Weighted-average shares outstanding - basic

203,487

198,491

202,067

190,541

Effect of dilutive securities:

Stock options

7,835

—

8,387

—

RSUs

6,660

—

8,065

—

TEUs

—

—

—

—

Other

—

—

—

—

Weighted-average shares outstanding - diluted

217,982

198,491

218,519

190,541

Basic income (loss) per share attributable to common shareholders:

Continuing operations

$

0.19

$

(
0.13

)

$

0.28

$

(
0.37

)

Discontinued operations

$

0.08

$

0.09

$

0.28

$

0.19

Net income (loss)

$

0.27

$

(
0.04

)

$

0.56

$

(
0.18

)

Diluted income (loss) per share attributable to common shareholders:

Continuing operations

$

0.17

$

(
0.13

)

$

0.26

$

(
0.37

)

Discontinued operations

$

0.09

$

0.09

$

0.26

$

0.19

Net income (loss)

$

0.26

$

(
0.04

)

$

0.52

$

(
0.18

)

The following potentially common share equivalents were excluded from the computation of diluted net income (loss) per share because their effect would have been anti-dilutive for the periods presented (in thousands):

For the Three Months Ended

For the Nine Months Ended

September 30,

September 30,

2025

2024

2025

2024

Stock options

245

15,096

1,303

15,096

RSUs

—

11,078

—

11,078

TEUs

—

1,881

—

1,881

Other

—

9

—

9

Total

245

28,064

1,303

28,064

23

11. Common Stock, Preferred Stock, and Share-Based Compensation
Common Stock and Preferred Stock
The Company’s Board of Directors approved a 
15.7027
-for-one
 stock split of the Company’s common stock on January 24, 2024. The stock split became effective on January 25, 2024. The par value per share of the Company’s common stock remained unchanged at $
0.01
 per share, and the authorized shares of the Company’s common stock increased from 
8,750,000
 to 
137,398,625
. Upon completion of the IPO Offerings in January 2024, the Company's Board of Directors approved an amendment to our articles of incorporation to authorize 
1,500,000,000
 and 
250,000,000
 shares of common stock and preferred stock, respectively, each with a par value of $
0.01
 per share.

Share-Based Compensation
In January 2025, the Company's Board of Directors approved the modification of certain equity awards in connection with the divestiture of the Community Living business, which resulted in $
1.7
 million and $
4.8
 million of incremental share-based compensation expense recognized during the three and nine months ended 
September 30, 2025
, respectively.
12. Fair Value
Assets and liabilities measured at fair value are based on one or more of the following three valuation techniques:

A.
Market approach: 
Prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities.
B.
Cost approach: 
Amount that would be required to replace the service capacity of an asset (replacement cost).
C.
Income approach: 
Techniques to convert future amounts to a single present amount based upon market expectations (including present value techniques, option-pricing and excess earnings models).
Assets and Liabilities Measured at Fair Value on a Recurring Basis
The financial assets or liabilities recorded at fair value on a recurring basis are set forth in the table below (in thousands):

September 30, 2025

December 31, 2024

Valuation Technique

Assets:

Interest rate swaps (Level 2)

$

275

$

10,633

A

Total assets

$

275

$

10,633

Liabilities:

Contingent consideration (Level 3)

$

950

$

8,386

C

Total liabilities

$

950

$

8,386

The fair values of our interest rate swaps are based upon Level 2 inputs, which include valuation models. The key inputs for the valuation models are quoted market prices, interest rates, forward yield curves, and credit risk adjustments that are necessary to reflect the probability of default by the counterparty or us. For disclosures about our derivative instruments, refer to Note 6.
The contingent consideration represents future earn-outs and a post-closing equity adjustment feature, both associated with acquisitions, which are recognized as a component of the purchase price at the estimated fair value on the acquisition date. These liabilities are classified as accrued expenses and long-term liabilities in our accompanying unaudited condensed consolidated balance sheets.

The fair values of the liabilities associated with future earn outs were derived using the income approach with unobservable inputs, including future earnings forecasts and present value assumptions, and there was little or no market data (Level 3). The Company will re-assess the fair values on each reporting period thereafter until settlement.

The 
fair value of the liability associated with the post-closing equity adjustment feature related to the Haven Hospice acquisition was derived with unobservable inputs using a Monte Carlo simulation, where the common stock price of the Company was evolved using a Geometric Brownian Motion of a period from the valuation date to the end of the fourth anniversary of closing. Estimated equity volatility was based on historical volatility, implied volatility, and peer group volatility over various periods. The Company will

24

re-assess 
the fair value at each reporting period with changes in value being recorded through the statement of operations. The ultimate settlement of the liability will be through either issuance of additional equity shares and/or additional cash paid in case of net realized losses on sales; or reduction of the outstanding balance of the seller note, in the case of net aggregate realized gain on sales up to the amounts previously paid.
13. Commitments and Contingencies
Legal Proceedings
On March 4, 2011, Relator Marc Silver, on behalf of the U.S. Government and various state governments, filed a complaint in the United States District Court for the District of New Jersey (“the District Court”) against PharMerica, seeking relief, with respect to alleged violations of the federal False Claims Act and state false claims acts. The U.S. Government and state governments declined to intervene in the case. The District Court issued an order dismissing the case in full in 2016. In 2018, however, the Third Circuit Court of Appeals issued an order reinstating the case. In June 2023, the District Court issued an order setting a trial date of December 4, 2023. In November 2023, the District Court denied our motion for summary judgment and the Company subsequently agreed to settle the matter without admitting liability. On May 29, 2024, the parties entered into a final settlement agreement, which was approved by both the United States Department of Justice and the District Court.

The total financial impact of the settlement was $
120.0
 million; $
90.0
 million was paid in June 2024, $
20.0
 million was paid in July 2024, and the remaining $
10.0
 million was paid in April 2025. The District Court entered an order dismissing the Silver action in its entirety, with prejudice, on July 3, 2024.
The Company is also party to various legal and/or administrative proceedings arising out of the operation of our programs and arising in the ordinary course of business. We record accruals for such contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. We do not believe the ultimate liability, if any, for outstanding proceedings or claims, individually or in the aggregate, in excess of amounts already provided, will have a material adverse effect on our consolidated financial condition, results of operations, or cash flows. It is reasonably possible that an adverse determination might have an impact on a particular period. While we believe our provision for legal contingencies is adequate, the outcome of legal proceedings is difficult to predict, and we may settle legal claims or be subject to judgments for amounts that exceed our estimates.
14. Related Party Transactions
The Company was party to a Monitoring Agreement with KKR and WBA, which required payment of an aggregate advisory fee equivalent to 
1
% of consolidated earnings before interest, taxes, depreciation, and amortization (“EBITDA”), payable in quarterly installments in arrears at the end of each quarter. The Monitoring Agreement terminated upon the completion of the IPO Offerings in January 2024.

Prior to the termination of the Monitoring Agreement, the Company recognized $
0.7
 million in monitoring and advisory fees during the first fiscal quarter of 2024 as a component of selling, general, and administrative expenses in our accompanying unaudited condensed consolidated statements of operations.

As a result of the termination of the Monitoring Agreement and in accordance with the agreement, the Company paid $
22.7
 million in termination fees to KKR and WBA in the fourth fiscal quarter of 2024. The termination fees were recognized in the first fiscal quarter of 2024 as selling, general, and administrative expense in our unaudited condensed consolidated statement of operations.
KKR Capital Markets LLC (“KCM”), a wholly owned subsidiary of KKR, acted as an underwriter in the IPO Offerings during the first fiscal quarter of 2024 and received $
7.4
 million in underwriting discounts and commission. In connection with debt refinancing in the first fiscal quarter of 2024, the Company paid underwriter, arranger, and transaction fees to KCM of $
1.9
 million. These fees are included within selling, general, and administrative expenses in our unaudited condensed consolidated statement of operations for the nine months ended 
September 30, 2024
. There were 
no
 similar fees paid to KCM during the three or six months ended 
September 30, 2024, and the three or nine months ended September 30, 2025.
KKR has ownership interests in a broad range of portfolio companies, and we may enter into commercial transactions for goods or services in the ordinary course of business with these companies. We do not believe such transactions are material to our business.

The Company had an agreement with WBA and/or certain of its affiliates under which the Company purchased significant volume of inventory, including a Joinder Agreement to the Pharmaceutical Purchase and Distribution Agreement (the “WBAD Membership Agreement”) between WBA and AmerisourceBergen Drug Corporation (“ABDC”). The WBAD Membership Agreement was terminated in the first fiscal quarter of 2025, and we entered into a separate agreement with ABDC on February 1, 2025.

25

15. Segment Information
The Company's Chief Operating Decision Maker (“CODM”) is its 
Chief Executive Officer
, who evaluates the performance of our segments and allocates resources based on segment EBITDA. 
Segment EBITDA is used as the key profitability measure when we set our annual operating plan for each segment, is the metric with which our CODM assesses segment results, and is a key component of our annual variable compensation plans. Segment EBITDA is commonly used as an analytical indicator within the health care industry and is utilized in the evaluation of segment operating performance as it is a profit measure that is generally within the control of the operating segments. 
For all segments, the CODM uses segment EBITDA in the annual budgeting and monthly forecasting process. The CODM considers actual-to budget and actual-to current forecast variances for segment EBITDA on a monthly basis for evaluating performance of each segment and making decisions about allocating capital and other resources to each segment.

Segment amounts exclude certain expenses not specifically identifiable to the segments for functions performed in a centralized manner, which include accounting, finance, human resources, legal, information technology, corporate office support, and overall corporate management. Segment assets and capital expenditures are not provided to the Company’s CODM and, therefore, are not disclosed.

The following tables set forth information about the Company’s reportable segments, along with the items necessary to reconcile the segment information to the totals reported in the Company’s unaudited condensed consolidated statements of operations as follows (in thousands):

For the Three Months Ended September 30, 2025

Pharmacy Solutions

Provider Services

Total Segments

Products revenue

$

2,966,966

$

—

$

2,966,966

Services revenue

—

367,140

367,140

Cost of drugs

2,541,723

—

2,541,723

Cost of services

—

220,784

220,784

Other direct costs
 (1)

179,591

—

179,591

Segment selling, general, and administrative expenses 
(2)

131,116

93,027

224,143

Segment depreciation and amortization expense
 (3)

26,451

7,340

33,791

Segment EBITDA

$

140,987

$

60,669

$

201,656

For the Three Months Ended September 30, 2024

Pharmacy Solutions

Provider Services

Total Segments

Products revenue

$

2,265,697

$

—

$

2,265,697

Services revenue

—

335,532

335,532

Cost of drugs

1,920,089

—

1,920,089

Cost of services

—

201,016

201,016

Other direct costs
 (1)

157,032

—

157,032

Segment selling, general, and administrative expenses 
(2)

117,336

88,507

205,843

Segment depreciation and amortization expense
 (3)

27,913

6,270

34,183

Segment EBITDA

$

99,153

$

52,279

$

151,432

For the Nine Months Ended September 30, 2025

Pharmacy Solutions

Provider Services

Total Segments

Products revenue

$

8,289,238

$

—

$

8,289,238

Services revenue

—

1,070,695

1,070,695

Cost of drugs

7,066,776

—

7,066,776

Cost of services

—

648,773

648,773

Other direct costs
 (1)

539,155

—

539,155

Segment selling, general, and administrative expenses 
(2)

382,894

275,000

657,894

Segment depreciation and amortization expense
 (3)

80,992

21,283

102,275

Segment EBITDA

$

381,405

$

168,205

$

549,610

26

For the Nine Months Ended September 30, 2024

Pharmacy Solutions

Provider Services

Total Segments

Products revenue

$

6,357,223

$

—

$

6,357,223

Services revenue

—

968,026

968,026

Cost of drugs

5,356,206

—

5,356,206

Cost of services

—

581,509

581,509

Other direct costs
 (1)

459,775

—

459,775

Segment selling, general, and administrative expenses 
(2)

341,803

254,779

596,582

Segment depreciation and amortization expense
 (3)

82,384

17,963

100,347

Segment EBITDA

$

281,823

$

149,701

$

431,524

(1)
Other direct costs primarily includes direct labor costs, delivery costs, insurance, and depreciation and amortization expense that relates to revenue-generating assets.
(2)
Segment selling, general, and administrative expense includes direct labor costs, depreciation and amortization, insurance, rent, lease, supplies, professional services, maintenance, repairs, utilities, and communications expense.
(3)
Total segment depreciation and amortization expense is presented in other direct costs, costs of services, and segment general and administrative expenses, based on the associated asset.

For the Three Months Ended

For the Nine Months Ended

September 30,

September 30,

2025

2024

2025

2024

Reconciliation of income or loss:

Total Segment EBITDA

$

201,656

$

151,432

$

549,610

$

431,524

Segment depreciation and amortization

33,791

34,183

102,275

100,347

Expenses not allocated at segment level:

Selling, general, and administrative expenses

73,060

81,802

239,047

259,640

Depreciation and amortization

6,962

6,350

21,149

19,122

Loss on extinguishment of debt

—

—

—

12,726

Interest expense, net

38,235

46,614

118,776

144,366

Income tax expense (benefit)

12,120

8,155

13,118

(
31,464

)

Net income (loss) from continuing operations

$

37,488

$

(
25,672

)

$

55,245

$

(
73,213

)

27

Ite
m 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
The following discussion analyzes our financial condition and results of operations and should be read in conjunction with our unaudited condensed consolidated financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q (our “Form 10-Q”). This discussion contains forward-looking statements that involve risks and uncertainties. See “Forward-Looking Statements.” When reviewing the discussion below, you should keep in mind the substantial risks and uncertainties that characterize our business. Known material factors that could affect our financial performance and actual results, and could cause actual results to differ materially from those expressed or implied in any forward-looking statements included in this discussion or otherwise made by our management, are described in Item 2 of Part I of this Form 10-Q, and in Item 1A, “Risk Factors” of Part I of our Annual Report on Form 10-K for the year ended December 31, 2024 (our “Form 10-K”). Factors that could cause or contribute to such difference are not limited to those identified in “Risk Factors.” When used in the following discussion, “Senior” patients and populations mean individuals who are aged 65 and older, “Specialty” patients and populations mean individuals who have unique, specialized and most often chronic/life-long health conditions and needs, and “Behavioral” patients and populations mean individuals with intellectual and developmental disabilities including mental illness.
Overview
We are a leading home and community-based healthcare services platform, focused on delivering complementary pharmacy and provider services to complex patients. We have a differentiated approach to care delivery, with an integrated and scaled model that addresses critical services that the highest-need and highest-cost patients require. With a focus on Senior and Specialty patients, which includes Behavioral populations, our platform provides pharmacy and provider services (both clinical and supportive care in nature) in lower-cost home and community settings largely to Medicare, Medicaid, and commercially-insured populations. We are an essential part of our nation’s health delivery network as a front-line provider of high-quality and cost-effective care to a large and growing number of people, who increasingly require a combination of specialized solutions to enable holistic health care management. Our presence spans all 50 states, we serve over 460,000 patients daily through our approximately 10,500 clinical providers and pharmacists, and our services make a profound impact in the lives and communities of the people we serve.

On January 17, 2025, the Company entered into a purchase agreement with National Mentor Holding, Inc. to divest our community living services, home and community based waiver programs, and intermediate care facilities (the “Community Living business”), for $835 million, subject to typical adjustments for working capital and other customary items. We expect the divestiture to close in the first fiscal quarter of 2026, subject to customary closing conditions. This transaction provides for continuity of important intellectual and developmental disability services while BrightSpring focuses on a concentrated group of customers, patients and stakeholders in the future. We believe the Company’s streamlined service offerings will result in increased strategic focus, operational efficiencies, a refined payer mix, and greater clinical integration and business synergy across the Provider Services segment. The divestiture will also augment our expected Revenue and Adjusted EBITDA growth rates and maximize exposure to target growth markets that require BrightSpring’s needed and valuable solutions, such as home health, rehab, primary care, and hospice.

The Company has determined the divestiture of the Community Living business represents a strategic shift that will have a major effect on its business and therefore met the criteria for classification as discontinued operations in the first fiscal quarter of 2025. As a result, in accordance with ASC 205-20, the financial results of the Community Living business, which were previously reported as part of our Provider Services segment, have been classified as discontinued operations in the unaudited condensed consolidated statements of operations, and the Community Living business's assets and liabilities have been classified as held for sale for all periods presented. Unless otherwise noted, amounts and disclosures throughout this Management’s Discussion and Analysis relate to our continuing operations. Refer to “PART I - Item 1. Note 2” of our Form 10-K for additional information regarding discontinued operations.
For additional overview of our business, see “PART I - Item 1. Business” of our Form 10-K.
Financial Performance Highlights: Third Quarter of 2025 Compared to Third Quarter of 2024
•
Revenue grew by $732.9 million, or 28.2%, to $3,334.1 million
•
Pharmacy Solutions segment revenue grew by $701.3 million, or 31.0%, to $2,967.0 million
•
Provider Services segment revenue grew by $31.6 million, or 9.4%, to $367.1 million
•
Net income increased by $63.2 million from net loss of $25.7 million to net income of $37.5 million 
•
Adjusted EBITDA
(1)
 increased by $43.5 million, or 37.2%, to $160.4 million
(1)
 Reconciliation of GAAP to non-GAAP results is provided below under the section entitled “Non-GAAP Financial Measures.”

28

Financial Performance Highlights: Third Quarter of 2025 Compared to Third Quarter of 2024 (continued)
•
Pharmacy Solutions segment EBITDA increased by $41.8 million, or 42.2%, to $141.0 million
•
Provider Services segment EBITDA grew by $8.4 million, or 16.0%, to $60.7 million
•
Diluted income per share increased by $0.30 from diluted loss per share of  $(0.13) to diluted income per share of $0.17
•
Adjusted EPS
(1)
 increased by $0.27 from $0.03 to $0.30
(1)
 Reconciliation of GAAP to non-GAAP results is provided below under the section entitled “Non-GAAP Financial Measures.”
Recent Developments

As previously disclosed, on October 22, 2025, KKR Stockholder and certain management selling stockholders completed a registered secondary public offering of 15,000,000 shares of the Company’s common stock (the “October 2025 Offering”). The Company did not sell any shares of common stock that were offered in the October 2025 Offering. Also, the Company did not receive any proceeds from the October 2025 Offering, other than proceeds received in connection with the cash exercise of stock options by the management selling stockholders in connection with the October 2025 Offering.

In connection with the October 2025 Offering, the Company concurrently purchased from the underwriter, out of the aggregate of 15,000,000 shares of common stock that were the subject of the October 2025 Offering, 1,500,000 shares of common stock at a price of $29.00 per share, for a total purchase price of $43.5 million. The purchase price reflected a discount to the closing market price on the date of purchase. The repurchase was reviewed and approved by the audit committee of our Board of Directors.
Our Service Offerings
We are one of the largest independent providers of home and community-based health services in the United States, delivering both pharmacy and provider services. We believe our high-quality and complementary health services offerings address significant and important patient and stakeholder needs. We enhance patient outcomes through the delivery and coordination of high-quality services that high-need, high-cost patients require. Our services are principally delivered in patient-preferred and lower-cost settings and often over longer periods of time, given the chronic nature of the patient conditions that we address. We believe our breadth of service capabilities and proven outcomes position us as a provider of choice for patients, families, referral sources, customers, and payors. We deliver services through two reportable segments: Pharmacy Solutions and Provider Services. For additional details regarding our diversified service offerings within each reportable segment see “PART I - Item 1. Business” of our Form 10-K.
The following table summarizes the revenues generated by each of our reportable segments:

For the Three Months Ended

For the Nine Months Ended

September 30,

September 30,

2025

2024

2025

2024

($ in millions)

Revenue

% of Revenue

Revenue

% of Revenue

Revenue

% of Revenue

Revenue

% of Revenue

Pharmacy Solutions

$

2,967.0

89.0

%

$

2,265.7

87.1

%

$

8,289.2

88.6

%

$

6,357.2

86.8

%

Provider Services

367.1

11.0

%

335.5

12.9

%

1,070.7

11.4

%

968.0

13.2

%

Consolidated BrightSpring

$

3,334.1

100.0

%

$

2,601.2

100.0

%

$

9,359.9

100.0

%

$

7,325.2

100.0

%

Payor Mix
We are characterized by payor diversification across our platform. Our payors are principally federal, state, and local governmental agencies, commercial insurance, private, and other payors. Additionally, our Medicaid payors can be further broken down across each individual state with our top 10 Medicaid states representing 7% of total Company revenue for the three and nine months ended September 30, 2025 and 2024.

We provide our services across all 50 states, Puerto Rico and Canada, with our top 10 states of operations comprising 53% of total Company revenues for the three and nine months ended September 30, 2025, compared to 52% for the three and nine months ended September 30, 2024. The federal, state, and local programs under which we operate are subject to legislative and budgetary changes that can influence reimbursement rates.

29

The following tables summarize the percentage of revenue generated by each payor type for each of our service offerings and reportable segments:

For the Three Months Ended September 30, 2025

Commercial insurance

Medicaid

Medicare Part A

Medicare Part B

Medicare Part C

Medicare Part D

Private & other

Total

Infusion and Specialty Pharmacy

21.8

%

6.8

%

—

0.6

%

17.8

%

23.5

%

0.8

%

71.3

%

Home and Community Pharmacy

2.7

%

1.8

%

4.3

%

—

0.0

%

8.2

%

0.7

%

17.7

%

Pharmacy Solutions

24.5

%

8.6

%

4.3

%

0.6

%

17.8

%

31.7

%

1.5

%

89.0

%

Home Health Care

0.3

%

0.3

%

3.8

%

0.0

%

0.9

%

—

0.3

%

5.6

%

Rehab Care

1.1

%

1.0

%

—

0.1

%

0.0

%

—

0.1

%

2.3

%

Personal Care

0.1

%

2.5

%

—

—

—

—

0.5

%

3.1

%

Provider Services

1.5

%

3.8

%

3.8

%

0.1

%

0.9

%

—

0.9

%

11.0

%

Consolidated BrightSpring

26.0

%

12.4

%

8.1

%

0.7

%

18.7

%

31.7

%

2.4

%

100.0

%

For the Three Months Ended September 30, 2024

Commercial insurance

Medicaid

Medicare Part A

Medicare Part B

Medicare Part C

Medicare Part D

Private & other

Total

Infusion and Specialty Pharmacy

20.7

%

5.9

%

—

0.6

%

15.6

%

21.1

%

0.6

%

64.5

%

Home and Community Pharmacy

3.1

%

2.3

%

5.5

%

—

0.0

%

10.7

%

1.0

%

22.6

%

Pharmacy Solutions

23.8

%

8.2

%

5.5

%

0.6

%

15.6

%

31.8

%

1.6

%

87.1

%

Home Health Care

0.2

%

0.4

%

4.4

%

0.1

%

1.4

%

—

0.0

%

6.5

%

Rehab Care

1.3

%

0.6

%

—

0.0

%

0.0

%

—

0.7

%

2.6

%

Personal Care

0.1

%

2.3

%

—

—

—

—

1.4

%

3.8

%

Provider Services

1.6

%

3.3

%

4.4

%

0.1

%

1.4

%

—

2.1

%

12.9

%

Consolidated BrightSpring

25.4

%

11.5

%

9.9

%

0.7

%

17.0

%

31.8

%

3.7

%

100.0

%

For the Nine Months Ended September 30, 2025

Commercial insurance

Medicaid

Medicare Part A

Medicare Part B

Medicare Part C

Medicare Part D

Private & other

Total

Infusion and Specialty Pharmacy

21.2

%

6.5

%

—

0.6

%

17.5

%

23.1

%

0.9

%

69.8

%

Home and Community Pharmacy

2.7

%

2.0

%

4.5

%

—

0.0

%

8.7

%

0.9

%

18.8

%

Pharmacy Solutions

23.9

%

8.5

%

4.5

%

0.6

%

17.5

%

31.8

%

1.8

%

88.6

%

Home Health Care

0.2

%

0.3

%

4.0

%

0.0

%

1.0

%

—

0.3

%

5.8

%

Rehab Care

1.2

%

0.7

%

—

0.0

%

0.0

%

—

0.5

%

2.4

%

Personal Care

0.1

%

2.2

%

—

—

—

—

0.9

%

3.2

%

Provider Services

1.5

%

3.2

%

4.0

%

0.0

%

1.0

%

—

1.7

%

11.4

%

Consolidated BrightSpring

25.4

%

11.7

%

8.5

%

0.6

%

18.5

%

31.8

%

3.5

%

100.0

%

For the Nine Months Ended September 30, 2024

Commercial insurance

Medicaid

Medicare Part A

Medicare Part B

Medicare Part C

Medicare Part D

Private & other

Total

Infusion and Specialty Pharmacy

20.3

%

5.8

%

—

0.7

%

15.3

%

21.7

%

0.9

%

64.7

%

Home and Community Pharmacy

2.8

%

2.4

%

5.4

%

0.0

%

0.0

%

10.4

%

1.1

%

22.1

%

Pharmacy Solutions

23.1

%

8.2

%

5.4

%

0.7

%

15.3

%

32.1

%

2.0

%

86.8

%

Home Health Care

0.2

%

0.4

%

4.5

%

0.3

%

1.2

%

—

0.1

%

6.7

%

Rehab Care

1.4

%

0.6

%

—

0.0

%

0.0

%

—

0.7

%

2.7

%

Personal Care

0.1

%

2.4

%

—

—

—

—

1.3

%

3.8

%

Provider Services

1.7

%

3.4

%

4.5

%

0.3

%

1.2

%

—

2.1

%

13.2

%

Consolidated BrightSpring

24.8

%

11.6

%

9.9

%

1.0

%

16.5

%

32.1

%

4.1

%

100.0

%

See Note 3 of the unaudited condensed consolidated financial statements and related notes in this Form 10-Q for more information regarding revenue by payor type for each reportable segment for the three and nine months ended September 30, 2025 and 2024.
Trends and Other Factors Affecting Business
Continued Growth of our Pharmacy Solutions Patient Populations
We focus on providing health-dependent medications in a timely and well-supported manner to our patients receiving pharmacy solutions in their home and community-based settings. Our pharmacy services are primarily delivered directly to patients in their place of residence, home, or stay, and sometimes in a clinic setting. According to industry reports, pharmacy solutions delivered to and tailored for the home environment, such as home infusion services, oncology services, and daily medication management services in the home, will continue to grow faster than the overall and general pharmacy market. We have continued to expand our pharmacy

30

capabilities to serve this need. Overall, our pharmacy has grown patient census by approximately 2%, in the third fiscal quarter of 2025 compared to the third fiscal quarter of 2024. We are a leading independent pharmacy provider in our respective pharmacy patient markets, and we expect to continue to increase our share, including home infusion patients, specialty oncology patients, behavioral patients, in-home Seniors, and hospice patients.

Continued Growth of our Provider Services Patient Populations
We focus on delivering high-touch and coordinated services to medically complex Senior and Specialty patients in the home and community-based settings where they live. As the baby boomer population ages, Seniors, who comprise a significant majority of our patients, will represent a higher percentage of the overall population. Given the proven value proposition of home-based health services, we believe patients will increasingly seek treatment and referral sources and payors will increasingly support treatment in homes more often than in higher cost, less convenient, higher acuity institutional settings.
The vast majority of patients we serve in our provider businesses are served in the home, and we have purposefully continued to expand our service offering and footprint to serve patients in this lower cost setting. Since 2019, we built upon supportive care services to patients, as we have meaningfully expanded our footprint of highly clinical and expert services to home health, rehabilitation, and hospice patients to address a large national healthcare need and more completely and better serve Senior and Specialty patients in the home as evidenced by continued census growth within the Provider Services segment. Our complementary services that address the multiple needs of these patient populations will increasingly provide integrated care opportunities to provide more complete and better coordinated services to patients across health settings and stages.
Stable Reimbursement Environment Across our Portfolio of Businesses
Our revenue is dependent upon our contracts and relationships with payors for our “must-serve” patient populations. We partner with a large and diverse set of payor groups nationally and in each of our markets, to form provider networks and to lower the overall cost of care. We structure our payor contracts to help both providers and payors achieve their objectives in a mutually aligned manner. Maintaining, supporting, and both deepening and increasing the number of these contracts and relationships, particularly as we continue to grow market share and enter new markets, is important for our long-term success.
We have observed relatively stable reimbursement rates from government and commercial payors in our pharmacy and provider services over a number of years, particularly for services provided to high-need, medically complex populations. Due to the medical necessity of our services, which are lower cost than healthcare services provided in other settings and reduce ER, hospital and institutional facility utilization, we have a history of reimbursement stability.
Culture of Quality and Compliance and Consistent Operations Execution
Quality and compliance are central to our strategies and mission. We have demonstrated leading and excellent service and customer/patient/family satisfaction scores across the organization, as referenced in prior filings such as our Form 10-K. In addition to quality and compliance resources and programs in field operations, we invest in people, training, auditing, signature programs, accreditations, advocacy, and technologies to support quality, compliance, and safety as part of our “Quality First” framework. We have demonstrated consistently high and often leading marks for service levels, satisfaction scores, and quality metrics in our industries.
Operational excellence is also an ongoing focus at the Company, including how we collect and share key metrics, hold operational reviews, audit, conduct training, deploy expert support resources, execute on corrective and preventative actions, and implement continuous improvement initiatives across the organization. We have continued to make investments in automation, data, and technology systems to support enhanced workflows, further scale, and future growth across service lines.
Ability to Build De Novo Locations
We have a proven ability to augment growth of existing operations by expanding our presence and opening new locations – in both of our reportable segments, Pharmacy Solutions and Provider Services – across geographies with consistent ramp-up in performance after site opening. We believe our platform can continue to build further scale nationally, adding density to additional and targeted key markets as a lever to facilitate maximum pharmacy and provider services overlap, integrated and value-based care, and growth. The Company’s geographic and operations scale, and platform of complementary segments and service lines, provides us with access to more de novo opportunities to consider and prioritize.
We typically identify and open new locations within proximity of an existing location as we leverage existing market knowledge and presence to expand in target markets, regions, and states. Our internal support resources in real estate, purchasing, IT, credentialing, payor contracting, HR, and sales and marketing, along with our Project Management Office, help to support and manage de novo locations from start to opening. We expect to continue to selectively and strategically expand our footprint within the United States and extend our service offerings to our patients and for customers, referral sources, and payors. We believe de novo investments facilitate more integrated care capability and are a meaningful organic growth driver for the Company.

31

Ability to Facilitate Integrated Care
Our operating model consists of complementary pharmacy and provider services that high-need Senior and Specialty populations require, and it is designed to increasingly coordinate, manage, and serve patients across our various needs and settings over time, leading to improved patient, family, physician, and referral source satisfaction, improved payor experiences, and better outcomes. Our performance and potential to drive increased service volume for increased patient and health outcomes impact is driven partly by our appeal with our patients, families, customers, referral sources, and payors to provide multiple integrated care services – either in the same setting at the same time or across settings and stages of health – within our collection of pharmacy solutions and provider services and differentiated overall capabilities.
We provide multiple pharmacy and provider services to approximately 8,000 patients today, and we believe that there are substantially more opportunities to deliver more integrated care, given the hundreds of thousands of patients we serve and a similar number of patients discharging from customers annually. Value-add, beneficial, and multiple integrated care opportunities exist for our customer base and all Senior and Specialty patient populations not only across pharmacy and provider services, but also within each segment. Within pharmacy services, CCRx is aimed at providing medication risk and therapy management continuously and longitudinally post discharge from hospitals and skilled nursing customers. Within provider services, patients often transition from home health to hospice services and can receive therapy and supportive care services concurrent with each other and with home health and hospice.
Aligning to Value-Based Care Reimbursement Models with Innovative Solutions
The scale and depth of our complimentary platform of diverse yet related customer and patient services – that complex patients require – positions us at the forefront with governmental and commercial payors who are increasingly seeking ways to expand value-based reimbursement models. Our high-quality services that are delivered in home and community-based and patient and family-preferred settings at lower comparable costs are well-positioned for the long-term, and we continue to add wraparound care management capabilities and offerings to our core services. In addition to our large Medicare and Medicaid beneficiary populations, we have a large number of non-governmental payor contracts across the organization today, which both diversifies our payor mix, and provides for additional value-based opportunities and partnerships. The Company’s focused build out of its (i) Home-Based Primary Care, transitional care programs, and in-home medication therapy management, and (ii) Clinical (Nursing) Hub, are key enablers to coordinate base pharmacy and provider services and drive improved quality and lower costs for value-based care constructs. In addition to numerous payor contracts that feature reimbursement incentives, in the past year the Company has entered into several accountable care organization (“ACO”) arrangements to participate in shared savings from its attributed primary care patients and other ACO partnerships and contract as a preferred provider.
Factors Affecting Results of Operations and Comparability
Legal Costs and Settlements Accrual
In November 2023, the Company agreed to settle the Silver matter without admitting liability, as discussed under Part I, Item 3. “Legal Proceedings” in our Annual Report on Form 10-K for the year ended December 31, 2024. On May 29, 2024, the parties entered into a final settlement agreement, which was approved by both the United States Department of Justice and the District Court. The total financial impact of the settlement was $120.0 million; all of which has been paid as of April 2025. We paid $110.0 million of the settlement in 2024, and the remainder in April 2025. The District Court entered an order dismissing the Silver action in its entirety, with prejudice, on July 3, 2024. See Note 13 “Commitments and Contingencies” within the unaudited condensed consolidated financial statements and related notes, included elsewhere in this Form 10-Q.
Discontinued Operations
On January 17, 2025, the Company entered into a definitive agreement to sell its Community Living business to National Mentor Holdings, Inc. (the “Purchaser”), for $835.0 million in cash upon closing, subject to certain post-closing adjustments. We entered into the transaction in order to streamline our service offerings and further focus on the senior and specialty populations. The transaction is currently expected to close in the first fiscal quarter of 2026, subject to receipt of customary regulatory approvals and satisfaction of other closing conditions.
The Company has determined the divestiture of the Community Living business represents a strategic shift that will have a major effect on its business and has concluded the criteria for classification as discontinued operations were met during the first fiscal quarter of 2025. Accordingly, the Community Living business is reported as discontinued operations in accordance with Accounting Standards Codification (“ASC”) 205-20, Discontinued Operations. The related assets and liabilities of the Community Living business are classified as assets and liabilities held for sale in the accompanying unaudited condensed consolidated balance sheet as of September 30, 2025, and the results of operations from the Community Living business are classified as discontinued operations in the unaudited condensed consolidated statements of operations. Applicable amounts in prior years have been recast to conform to this

32

discontinued operations presentation. The Community Living business was historically presented as a part of the Provider Services reportable segment.
See Note 2 “Discontinued Operations” within the unaudited condensed consolidated financial statements and related notes, included elsewhere in this Form 10-Q.
Components of Results of Operations
Revenues
. The Company recognizes the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. For transactions involving the transfer of goods, revenues are primarily recognized when the customer obtains control of the products sold, which is generally upon shipment or delivery, depending on the delivery terms specified in the sales agreement. For transactions exclusively involving provision of services, revenues are recognized over time based on an appropriate measure of progress.
Cost of Goods and Cost of Services
. We classify expenses directly related to providing goods and services, including depreciation and amortization, as cost of goods and cost of services. Direct costs and expenses principally include cost of drugs, net of rebates, salaries and benefits for direct care and service professionals, contracted labor costs, insurance costs, transportation costs for clients requiring services, certain client expenses such as food, supplies and medicine, residential occupancy expenses, which primarily comprise rent and utilities, and other miscellaneous direct goods or service-related expenses.
Selling, General, and Administrative Expenses
. Selling, general, and administrative expenses consist of expenses incurred in support of our operations and administrative functions and include labor costs, such as salaries, bonuses, commissions, benefits, and travel-related expenses, distribution expenses, facilities rental costs, third-party revenue cycle management costs, and corporate support costs including finance, information technology, legal costs and settlements, human resources, procurement, and other administrative costs.
Loss on Extinguishment of Debt. 
Loss on extinguishment of debt reflects the write-off of unamortized debt issuance costs upon the early repayment of our Second Lien Facility in 2024.
Interest Expense, net
. Interest expense, net includes the debt service costs associated with our various debt instruments, including our First Lien Facilities, and the amortization of related deferred financing fees, which are amortized over the term of the respective credit agreement. Interest expense, net also includes the portion of the gain or loss on our interest rate swap agreements that is reclassified into earnings.
Income Tax Expense (Benefit)
. Our provision for income taxes is based on permanent book/tax differences and statutory tax rates in the various jurisdictions in which we operate. Significant estimates and judgments are required in determining the provision for income taxes.

33

Results of Operations
Consolidated Results of Operations
Three Months Ended September 30, 2025 Compared to Three Months Ended September 30, 2024
The following table sets forth, for the periods indicated, our consolidated results of operations.

($ in thousands)

For the Three Months Ended September 30,

Change

2025

2024

Amount

%

Revenues:

Products

$

2,966,966

$

2,265,697

$

701,269

31.0

%

Services

367,140

335,532

31,608

9.4

%

Total revenues

3,334,106

2,601,229

732,877

28.2

%

Cost of goods

2,721,314

2,077,121

644,193

31.0

%

Cost of services

220,784

201,016

19,768

9.8

%

Gross profit

392,008

323,092

68,916

21.3

%

Selling, general, and administrative expenses

304,165

293,995

10,170

3.5

%

Operating income

87,843

29,097

58,746

201.9

%

Interest expense, net

38,235

46,614

(8,379

)

(18.0

)%

Income (loss) before income taxes

49,608

(17,517

)

67,125

n.m.

Income tax expense

12,120

8,155

3,965

n.m.

Net income (loss)

$

37,488

$

(25,672

)

$

63,160

n.m.

Adjusted EBITDA 
(1)

$

160,443

$

116,940

$

43,503

37.2

%

* n.m.: not meaningful
(1) Reconciliation of GAAP to non-GAAP results is provided below under the section entitled “Non-GAAP Financial Measures.”
         The following discussion of our results of operations should be read in conjunction with the foregoing table summarizing our consolidated results of operations.
Revenues
Revenues were $3,334.1 million for the three months ended September 30, 2025, as compared with $2,601.2 million for the three months ended September 30, 2024, an increase of $732.9 million or 28.2%. The increase resulted from growth in our Pharmacy Solutions and Provider Services segments. See additional discussion in “—Segment Results of Operations” below.
Cost of Goods
Cost of goods was $2,721.3 million for the three months ended September 30, 2025, as compared with $2,077.1 million for the three months ended September 30, 2024, an increase of $644.2 million or 31.0%. The increase resulted from an increase in Pharmacy Solutions cost of goods. See additional discussion in “—Segment Results of Operations” below.
Cost of Services
Cost of services was $220.8 million for the three months ended September 30, 2025, as compared with $201.0 million for the three months ended September 30, 2024, an increase of $19.8 million or 9.8%. The increase resulted from an increase in Provider Services cost of services. See additional discussion in “—Segment Results of Operations” below.
Selling, General, and Administrative Expenses
Selling, general, and administrative expenses were $304.2 million for the three months ended September 30, 2025, as compared with $294.0 million for the three months ended September 30, 2024, an increase of $10.2 million or 3.5%. The increase primarily resulted from the following segment activity and factors:
•
an increase of $18.3 million, or 6.2%, growth on consolidated third quarter of 2024 selling, general, and administrative expenses, as a result of growth in our Pharmacy Solutions and Provider Services segments. See additional discussion in “—Segment Results of Operations” below; 

34

•
an increase of $1.5 million, or 0.5%, growth on consolidated third quarter of 2024 selling, general, and administrative expenses, due to non-cash share-based compensation related to the equity awards granted to management and certain full-time employees; offset by,
•
a decrease of $6.3 million, or 2.1%, decline in consolidated third quarter of 2024 selling, general, and administrative expenses, as a result of a decrease in acquisition, integration and transaction-related expenses; and,
•
a decrease of $3.3 million, or 1.1%, decline in consolidated third quarter of 2024 selling, general, and administrative expenses, as a result of a decrease in other operational expenses year-over-year.
Interest Expense, net
Interest expense, net was $38.2 million for the three months ended September 30, 2025, as compared with $46.6 million for the three months ended September 30, 2024, a decrease of $8.4 million or 18.0%. The decrease primarily resulted from a decrease in both the variable-rate and applicable margin for the three months ended September 30, 2025 as compared to the prior period, offset by a $5.2 million decrease in interest income received related to cash flow hedges of interest rate risk.
Income Tax Expense

Income tax expense was $12.1 million for the three months ended September 30, 2025, as compared with $8.2 million for the three months ended September 30, 2024, an increase in the expense of $4.0 million. The increase in the income tax expense is primarily driven by the increase in pre-tax book income for the three months ended September 30, 2025 as compared to the three months ended September 30, 2024, and an increase in the effective tax rate for the three months ended September 30, 2025 of 24.4% compared to (46.6)% for the three months ended September 30, 2024. The increase in the effective tax rate is primarily as a result of the cumulative impact of the year-to-date estimated tax rate on 2024 pre-tax book losses as well as the 2023 return-to-provision adjustment.

Net Income (Loss)
Net income was $37.5 million for the three months ended September 30, 2025, as compared with a net loss of $25.7 million for the three months ended September 30, 2024, an increase of $63.2 million. The increase in net income is primarily attributable to the increase in gross profit and the aforementioned decrease in interest expense, net, offset by an increase in selling, general, and administrative expenses and income tax expense.
Adjusted EBITDA
 (1)
Adjusted EBITDA was $160.4 million for the three months ended September 30, 2025, as compared with $116.9 million for the three months ended September 30, 2024, an increase of $43.5 million or 37.2%. The increase primarily resulted from the following segment activity and factors:
•
an increase of $50.2 million, or 42.9% growth on consolidated third quarter of 2024 Adjusted EBITDA, as a result of growth in our Pharmacy Solutions and Provider Services segments. See additional discussion in “—Segment Results of Operations” below; offset by
•
a decrease of $6.7 million, or 5.7% decline in consolidated third quarter of 2024 Adjusted EBITDA, as a result of increases in certain public company costs incurred, investments in information technology, and positions to support growth within the business.
(1)
 Reconciliation of GAAP to non-GAAP results is provided below under the section entitled “Non-GAAP Financial Measures.”

35

Nine Months Ended September 30, 2025 Compared to Nine Months Ended September 30, 2024
The following table sets forth, for the periods indicated, our consolidated results of operations.

($ in thousands)

For the Nine Months Ended September 30,

Change

2025

2024

Amount

%

Revenues:

Products

$

8,289,238

$

6,357,223

$

1,932,015

30.4

%

Services

1,070,695

968,026

102,669

10.6

%

Total revenues

9,359,933

7,325,249

2,034,684

27.8

%

Cost of goods

7,605,931

5,815,981

1,789,950

30.8

%

Cost of services

648,773

581,509

67,264

11.6

%

Gross profit

1,105,229

927,759

177,470

19.1

%

Selling, general, and administrative expenses

918,090

875,344

42,746

4.9

%

Operating income

187,139

52,415

134,724

257.0

%

Loss on extinguishment of debt

—

12,726

(12,726

)

n.m.

Interest expense, net

118,776

144,366

(25,590

)

(17.7

)%

Income (loss) before income taxes

68,363

(104,677

)

173,040

n.m.

Income tax expense (benefit)

13,118

(31,464

)

44,582

n.m.

Net income (loss)

$

55,245

$

(73,213

)

$

128,458

n.m.

Adjusted EBITDA 
(1)

$

434,022

$

329,792

$

104,230

31.6

%

* n.m.: not meaningful
(1) Reconciliation of GAAP to non-GAAP results is provided below under the section entitled “Non-GAAP Financial Measures.”
The following discussion of our results of operations should be read in conjunction with the foregoing table summarizing our consolidated results of operations.
Revenues
Revenues were $9,359.9 million for the nine months ended September 30, 2025, as compared with $7,325.2 million for the nine months ended September 30, 2024, an increase of $2,034.7 million or 27.8%. The increase resulted from growth in our Pharmacy Solutions and Provider Services segments. See additional discussion in “—Segment Results of Operations” below.
Cost of Goods
Cost of goods was $7,605.9 million for the nine months ended September 30, 2025, as compared with $5,816.0 million for the nine months ended September 30, 2024, an increase of $1,790.0 million or 30.8%. The increase resulted from an increase in Pharmacy Solutions cost of goods. See additional discussion in “—Segment Results of Operations” below.
Cost of Services
Cost of services was $648.8 million for the nine months ended September 30, 2025, as compared with $581.5 million for the nine months ended September 30, 2024, an increase of $67.3 million or 11.6%. The increase resulted from an increase in Provider Services cost of services. See additional discussion in “—Segment Results of Operations” below.
Selling, General, and Administrative Expenses
Selling, general, and administrative expenses were $918.1 million for the nine months ended September 30, 2025, as compared with $875.3 million for the nine months ended September 30, 2024, an increase of $42.7 million or 4.9%. The increase primarily resulted from the following segment activity and factors:
•
an increase of $61.3 million, or 7.0% growth on consolidated 2024 selling, general, and administrative expenses, as a result of growth in our Pharmacy Solutions and Provider Services segments. See additional discussion in “—Segment Results of Operations” below; 
•
an increase of $9.5 million, or 1.1%, growth in consolidated third quarter of 2024 selling, general, and administrative expenses, as a result of an increase in acquisition, integration and transaction-related expenses; offset by,

36

•
a decrease of $22.7 million, or 2.6%, decline in consolidated 2024 selling, general, and administrative expenses, as a result of the termination fees incurred at the time of the IPO Offerings in connection with the termination of our Monitoring Agreement for which there is no comparable expense in 2025; 
•
a decrease of $3.6 million, or 0.4%, decline in consolidated 2024 selling, general, and administrative expenses, due to non-cash share-based compensation related to the equity awards granted to management and certain full-time employees; and
•
a decrease of $1.8 million, or 0.2%, decline in consolidated 2024 selling, general, and administrative expenses, as a result of a decrease in other operational expenses year-over-year.
Loss on Extinguishment of Debt
          During the nine months ended September 30, 2024, we used proceeds from the IPO Offerings to repay the Second Lien on January 30, 2024 and as a result incurred a loss on extinguishment of debt of $12.7 million related to the write-off of unamortized debt issuance costs. There was no loss on extinguishment of debt recognized for the nine months ended September 30, 2025.
Interest Expense, net
Interest expense, net was $118.8 million for the nine months ended September 30, 2025, as compared with $144.4 million for the nine months ended September 30, 2024, a decrease of $25.6 million or 17.7%. The decrease primarily resulted from a decrease in both the variable-rate and applicable margin for the nine months ended September 30, 2025 as compared to the prior periods and lower outstanding term debt as compared to the prior period, offset by a $15.5 million decrease in interest income received related to cash flow hedges of interest rate risk.
Income Tax Expense (Benefit)
Income tax expense was $13.1 million for the nine months ended September 30, 2025, as compared with an income tax benefit of $31.5 million for the nine months ended September 30, 2024, an increase in the income tax expense of $44.6 million. The increase in the income tax expense is primarily driven by the increase in pre-tax book income for the nine months ended September 30, 2025 as compared to the nine months ended September 30, 2024, and a decrease in the effective tax rate for the nine months ended September 30, 2025 of 19.2% compared to 30.1% for the nine months ended September 30, 2024. The decrease in the effective tax rate is primarily as a result of $4.7 million in tax benefits resulting from the recognition of excess tax benefits from stock-based compensation partially offset by limitations on the deductibility of certain executive compensation as a percentage of estimated pre-tax book income for the nine months ended September 30, 2025. In addition, the discrete tax benefit related to the Silver matter increased the effective tax rate on pre-tax book loss for the nine months ended September 30, 2024.
Net Income (Loss)
Net income was $55.2 million for the nine months ended September 30, 2025, as compared with a net loss of $73.2 million for the nine months ended September 30, 2024, an increase of $128.5 million. The increase in net income is primarily attributable to the increase in gross profit and the aforementioned decrease in interest expense, net, and loss on extinguishment of debt, partially offset by an increase in selling, general, and administrative expenses and income tax expense (benefit).
Adjusted EBITDA
 (1)
Adjusted EBITDA was $434.0 million for the nine months ended September 30, 2025, as compared with $329.8 million for the nine months ended September 30, 2024, an increase of $104.2 million or 31.6%. The increase primarily resulted from the following segment activity and factors:
•
an increase of $118.1 million, or 35.8% growth on consolidated 2024 Adjusted EBITDA, as a result of growth in our Pharmacy Solutions and Provider Services segments. See additional discussion in “—Segment Results of Operations” below; offset by
•
a decrease of $13.9 million, or 4.2% decline in consolidated 2024 Adjusted EBITDA, as a result of increases in certain public company costs incurred, investments in information technology, and positions to support growth within the business.
(1)
 Reconciliation of GAAP to non-GAAP results is provided below under the section entitled “Non-GAAP Financial Measures.”

37

Segment Results of Operations
Pharmacy Solutions Segment
Three Months Ended September 30, 2025 Compared to Three Months Ended September 30, 2024
The following table sets forth, for the periods indicated, our segment results of operations for Pharmacy Solutions.

Pharmacy Solutions

($ in thousands, except Business Metrics)

For the Three Months Ended

September 30,

Change

2025

2024

Amount

%

Revenues

$

2,966,966

$

2,265,697

$

701,269

31.0

%

Cost of goods

2,721,314

2,077,121

644,193

31.0

%

Gross profit

245,652

188,576

57,076

30.3

%

Selling, general, and administrative expenses

131,116

117,336

13,780

11.7

%

Segment operating income

$

114,536

$

71,240

$

43,296

60.8

%

Segment EBITDA

$

140,987

$

99,153

$

41,834

42.2

%

Business Metrics:

Prescriptions dispensed

10,793,219

10,874,429

(81,210

)

(0.7

)%

Revenue per script

$

274.89

$

208.35

$

66.54

31.9

%

Gross profit per script

$

22.76

$

17.34

$

5.42

31.3

%

The following discussion of our Pharmacy Solutions segment results of operations should be read in conjunction with the foregoing table summarizing our segment results of operations.
Revenues
Revenues were $2,967.0 million for the three months ended September 30, 2025, as compared with $2,265.7 million for the three months ended September 30, 2024, an increase of $701.3 million or 31.0%. The increase primarily resulted from volume growth in prescriptions dispensed within Infusion and Specialty Pharmacy partially offset by a decline in prescriptions dispensed within Home and Community Pharmacy. Revenues attributable to Infusion and Specialty Pharmacy were $2,377.0 million for the three months ended September 30, 2025, as compared with $1,678.1 million for the three months ended September 30, 2024, an increase of $698.9 million or 41.6% attributable to an increase in prescriptions dispensed on certain specialty branded drugs. Revenues attributable to Home and Community Pharmacy were $590.0 million for the three months ended September 30, 2025, as compared with $587.6 million for the three months ended September 30, 2024, an increase of $2.4 million or 0.4% attributable to mix changes in prescriptions dispensed.
The increase in revenue per prescription dispensed is due to mix changes year-over-year and a greater relative increase in volume growth in certain specialty brand drugs, which carry a higher revenue per prescription dispensed.
Cost of Goods
Cost of goods was $2,721.3 million for the three months ended September 30, 2025, as compared with $2,077.1 million for the three months ended September 30, 2024, an increase of $644.2 million or 31.0%. The increase primarily resulted from the aforementioned revenue growth in the period as well as an increase in cost per prescription dispensed as a result of mix shift.

Gross profit was $245.7 million for the three months ended September 30, 2025, as compared with $188.6 million for the three months ended September 30, 2024, an increase of $57.1 million or 30.3%. The increase primarily resulted from the aforementioned revenue growth in the period, primarily the result of outsized volume growth as well as mix in certain specialty branded drugs, which have lower margins.
Gross profit margin for the three months ended September 30, 2025 and September 30, 2024 remained consistent at 8.3%.

38

Selling, General, and Administrative Expenses
Selling, general, and administrative expenses were $131.1 million for the three months ended September 30, 2025, as compared with $117.3 million for the three months ended September 30, 2024, an increase of $13.8 million or 11.7%. The increase primarily resulted from the aforementioned revenue growth in the period with selling, general, and administrative expenses growing less than revenue due to demonstrating economies of scale.
Segment EBITDA
          Segment EBITDA was $141.0 million for the three months ended September 30, 2025, as compared with $99.2 million for the three months ended September 30, 2024, an increase of $41.8 million or 42.2%. The increase primarily resulted from the aforementioned revenue and gross profit growth in the period. See Note 15 “Segment Information” to our unaudited condensed consolidated financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q for further discussion.
Nine Months Ended September 30, 2025 Compared to Nine Months Ended September 30, 2024
The following table sets forth, for the periods indicated, our segment results of operations for Pharmacy Solutions.

Pharmacy Solutions

($ in thousands, except Business Metrics)

For the Nine Months Ended

September 30,

Change

2025

2024

Amount

%

Revenues

$

8,289,238

$

6,357,223

$

1,932,015

30.4

%

Cost of goods

7,605,931

5,815,981

1,789,950

30.8

%

Gross profit

683,307

541,242

142,065

26.2

%

Selling, general, and administrative expenses

382,894

341,803

41,091

12.0

%

Segment operating income

$

300,413

$

199,439

$

100,974

50.6

%

Segment EBITDA

$

381,405

$

281,823

$

99,582

35.3

%

Business Metrics:

Prescriptions dispensed

32,522,286

30,849,121

1,673,165

5.4

%

Revenue per script

$

254.88

$

206.07

$

48.81

23.7

%

Gross profit per script

$

21.01

$

17.54

$

3.47

19.8

%

The following discussion of our Pharmacy Solutions segment results of operations should be read in conjunction with the foregoing table summarizing our segment results of operations.
Revenues
Revenues were $8,289.2 million for the nine months ended September 30, 2025, as compared with $6,357.2 million for the nine months ended September 30, 2024, an increase of $1,932.0 million or 30.4%. The increase primarily resulted from volume growth in prescriptions dispensed across and within the Pharmacy Solutions segment. Revenues attributable to Infusion and Specialty Pharmacy were $6,531.9 million for the nine months ended September 30, 2025, as compared with $4,729.8 million for the nine months ended September 30, 2024, an increase of $1,802.1 million or 38.1% attributable to an increase in prescriptions dispensed on certain specialty branded drugs. Revenues attributable to Home and Community Pharmacy were $1,757.3 million for the nine months ended September 30, 2025, as compared with $1,627.4 million for the nine months ended September 30, 2024, an increase of $129.9 million or 8.0% attributable to volume growth.
The increase in revenue per prescription dispensed is due to mix changes year-over-year and a greater relative increase in volume growth in certain specialty brand drugs, which carry a higher revenue per prescription dispensed.
Cost of Goods
Cost of goods was $7,605.9 million for the nine months ended September 30, 2025, as compared with $5,816.0 million for the nine months ended September 30, 2024, an increase of $1,790.0 million or 30.8%. The increase primarily resulted from the aforementioned revenue growth in the period as well as an increase in cost per prescription dispensed as a result of mix shift.

Gross profit was $683.3 million for the nine months ended September 30, 2025, as compared with $541.2 million for the nine months ended September 30, 2024, an increase of $142.1 million or 26.2%. The increase primarily resulted from the aforementioned revenue growth in the period, primarily the result of outsized volume growth as well as mix in certain specialty branded drugs, which have lower margins.

39

Gross profit margin for the nine months ended September 30, 2025 was 8.2% compared to 8.5% for the nine months ended September 30, 2024. The decrease in gross profit margin is due to mix shift in the Pharmacy Solutions segment with greater relative volume growth in Infusion and Specialty Pharmacy, along with product-level mix shifts, rate changes, and an increase in the fulfillment cost per script in Home and Community Pharmacy.
Selling, General, and Administrative Expenses
Selling, general, and administrative expenses were $382.9 million for the nine months ended September 30, 2025, as compared with $341.8 million for the nine months ended September 30, 2024, an increase of $41.1 million or 12.0%. The increase primarily resulted from the aforementioned revenue growth in the period with selling, general, and administrative expenses growing less than the volume growth rate and demonstrating economies of scale.
Segment EBITDA
Segment EBITDA was $381.4 million for the nine months ended September 30, 2025, as compared with $281.8 million for the nine months ended September 30, 2024, an increase of $99.6 million or 35.3%. The increase primarily resulted from the aforementioned revenue and gross profit growth in the period. See Note 15 “Segment Information” to our unaudited condensed consolidated financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q for further discussion.

Provider Services Segment
Three Months Ended September 30, 2025 Compared to Three Months Ended September 30, 2024

Provider Services

($ in thousands, except Business Metrics)

For the Three Months Ended

September 30,

Change

2025

2024

Amount

%

Revenues

$

367,140

$

335,532

$

31,608

9.4

%

Cost of services

220,784

201,016

19,768

9.8

%

Gross profit

146,356

134,516

11,840

8.8

%

Selling, general, and administrative expenses

93,027

88,507

4,520

5.1

%

Segment operating income

$

53,329

$

46,009

$

7,320

15.9

%

Segment EBITDA

$

60,669

$

52,279

$

8,390

16.0

%

Business Metrics:

Home Health Care average daily census

29,592

28,650

942

3.3

%

Rehab Care persons served

7,321

6,571

750

11.4

%

Personal Care persons served

16,134

15,910

224

1.4

%

The following discussion of our Provider Services segment results of operations should be read in conjunction with the foregoing table summarizing our segment results of operations.
Revenues
Revenues were $367.1 million for the three months ended September 30, 2025, as compared with $335.5 million for the three months ended September 30, 2024, an increase of $31.6 million or 9.4%. The increase primarily resulted from volume growth as well as rate increases received during the period. Revenues attributable to Home Health Care were $188.3 million for the three months ended September 30, 2025, as compared with $168.2 million for the three months ended September 30, 2024, an increase of $20.1 million or 12.0%. Revenues attributable to Rehab Care were $76.4 million for the three months ended September 30, 2025, as compared with $70.2 million for the three months ended September 30, 2024, an increase of $6.2 million or 8.8%. Revenues attributable to Personal Care were $102.4 million for the three months ended September 30, 2025, as compared with $97.1 million for the three months ended September 30, 2024, an increase of $5.3 million or 5.5%.
Cost of Services
Cost of services was $220.8 million for the three months ended September 30, 2025, as compared with $201.0 million for the three months ended September 30, 2024, an increase of $19.8 million or 9.8%. The increase primarily resulted from the aforementioned revenue growth.

40

Gross profit was $146.4 million for the three months ended September 30, 2025, as compared with $134.5 million for the three months ended September 30, 2024, an increase of $11.8 million or 8.8%. The increase primarily resulted from the aforementioned revenue growth and costs of services improvements in the period.
Selling, General, and Administrative Expenses
Selling, general, and administrative expenses were $93.0 million for the three months ended September 30, 2025, as compared with $88.5 million for the three months ended September 30, 2024, an increase of $4.5 million or 5.1%. The increase primarily resulted from the aforementioned revenue growth in the period with selling, general, and administrative expenses growing less than the volume growth rate and demonstrating economies of scale.
Segment EBITDA
Segment EBITDA was $60.7 million for the three months ended September 30, 2025, as compared with $52.3 million for the three months ended September 30, 2024, an increase of $8.4 million or 16.0%. The increase primarily resulted from the aforementioned revenue growth. See Note 15 “Segment Information" to our unaudited condensed consolidated financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q for further discussion.
Nine Months Ended September 30, 2025 Compared to Nine Months Ended September 30, 2024
The following table sets forth, for the years indicated, our segment results of operations for Provider Services.

Provider Services

($ in thousands, except Business Metrics)

For the Nine Months Ended

September 30,

Change

2025

2024

Amount

%

Revenues

$

1,070,695

$

968,026

$

102,669

10.6

%

Cost of services

648,773

581,509

67,264

11.6

%

Gross profit

421,922

386,517

35,405

9.2

%

Selling, general, and administrative expenses

275,000

254,779

20,221

7.9

%

Segment operating income

$

146,922

$

131,738

$

15,184

11.5

%

Segment EBITDA

$

168,205

$

149,701

$

18,504

12.4

%

Business Metrics:

Home Health Care average daily census

29,970

28,034

1,936

6.9

%

Rehab Care persons served

7,048

6,615

433

6.5

%

Personal Care persons served

16,046

15,880

166

1.0

%

The following discussion of our Provider Services segment results of operations should be read in conjunction with the foregoing table summarizing our segment results of operations.
Revenues
Revenues were $1,070.7 million for the nine months ended September 30, 2025, as compared with $968.0 million for the nine months ended September 30, 2024, an increase of $102.7 million or 10.6%. The increase primarily resulted from volume growth as well as rate increases received during the period. Revenues attributable to Home Health Care were $551.2 million for the nine months ended September 30, 2025, as compared with $473.3 million for the nine months ended September 30, 2024, an increase of $77.9 million or 16.5%. Revenues attributable to Rehab Care were $219.5 million for the nine months ended September 30, 2025, as compared with $206.9 million for the nine months ended September 30, 2024, an increase of $12.6 million or 6.1%. Revenues attributable to Personal Care were $300.0 million for the nine months ended September 30, 2025, as compared with $287.8 million for the nine months ended September 30, 2024, an increase of $12.2 million or 4.2%.
Cost of Services
Cost of services was $648.8 million for the nine months ended September 30, 2025, as compared with $581.5 million for the nine months ended September 30, 2024, an increase of $67.3 million or 11.6%. The increase primarily resulted from the aforementioned revenue growth.

Gross profit was $421.9 million for the nine months ended September 30, 2025, as compared with $386.5 million for the nine months ended September 30, 2024, an increase of $35.4 million or 9.2%. The increase primarily resulted from the aforementioned revenue growth and costs of services improvements in the period.

41

Selling, General, and Administrative Expenses
Selling, general, and administrative expenses were $275.0 million for the nine months ended September 30, 2025, as compared with $254.8 million for the nine months ended September 30, 2024, an increase of $20.2 million or 7.9%. The increase primarily resulted from the aforementioned revenue growth in the period with selling, general, and administrative expenses growing less than the volume growth rate and demonstrating economies of scale.
Segment EBITDA
Segment EBITDA was $168.2 million for the nine months ended September 30, 2025, as compared with $149.7 million for the nine months ended September 30, 2024, an increase of $18.5 million or 12.4%. The increase primarily resulted from the aforementioned revenue growth. See Note 15 “Segment Information" to our unaudited condensed consolidated financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q for further discussion.

Non-GAAP Financial Measures
In addition to our results of operations prepared in accordance with U.S. GAAP, which we have discussed above, we also evaluate our financial performance using EBITDA, Adjusted EBITDA, and Adjusted EPS. These non-GAAP financial measures are not intended to replace financial performance measures determined in accordance with U.S. GAAP, such as net income (loss) and diluted EPS. Rather, we present EBITDA, Adjusted EBITDA, and Adjusted EPS as supplemental measures of our performance.
EBITDA, Adjusted EBITDA, and Adjusted EPS
The following are key financial metrics and, when used in conjunction with U.S. GAAP measures, we believe they provide useful information for evaluating our core business performance, enable comparison of financial results across periods, and allow for greater transparency with respect to key metrics used by management for financial and operational decision-making. We define EBITDA as net income (loss) before income tax expense (benefit), interest expense, net, and depreciation and amortization. Adjusted EBITDA and Adjusted EPS exclude certain other items that are either non-recurring, infrequent, non-cash, unusual, or items deemed by management to not be indicative of the performance of our core operations, including non-cash, share-based compensation; acquisition, integration, and transaction-related costs; restructuring and divestiture-related and other costs; legal costs associated with certain historical matters for PharMerica and settlement costs; significant projects; and management fees. In determining which adjustments are made to arrive at Adjusted EBITDA and Adjusted EPS, management considers both (1) certain non-recurring, infrequent, non-cash, or unusual items, which can vary significantly from year to year, as well as (2) certain other items that may be recurring, frequent, or settled in cash but which management does not believe are indicative of our core operating performance. The financial measure calculated under U.S. GAAP which is most directly comparable to Adjusted EBITDA is net income (loss). The financial measure calculated under U.S. GAAP which is most directly comparable to Adjusted EPS is diluted EPS.

We have historically incurred substantial acquisition, integration, and transaction-related costs. The underlying acquisition activities take place over a defined timeframe, have distinct project timelines, and are incremental to activities and costs that arise in the ordinary course of our business. Therefore, we have excluded these costs from our Adjusted EBITDA and Adjusted EPS because it provides management a normalized view of our core, ongoing operations after integrating our acquired companies.
The legal costs and settlements adjustment represents defense costs associated with certain PharMerica litigation matters, all of which have been finalized as of September 30, 2025, that commenced prior to KKR Stockholder’s and Walgreen Stockholder’s acquisition of PharMerica in December 2017, as well as settlement costs associated with these historical PharMerica cases including the Silver matter, which settled in November 2023. We have excluded defense costs associated with these PharMerica litigation matters from our Adjusted EBITDA and Adjusted EPS due to the magnitude of these cases and the costs attributable to them, the timing of the commencement of the cases and the fact that no similar cases have been brought against the Company since the acquisition of PharMerica, and the fact that these cases are unlike our routine legal and regulatory proceedings that we see in the normal course of business. Further, we have excluded settlement costs associated with the Silver matter from our Adjusted EBITDA and Adjusted EPS due to the magnitude of the case and the costs attributable to it, as well as the fact that the Silver matter is unlike our routine legal and regulatory proceedings that we see in the normal course of business.
The significant projects adjustment represents costs associated with certain transformational projects, which are not considered to be a part of our normal and recurring business operations and are not expected to recur in our future business plans. Moreover, the costs associated with significant projects, which are incurred on an infrequent and limited basis, are not reflective of our operating performance. Due to the aforementioned reasons, we have excluded the costs related to significant projects from our Adjusted EBITDA and Adjusted EPS, as such adjustment provides a more meaningful understanding to investors and others of our ongoing results.
The management fees adjustment represents fees paid historically under the Monitoring Agreement related to either (i) activities that are expected to be performed by our existing personnel upon the termination of the Monitoring Agreement, and thus not expected

42

to result in incremental costs subsequent to the IPO Offerings, or (ii) acquisitions, divestitures, and external financing activities, which costs would otherwise be excluded from our Adjusted EBITDA and Adjusted EPS. Therefore, we have excluded management fees from our Adjusted EBITDA and Adjusted EPS, as such fees are no longer applicable and representative of our ordinary operating performance as a result of the completion of the IPO Offerings.
EBITDA, Adjusted EBITDA, and Adjusted EPS are not measures of financial performance under U.S. GAAP and should be considered in addition to, and not as a substitute for, net income (loss), diluted EPS or other financial measures calculated in accordance with U.S. GAAP. Our method of determining non-GAAP financial measures may differ from other companies’ financial measures and therefore may not be comparable to methods used by other companies.
Given our determination of adjustments in arriving at our computations of EBITDA, Adjusted EBITDA and Adjusted EPS, these non-GAAP measures have limitations as analytical tools and should not be considered in isolation or as substitutes or alternatives to net income or loss, operating income or loss, earnings or loss per diluted share, cash flows from operating activities, total indebtedness, or any other financial measures calculated in accordance with U.S. GAAP.
The following table reconciles net income (loss) to EBITDA and Adjusted EBITDA:

($ in thousands)

For the Three Months Ended

For the Nine Months Ended

September 30,

September 30,

2025

2024

2025

2024

Net income (loss)

$

37,488

$

(25,672

)

$

55,245

$

(73,213

)

Income tax expense (benefit)

12,120

8,155

13,118

(31,464

)

Interest expense, net

38,235

46,614

118,776

144,366

Depreciation and amortization

40,753

40,533

123,424

119,469

EBITDA

$

128,596

$

69,630

$

310,563

$

159,158

Non-cash share-based compensation (1)

14,173

12,720

46,155

49,793

Acquisition, integration, and transaction-related costs (2)

5,462

11,766

34,811

25,328

Restructuring and divestiture-related and other costs (3)

12,212

12,904

42,493

47,642

Legal costs and settlements (4)

—

8,920

—

21,886

Significant projects (5)

—

1,000

—

2,604

Management fee (6)

—

—

—

23,381

Total adjustments

$

31,847

$

47,310

$

123,459

$

170,634

Adjusted EBITDA

$

160,443

$

116,940

$

434,022

$

329,792

(1)
Represents non-cash share-based compensation to certain members of our management and full-time employees. The nine months ended September 30, 2024 includes $15.0 million of previously unrecognized share-based compensation expense related to performance-vesting options under the 2017 Stock Plan, a portion of which vested upon completion of the IPO. 
(2)
Represents transaction costs incurred in connection with planned, completed, or terminated acquisitions, which include investment banking fees, legal diligence and related documentation costs, finance and accounting diligence and documentation; costs associated with the integration of acquisitions, including any facility consolidation, integration travel, or severance; and costs associated with other planned, completed, or terminated non-routine transactions. The three and nine months ended September 30, 2025 includes other non-routine transaction costs of $1.1 million and $23.4 million, respectively, as compared to $0.7 million and $1.4 million in the three and nine months ended September 30, 2024.
(3)
Represents costs associated with restructuring-related activities, including closure, and related license impairment, and severance expenses associated with certain enterprise-wide or significant business line cost-savings measures. These costs include $3.8 million and $18.5 million of costs that did not meet the criteria for discontinued operations related to the Community Living divestiture for the three and nine months ended September 30, 2025, respectively, as compared to $6.2 million and $19.6 million for the three and nine months ended September 30, 2024, respectively. These costs also include $12.7 million of unamortized debt issuance costs associated with the extinguishment of our Second Lien Facility in the nine months ended September 30, 2024.
(4)
Represents settlement and defense costs associated with certain historical PharMerica litigation matters, including the Silver matter, all of which were finalized in 2024. See Note 13 within the unaudited condensed consolidated financial statements and related notes in this Quarterly Report on Form 10-Q for additional information.

43

(5)
Represents costs associated with certain transformational projects and for the periods presented primarily included general ledger system implementation, pharmacy billing system implementation, and ransomware attack response costs, all of which were finalized in 2024. 
(6)
Represents annual management fees payable to the Managers under the Monitoring Agreement through the date of the IPO, and $22.7 million of termination fees resulting from the termination of the Monitoring Agreement upon completion of the IPO Offerings. All management fees ceased following the completion of the IPO in 2024.
The following table reconciles diluted EPS to Adjusted EPS:

(shares in thousands)

For the Three Months Ended

For the Nine Months Ended

September 30,

September 30,

2025

2024

2025

2024

Diluted EPS

$

0.17

$

(0.13

)

$

0.26

$

(0.37

)

Non-cash share-based compensation (1)

0.07

0.06

0.21

0.25

Acquisition, integration, and transaction-related costs (1)

0.03

0.06

0.16

0.13

Restructuring and divestiture-related and other costs (1)

0.06

0.06

0.19

0.24

Legal costs and settlements (1)

—

0.04

—

0.11

Significant projects (1)

—

0.00

—

0.01

Management fee (1)

—

—

—

0.12

Income tax impact on adjustments (2)(3)

(0.03

)

(0.06

)

(0.13

)

(0.29

)

Adjusted EPS

$

0.30

$

0.03

$

0.69

$

0.20

Weighted average common shares outstanding used in calculating 
     diluted U.S. GAAP net income (loss) per share

217,982

198,491

218,519

190,541

Weighted average common shares outstanding used in calculating 
     diluted Non-GAAP income per share

217,982

208,694

218,519

199,930

(1)
This adjustment reflects the per share impact of the adjustment reflected within the definition of Adjusted EBITDA.
(2)
The income tax impact of non-GAAP adjustments is calculated using the estimated tax rate for the respective non-GAAP adjustment. 
(3)
For the nine months ended September 30, 2024, the income tax impact on adjustments is inclusive of a discrete tax benefit related to the Silver matter that was finalized in connection with the signing of the settlement agreement during the second fiscal quarter of 2024. 
Liquidity and Capital Resources

Our principal sources of cash have historically been from operating activities. Our principal source of liquidity in excess of cash from operating activities has historically been from proceeds from our debt facilities and issuances of common stock. Our principal uses of cash and liquidity have historically been for acquisitions, debt service requirements, and financing of working capital. We believe that our operating cash flows, available cash on hand, and availability under our Revolving Credit Facility and the LC Facility will be sufficient to meet our cash requirements for the next twelve months and beyond. Our cash flows are primarily provided by the continuing operations of the Company. Cash provided by operating activities of the discontinued operations is expected to be offset at the closing of the transaction through proceeds from the sale, which may be utilized for the paydown of debt. Our future capital requirements will depend on many factors that are difficult to predict, including the size, timing, and structure of any future acquisitions, future capital investments, and future results of operations. We cannot assure you that cash provided by operating activities or cash and cash equivalents will be sufficient to meet our future needs. If we are unable to generate sufficient cash flows from operations in the future, we may have to obtain additional financing. If we obtain additional capital by issuing equity, the interests of our existing stockholders will be diluted. If we incur additional indebtedness, that indebtedness may contain significant financial and other covenants that may significantly restrict our operations. We cannot assure you that we could obtain refinancing or additional financing on favorable terms or at all.
We evaluate our liquidity based upon the availability we have under our First Lien Facilities in addition to the net cash provided by (used in) operating, investing, and financing activities. Specifically, we review the activity under the Revolving Credit Facility and the LC Facility and consider period end balances outstanding under the Revolving Credit Facility and the LC Facility. Based upon the outstanding borrowings and letters of credit under the Revolving Credit Facility and the LC Facility, we calculate the availability for incremental borrowings under the Revolving Credit Facility and the LC Facility. Such amount, in addition to cash on our balance sheet, is what we consider to be our “Total Liquidity.”

44

The following table provides a calculation of our Total Liquidity:

($ in thousands)

For the Nine Months Ended September 30,

For the Year Ended
December 31,

2025

2024

Revolving Credit Facility Rollforward

Beginning Revolving Credit Facility balance

$

63,300

$

50,700

(Repayments) borrowings of the Revolving Credit Facility, net

(63,300

)

12,600

Ending Revolving Credit Facility balance

$

—

$

63,300

Calculation of Revolving Credit Facility and LC Facility availability

Revolving Credit Facility and LC Facility limit

$

540,000

$

540,000

Less: outstanding Revolving Credit Facility balance

—

63,300

Less: outstanding letters of credit subject to LC Sublimit

—

—

Less: outstanding letters of credit under the LC Facility

62,790

61,821

End of period Revolving Credit Facility and LC Facility availability

477,210

414,879

End of period cash balance

140,344

60,954

Total Liquidity, end of period

$

617,554

$

475,833

Cash Flow Activity

The activity discussed in this section relates to our consolidated company results and includes the impacts of discontinued operations.
Nine Months Ended September 30, 2025 and 2024
The following table sets forth a summary of our cash flows provided by (used in) operating, investing, and financing activities for the periods presented:

($ in thousands)

For the Nine Months Ended September 30,

2025

2024

Variance

Net cash provided by (used in) operating activities

$

258,610

$

(66,838

)

$

325,448

Net cash used in investing activities

$

(71,195

)

$

(124,457

)

$

53,262

Net cash (used in) provided by financing activities

$

(107,368

)

$

214,197

$

(321,565

)

Operating Activities
Net cash provided by operating activities was $258.6 million for the nine months ended September 30, 2025 compared to net cash used in operating activities of $66.8 million for the nine months ended September 30, 2024. The change was primarily due to the following:

•
a $157.7 million increase in operating income in 2025 as compared to 2024;
•
a $30.9 million decrease in one-time cash outflows for direct and indirect remuneration (“DIR”) fees paid in connection with the conclusion of the DIR program; 
•
a $100.0 million decrease in cash outflows attributable to the timing of Silver legal settlement payments;
•
a $27.1 million decrease in cash outflows for interest, net primarily as a result of a reduction in the variable interest rates applicable to our outstanding term debt; and
•
a $9.5 million decrease in cash outflows for income taxes.
Investing Activities
Net cash used in investing activities decreased by $53.3 million, from $124.5 million in the nine months ended September 30, 2024 to $71.2 million in the nine months ended September 30, 2025. The decrease was primarily due to a $51.4 million decrease in cash paid for acquisitions in 2025 compared to 2024.

45

Financing Activities
Net cash used in financing activities was $107.4 million for the nine months ended September 30, 2025, primarily attributable to repayments on our long-term debt of $37.9 million, net repayments on our Revolving Credit Facility of $63.3 million, and payment of finance lease obligations of $10.1 million, offset by other financing activities.
Net cash provided by financing activities was $214.2 million for the nine months ended September 30, 2024, primarily attributable to net proceeds received from the IPO Offerings of $1,045.5 million, offset by extinguishment of and net repayments on our long-term debt of $818.6 million, net borrowings on our Revolving Credit Facility of $46.4 million, payment of debt issuance costs of $43.2 million, and other financing activities.
Debt
We typically incur debt to finance mergers and acquisitions, and we borrow under our Revolving Credit Facility for working capital purposes, as well as to finance acquisitions, as needed. Below is a summary of our long-term indebtedness as of September 30, 2025 and December 31, 2024.

We were in compliance with all applicable financial covenants as of September 30, 2025 and December 31, 2024.

First Lien Credit Agreement

On March 5, 2019, the Company entered into the First Lien Credit Agreement, among Phoenix Intermediate Holdings Inc., as Holdings, Phoenix Guarantor Inc., as the Borrower, the several lenders from time to time parties thereto and Morgan Stanley Senior Funding, Inc., as the Administrative Agent and Collateral Agent (the “First Lien Credit Agreement”). The First Lien Credit Agreement originally consisted of a principal amount of $1,650.0 million. In 2019, an additional delayed draw of $150.0 million was made on the First Lien Credit Agreement (“Tranche B-1”). The First Lien Credit Agreement was further amended in 2020 (“Tranche B-2”) and 2021 (“Tranche B-3”) to establish additional borrowings of $550.0 million and $675.0 million, respectively, resulting in a total gross borrowings of $3,025.0 million.

On June 30, 2023, the Company amended the terms of the First Lien Credit Agreement to reflect a change in reference rate to the Secured Overnight Financing Rate (“SOFR”).

On February 21, 2024, we used a portion of the net proceeds received from the IPO Offerings to repay $343.3 million of the borrowings under the First Lien, and established Tranche B-4 to refinance the remaining $2,566.0 million of borrowings under the First Lien Credit Agreement at a rate equal to SOFR plus 3.25%. Tranche B-4 has a maturity date of February 21, 2031. On December 11, 2024 we amended the First Lien to refinance Tranche B-4 by establishing Tranche B-5 in an aggregate principal amount of $2,553.2 million at a rate equal to SOFR plus 2.50% or ABR plus 1.50% with a maturity date of February 21, 2031.
 For additional information about our First Lien Credit Agreement, see Note 6 of the unaudited condensed consolidated financial statements and related notes in this Quarterly Report on Form 10-Q.
The First Lien Credit Agreement described above contain customary negative covenants, including, but not limited to, restrictions on the Company and its restricted subsidiaries’ ability to merge and consolidate with other companies, incur indebtedness, grant liens or security interests on assets, make acquisitions, loans, advances, or investments, pay dividends, sell or otherwise transfer assets, prepay or modify terms of certain junior indebtedness, enter into transactions with affiliates, or change their lines of business or fiscal year. In addition, under the Revolving Credit Facility, the Company will not permit the consolidated first lien secured debt to consolidated EBITDA (as defined in the First Lien Credit Agreement) ratio to be greater than 6.90 to 1.00, which shall be tested as of the end of the most recent quarter at any time when the aggregate revolving credit loans exceed 35% of the total revolving credit commitments.

Revolving Credit Facility

The total borrowing capacity under the Revolving Credit Facility included in the First Lien Credit Agreement (the “Revolver”) was $475.0 million as of September 30, 2025 and December 31, 2024. As of September 30, 2025, the Company had $475.0 million of borrowing capacity available under the Revolver as there were no borrowings under the Revolver or letters of credit outstanding. As of December 31, 2024, the Company had $63.3 million of borrowings outstanding under the Revolver and no letters of credit, reducing the available borrowing capacity to $411.7 million.
The First Lien Credit Agreement, as amended on September 17, 2024, provides for an additional $65.0 million of letter of credit commitments, or the LC Facility, which are not subject to the LC Sublimit. As of September 30, 2025, there were $62.8 million of letters of credit outstanding under the LC Facility, resulting in an available borrowing capacity of $2.2 million. As of December 31, 2024, there were $61.8 million of letters of credit outstanding under the LC Facility, resulting in an available borrowing capacity of $3.2 million.

46

 For additional information about our Revolving Credit Facility and LC Facility, see Note 6 of the unaudited condensed consolidated financial statements and related notes in this Quarterly Report on Form 10-Q.
Second Lien Credit Agreement

On March 5, 2019, the Company entered into a $450.0 million Second Lien Facility. Borrowings under the Second Lien Facility were subordinated to the First Lien Credit Agreement. On January 30, 2024, we used a portion of the net proceeds received from the IPO Offerings to repay all outstanding borrowings under the Second Lien Facility. No further obligation exists related to the Second Lien Facility. This transaction was accounted for as a debt extinguishment and the Company incurred a loss on extinguishment of debt of $12.7 million related to the write-off of unamortized debt issuance costs.

Interest Rate Swap Agreements

To manage fluctuations in cash flows resulting from changes in the variable interest rates, the Company entered into pay-fixed interest rate swap agreements. For the nine months ended September 30, 2025 and the year ended December 31, 2024, interest expense, net includes interest income received related to cash flow hedges of interest rate risk of $13.4 million and $35.3 million, respectively. Refer to Note 6 within our unaudited condensed consolidated financial statements and related notes in this Quarterly Report on Form 10-Q for further discussion.
Tangible Equity Units
Concurrently with the IPO, we issued 8,000,000 TEUs, which have a stated amount of $50.00 per unit. Each TEU is comprised of a prepaid stock purchase contract (“Purchase Contract”) and a senior amortizing note (“Amortizing Note”) due February 1, 2027, each issued by the Company. The Company will pay equal quarterly cash installments of $0.8438 per Amortizing Note on February 1, May 1, August 1 and November 1, commencing on May 1, 2024, except for the May 1, 2024 installment payment, which was $0.8531 per Amortizing Note, with a final installment payment date of February 1, 2027. In the aggregate, the annual quarterly cash installments will be equivalent of 6.75% per year. Each installment payment constitutes a payment of interest and a partial repayment of principal. Each TEU may be separated by a holder into its constituent Purchase Contract and Amortizing Note. Refer to Note 7 within our unaudited condensed consolidated financial statements and related notes in this Quarterly Report on Form 10-Q for further discussion.

47

The table below summarizes the total outstanding debt of the Company:

($ in thousands)

Rate

Long-term obligation and note payable

Interest Expense

September 30, 2025

December 31, 2024

September 30, 2025

December 31, 2024

Nine Months Ended September 30, 2025

Fiscal Year 2024

First Lien - payable to lenders at SOFR
    plus applicable margin

—

—

$

—

$

—

$

—

$

18,151

First Lien Incremental Term Loans
    Tranches B-2 and B-3 - payable to
    lenders at SOFR plus applicable
    margin

—

—

—

—

—

12,923

First Lien Incremental Term Loan 
    Tranche B-4 - payable to lenders at 
    SOFR plus applicable margin

—

—

—

—

—

150,759

First Lien Incremental Term Loan 
   Tranche B-5 - payable to lenders at 
   SOFR plus applicable margin

6.66

%

6.86

%

2,527,638

2,546,787

110,975

8,857

Second Lien - payable to lenders at
    SOFR plus applicable margin

—

—

—

—

—

4,482

Revolving Credit Loans - payable to 
    lenders at SOFR plus applicable
    margin

6.91

%

7.61

%

—

—

—

331

Swingline/Base Rate - payable to 
    lenders at ABR plus applicable 
    margin

9.25

%

9.75

%

—

63,300

6,321

10,602

Amortizing Notes

37,181

53,804

3,350

4,899

Notes payable and other

17,267

19,428

663

316

Amortization of deferred financing 
    costs and other, net of interest 
    income from cash flow hedges

—

—

(2,533

)

(20,774

)

Total debt

$

2,582,086

$

2,683,319

$

118,776

$

190,546

Less: debt issuance costs, net

64,882

72,736

Total debt, net of debt issuance costs

2,517,204

2,610,583

Less: current portion of long-term debt

51,870

48,725

Total long-term debt, net of current 
    portion

$

2,465,334

$

2,561,858

Our Company leverage, as calculated under our First Lien Credit Agreement, was 3.31x and 4.16x at September 30, 2025 and December 31, 2024, respectively. The results of the Community Living business are included in such calculation pursuant to the terms of our First Lien Credit Agreement and the Second Lien Credit Agreement.
Critical Accounting Policies and Use of Estimates
In preparing our unaudited condensed consolidated financial statements in conformity with U.S. GAAP, we must use estimates and assumptions that affect the reported amounts of assets and liabilities and related disclosures and the reported amounts of revenue and expenses. In general, our estimates are based on historical experience and various other assumptions we believe are reasonable under the circumstances. We evaluate our estimates on an ongoing basis and make changes to the estimates and related disclosures as experience develops or new information becomes known. Actual results could differ from those estimates.
We consider our critical accounting policies and estimates to be those that involve significant judgments and uncertainties and may potentially result in materially different results under different assumptions and conditions. There have been no material changes to our critical accounting policies and estimates from those disclosed in Part II, Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2024, which are hereby incorporated by reference.
Ite
m 3. Quantitative and Qualitative Disclosures About Market Risk.
Impact of Inflation
Wages and other expenses increase during periods of inflation and when labor shortages occur in the marketplace. The impact of inflation on the Company is primarily in the area of labor costs. The healthcare industry is labor intensive. There can be no guarantee we will not experience increases in the cost of labor, particularly given the shortage of qualified caregivers in our markets, and the demand for homecare services is expected to grow.

48

In addition, increases in healthcare costs are typically higher than inflation and impact our costs under our employee benefit plans. Managing these costs remains a significant challenge and priority for us. While we believe the effects of inflation, if any, and labor shortages on our results of operations and financial condition have not been significant, there can be no guarantee we will not experience the effect of inflation in the future.
In addition, suppliers pass along rising costs to us in the form of higher prices, which impacts us primarily in the area of pharmaceutical drug costs in our Pharmacy Solutions segment. Changes in costs of drugs can be accompanied by a change in rate that we pass along to our customers. Additionally, our supply chain efforts have enabled us to effectively manage and mitigate any inflationary impacts in our supply chain over recent years. However, we cannot predict our ability to cover future cost increases.

We have little or no ability to pass on certain of these increased costs associated with providing services to Medicare and Medicaid patients due to federal and state laws that establish fixed reimbursement rates.

Interest Rate Risk
The Company is exposed to interest rate risk related to changes in interest rates for borrowings under our First Lien Facilities. Although we hedge a portion of our interest rate risk through interest rate swaps, any borrowings under our First Lien Facility in excess of the notional amount of the swaps will be subject to variable interest rates. By using a derivative instrument to hedge exposures to changes in interest rates, we expose ourselves to credit risk due to the possible failure of the counterparty to perform under the terms of the derivative contract.
As of September 30, 2025, our debt outstanding was $2.6 billion and we had four existing interest rate swaps with a combined notional value of $1.5 billion that were designated as cash flow hedges of interest rate risk. A hypothetical 1% increase in interest rates would decrease our net income and our cash flows by $10.3 million on an annual basis based upon our borrowing level at September 30, 2025. The market risks associated with our debt obligations as of September 30, 2025 have not changed from those reported in “Part II. Item 7A. Quantitative and Qualitative Disclosure About Market Risk” in our Annual Report on Form 10-K for the year ended December 31, 2024. See Note 6 within the unaudited condensed consolidated financial statements and related notes, included elsewhere in the Quarterly Report on Form 10-Q.
Ite
m 4. Controls and Procedures.
Disclosure Controls and Procedures
Under the supervision and with the participation of the Company’s management, including its Chief Executive Officer and Chief Financial Officer, the Company has evaluated the effectiveness of the design and operation of its disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)). Based upon this evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this report, the Company’s disclosure controls and procedures were effective.
Changes in Internal Control Over Financial Reporting
There were no changes to our internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) that occurred during the quarter ended September 30, 2025 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

49

PART II—OTHE
R INFORMATION
Ite
m 1. Legal Proceedings.
From time to time, we are involved in various legal and/or administrative proceedings and subject to claims that arise in the ordinary course of business. We do not believe the ultimate liability, if any, for outstanding proceedings or claims, individually or in the aggregate, in excess of amounts already provided in our consolidated financial statements, will have a material adverse effect on our business, financial condition, or results of operations. It is reasonably possible that an adverse determination might have an impact on a particular period. Regardless of the outcome, litigation has the potential to have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors.
For a summary of our material legal proceedings, refer to Note 13 of the unaudited condensed consolidated financial statements and related notes in this Quarterly Report on Form 10-Q.
Ite
m 1A. Risk Factors.
There have been no material changes to the risk factors affecting our business, financial condition, or results of operations from those set forth under the heading “Summary Risk Factors” or in Part I, Item 1A. “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial may also materially adversely affect our business, financial condition, or results of operations.
Ite
m 2. Unregistered Sales of Equity Securities and Use of Proceeds.
None.
Ite
m 3. Defaults Upon Senior Securities.
None.
Ite
m 4. Mine Safety Disclosures.
Not applicable.
Ite
m 5. Other Information.
None
.

50

Ite
m 6. Exhibits.

Incorporated by Reference

Exhibit
Number

Description

Form

File No.

Exhibit

Filing Date

3.1

Second Amended and Restated Certificate of Incorporation of BrightSpring Health Services, Inc.

8-K

001-41938

3.1

1/30/2024

3.2

Amended and Restated Bylaws of BrightSpring Health Services, Inc.

8-K

001-41938

3.2

1/30/2024

4.1

Purchase Contract Agreement, dated as of January 30, 2024, between BrightSpring Health Services, Inc. and U.S. Bank Trust Company, National Association, as purchase contract agent, as attorney-in-fact for the Holders from time to time as provided therein and as trustee under the indenture referred to therein.

8-K

001-41938

4.1

1/30/2024

4.2

Form of Unit (included in Exhibit 4.1).

8-K

001-41938

4.2

1/30/2024

4.3

Form of Purchase Contract (included in Exhibit 4.1).

8-K

001-41938

4.3

1/30/2024

4.4

Indenture, dated as of January 30, 2024, between BrightSpring Health Services, Inc. and U.S. Bank Trust Company, National Association, as trustee.

8-K

001-41938

4.4

1/30/2024

4.5

First Supplemental Indenture, dated as of January 30, 2024, between BrightSpring Health Services, Inc. and U.S. Bank Trust Company, National Association, as trustee, paying agent and security registrar.

8-K

001-41938

4.5

1/30/2024

4.6

Form of Amortizing Note (included in Exhibit 4.5).

8-K

001-41938

4.6

1/30/2024

4.7

Registration Rights Agreement, dated December 7, 2017, by and among Phoenix Parent Holdings Inc., KKR Phoenix Aggregator L.P., and Walgreens Co.

S-1/A

333-276348

4.1

1/10/2024

31.1

Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2

Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1

Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2

Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS

Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.

101.SCH

Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

51

SIG
NATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

BrightSpring Health Services, Inc.

Date: October 28, 2025

By:

/s/ Jon Rousseau

Jon Rousseau

Chairman, President, and Chief Executive Officer

(Principal Executive Officer)

Date: October 28, 2025

By:

/s/ Jennifer Phipps

Jennifer Phipps

Executive Vice President and Chief Financial Officer

(Principal Financial Officer)

52